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This thesis has studied the pathophysiological events
which accompany upper GI haemorrhage in an attempt to more
fully understand its natural history. Despite the
multiplicity of aggressive factors present in the upper GI
tract most gastroduodenal bleeds stop spontaneously. This
is surprising in view of the high acidity, proteolytic
activity, vascularity and motile nature of the upper GI
tract, all factors which act to inhibit haemostasis and
promote haemorrhage. During investigation of this paradox
I have discovered inhibition of gastric secretion and
motility following simulated intraduodenal haemorrhage,
events which may represent a protective physiological
response to facilitate haemostasis in the adverse
environment of the upper GI tract. The relatively
prolonged nature of these inhibitory responses following
simulated intraduodenal haemorrhage provides additional
evidence to support a possible beneficial role in
haemostatic defence. Further studies have suggested these
inhibitory responses may also occur with intragastric
bleeding. To confirm these experimental observations
initial clinical studies have revealed increases in
gastric pH following active peptic ulcer bleeding which
may also reflect gastric secretory inhibition.
The mediation of these events has been the subject of
initial investigations both in simulated and true upper GI
bleeding assessing changes in GI hormones associated with
gastric secretion and motility. In both study groups this
has revealed a significant increase in GIP concentrations
suggesting this hormone may be involved in the mediation
of these inhibitory responses.
In the clinical situation where defence mechanisms
break down the identification and treatment by endoscopic
means of those patients at highest risk of rebleeding is
important. I have demonstrated an improvement in the
ability to predict rebleeding by identifying 'high risk'
peptic ulcer patients with a patent vessel in their ulcer
base using an endoscopic Doppler device. In these high
risk patients I have shown that endoscopic heater probe
therapy can provide haemostasis effectively and safely
thereby altering the natural history of peptic ulcer
haemorrhage.
In conclusion, improved understanding of the
pathophysiological principles governing haemostasis in the
upper GI tract and the effective prediction and treatment
of those patients where defence mechanisms fail are likely




The pathophysiological events accompanying upper GI
haemorrhage are poorly understood. In an attempt to
improve our knowledge of these events I have examined in
this thesis the effects of simulated and true upper GI
haemorrhage on gastric secretory function, gastric
motility and gastrointestinal hormone release. I have
also examined factors predicting rebleeding in peptic
ulcers and have demonstrated how its natural history may
be influenced by endoscopic therapy.
Although the local environment of the upper GI tract
is haemostatically adverse, up to 80% of all upper GI
bleeds stop spontaneously. This suggests the existence o
local homeostatic mechanisms which may promote haemostasi
despite the aggressive factors of high acidity,
proteolytic enzymes, continuing peristalsis and
vascularity encountered in the upper GI tract. I have
investigated three of these factors - acidity, proteolyti
enzymes and motility to determine how they are influenced
by a simulated upper GI bleed. This work was performed
initially in healthy volunteers using an experimental
study method simulating an intraduodenal bleed. The
effects of intraduodenal infusion of 160ml of fresh
autologous venous blood on pentagastrin stimulated
submaximal gastric secretion was studied. This revealed
mean inhibition of acid and pepsin output of 30% and 40%
XII
respectively following blood infusion compared with the
pre-infusion values. In a similarly designed study the
effect of intraduodenal infusion of autologous venous
blood on gastric emptying was performed using a double
dilution liquid meal technique. Gastric emptying was
significantly delayed after blood infusion compared with
control study. This inhibition of gastric secretion and
motility seen after simulated upper GI haemorrhage may
therefore represent a protective physiological response t
facilitate haemostasis.
The effects of intraduodenal blood infusion on
gastrointestinal hormones was also studied to determine
any possible mediating role in these inhibitory
responses. A selective increase in gastric inhibitory
peptide (GIP) was seen after intraduodenal blood
infusion. GIP is a duodenal polypeptide with known
inhibitory effects on gastric secretion and motility in
dogs. Its only confirmed physiological function in man
however, relates to its insulinotropic action in glucose
metabolism. The observed increase in GIP concentrations
after intraduodenal blood infusion with concomitant
inhibition of gastric secretion and motility may suggest
possible mediating role in these responses.
The duration of acid inhibition after intraduodenal
blood infusion was studied initially up to 3 hours
following duodenal blood infusion. This revealed
progressive inhibition of pentagastrin stimulated
XIII
submaximal acid secretion up to 3 hours after blood
infusion. The effect of a simulated upper GI bleed at
8pm on overnight gastric acidity and submaximal gastric
secretion 12 hours later was also studied. Overnight
gastric pH was increased after intraduodenal blood
infusion compared with a control protein infusion
suggesting continuing inhibition of overnight basal
gastric secretion. In addition, pentagastrin stimulated
submaximal gastric acid output was significantly lower 12
hours after the simulated bleed compared with the control
study suggesting a persisting effect some 12 hours
later.
A possible additional protective physiological
response seen after upper GI haemorrhage relates to the
induction of a systemic hypercoagulable state which may
facilitate haemostasis. In order to document whether this
observation reflects a GI mediated event or simply results
from a non-specific systemic response to haemorrhage, the
effect of intraduodenal blood infusion on blood
coagulation parameters was measured. No effect was noted
following blood infusion suggesting the latter explanation
may be correct.
Intragastric blood is common to most upper GI bleeds
and the effect of blood as a chemical buffer was studied
in an in-vitro study to determine its buffering capacity.
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A mixture of blood:gastric juice of >1 was required to
raise the combined pH to above 6.0 where coagulation may
be initiated.
The effect of simulated intragastric haemorrhage on
gastric acid secretion, gastric motility and serum gastrin
was investigated to determine whether additional
inhibitory mechanisms exist. On separate days 160ml of
fresh heparinised venous blood or 160ml egg-white acting
as control were instilled into the stomach and the
subsequent rates of gastric secretion and emptying, and
the changes in serum gastrin were noted. Compared with
the control protein meal intragastric blood inhibited
gastric emptying and produced 70% less acid secretion. In
addition, each produced a similar small increase in serum
gastrin concentrations suggesting that these secretory
changes could not be explained by differences in gastrin
alone. These events may also indicate additional
protective physiological responses initiated by gastric
bleeding.
Studies were performed in patients presenting with
upper GI haemorrhage to determine whether the observed
changes in gastric secretory function and GI hormones
after simulated upper GI haemorrhage occur in the clinical
situation. In patients with endoscopic evidence of active
peptic ulcer haemorrhage intragastric pH measured by a
combined glass electrode for 24 hours was significantly
elevated for prolonged periods compared with a control
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group. These changes occurred in the absence of
significant concentrations of intragastric blood
suggesting an effect independent of simple blood
buffering. Such responses indicate possible inhibition of
gastric secretion during the active phase of upper GI
haemorrhage. In addition, in patients admitted with upper
GI bleeding a selective increase in GIP concentrations was
seen throughout the 24 hour period in agreement with the
original intraduodenal studies. These observed changes in
intragastric pH and GIP concentrations agree with my
original experimental findings and may represent a local
physiological response to facilitate haemostasis. Future
studies are reguired however to confirm these findings, to
identify the blood based activation factor/s and to
examine the role of GIP in the mediation of these
responses. The identification of these apparent defence
mechanisms in the upper GI tract in response to local
haemorrhage may be important increasing our understanding
of the pathophysiology of this common condition.
Although the majority of all upper GI bleeds stop
spontaneously the minority who continue to bleed or
rebleed constitute a major clinical problem particularly
as the age of the presenting population increases.
Improved methods of predicting those patients who rebleed
is therefore of clinical relevance particularly as
improved endoscopic treatment methods are developed
allowing selective treatment of 'high risk' patients. A
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study was performed in patients with peptic ulcer
haemorrhage presenting to the Western Infirmary, Glasgow
to determine the predictive value of a localised arterial
signal in proximity to an ulcer base using a
Transendoscopic vascular detector (TVD) which utilises
Doppler ultrasound to detect pulsatile arterial flow. A
positive arterial signal in relation to the ulcer base
correctly predicted rebleeding in 87% of cases which was
similar to that predicted by visual stigmata. The
combination of visual stigmata (visible vessel) and a
positive Doppler signal however, predicted rebleeding in
100% of cases suggesting the ability to identify a vessel
in an ulcer base with arterial flow within may be the best
predictor of patients outcome.
The natural history of peptic ulcer haemorrhage has
only convincingly been altered by surgery. Endoscopic
therapy however appears to offer the ideal treatment
method for an increasingly elderly and unfit population
although many of the available techniques have not yet
been subjected to rigorous controlled clinical trials.
The heater probe is an endoscopic device which from
experimental studies is the safest and most effective in
producing vessel coagulation. A controlled randomised
trial of heater probe (HP) therapy was performed to
determine whether the HP can reduce the incidence of
rebleeding in peptic ulcers presenting with haemorrhage.
In a study of 43 patients with haemorrhage from high-risk
XVII
peptic ulcers 22% of sham treated patients rebled while no
heater probe treated patient rebled. This study suggested
heater probe therapy may be beneficial in reducing the
rebleeding rate in peptic ulcer haemorrhage.
These studies may improve our understanding of the
pathophysiology of upper GI haemorrhage thereby providing




PATHOPHYSIOLOGY OF UPPER GASTROINTESTINAL HAEMORRHAGE
1
1.1. INTRODUCTION
Upper gastrointestinal (GI) haemorrhage is a major
cause of emergency hospital admissions accounting for
approximately 30,000 new admissions each year in the UK
(SCHILLER et al 1970). Due to an increasing proportion of
elderly patients the mortality has remained about 10%
despite significant advances in diagnostic and
resuscitation techniques (ALLAN and DYKES 1976).
Although upper GI haemorrhage is a common condition
we understand little of the local physiological changes
which accompany it. Without a sound knowledge of the
underlying pathophysiological events, treatment regimes in
upper GI bleeding have been based on longstanding widely
held, but often unqualified beliefs. As a consequence
medical management of acute non variceal upper GI bleeding
has been generally ineffective and to date no therapeutic
regime has proven benefit over placebo. A better
understanding of the pathophysiological changes
accompanying upper GI bleeding may provide new and more
rational approaches to therapy.
1.2 HISTORICAL ASPECTS OF UPPER GI HAEMORRHAGE
Peptic ulcer haemorrhage and the prognostic
implications of arterial bleeding have been known since
Ancient Greek times. In 400 BC Hippocrates wrote in his
Aphorisms: 'Spurting haemorrhage coming from ulcers is bad
news' (HIPPOCRATES 400BC). The first documented fatality
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from upper GI haemorrhage may date to Roman times (AD 453)
where Attila the Hun apparently succumbed to a bleeding
peptic ulcer: 'An artery had suddenly burst and as Attila
lay in a supine posture, he was suffocated by a torrent of
blood which, instead of finding a passage through the
nostril, regurgitated into the lungs and stomach' (GIBBON
1901). Although the symptoms and signs of upper GI
bleeding had been recognised, there were to be no
significant advances in the understanding of the
pathophysiology of ulcer haemorrhage until the 19th
Century.
The first clear description of the pathological
characteristics of a bleeding chronic gastric ulcer came
from the French pathologist Jean Cruveilhier in 1829. He
describes his findings in a post-mortem study of a young
carpenter who died after several upper GI bleeds:
"At the level of the lesser curve there is a deep
ulceration. The edge and floor of the ulcer are
cicatrised excepting at a point where there is a clot of
blood elevated like a nipple: a stylet introduced into the
coronary (left gastric) artery of the stomach and directed
toward the end of the vessel, pushes the clot out and
enters the cavity of the stomach; but on withdrawing the
stylet a little and pushing it in the same direction it
can be made to re-enter the vessel which was not
completely severed but only cut about three-guarters of
its circumference" (CRUVEILHIER 1829).
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Since Cruveilhier1s time the association between
major peptic ulcer haemorrhage and exposed vessels in the
ulcer base has been noted by several authors (ROKITANSKY
1842; TROUSSEAU 1889; OSBORN 1954). The early rigid and
semi-flexible gastroscopes offered a limited view of the
upper GI tract, although drawings revealed that the early
endoscopists had identified the 'visible vessel' in
patients presenting with upper GI bleeding (SCHINDLER
1937; AVERY JONES 1947). However, with the advent of
fibreoptic endoscopy in the 1970s for the first time the
source of bleeding in the upper GI tract could be
accurately identified and prognostic significance attached
to lesions with identifiable stigmata of recent
haemorrhage (SRH) (COTTON et. al 1973; FORREST et al 1974;
FOSTER et al 1978) (Fig.1). The importance of a vessel in
the ulcer base was again highlighted by the endoscopic
identification of the 'visible vessel' (GRIFFITHS et al
1979; JOHNSTON 1984; WARA 1985). Although this is a
misnomer (the underlying artery in an ulcer base being
generally invisible but the protruding clot visible),
recent histological studies have confirmed that the
endoscopic 'visible vessel' appearance does represent a





Endoscopic appearance of (a) non-bleeding visible vessel
in a high lesser curve gastric ulcer and (b) the same
vessel a few seconds later actively spurting.
1.3 PATHOPHYSIOLOGY OF ULCER HAEMORRHAGE
Up to 80% of all upper GI bleeds stop spontaneously
(NORTHFIELD 1971) despite the haemostatically aggressive
surrounding environment. This in itself may suggest the
presence of specialised locally protective physiological
mechanisms to promote haemostasis.
Ulcer vessel pathology
Major peptic ulcer bleeding occurs when an artery in
the ulcer base is eroded (MacKAY 1954). These arteries
are small (normally < 1mm) and lie in the submucosa in 60%
and subserosa in 40% of cases (Fig.2). The pathological
characteristics of these vessels have been documented by
Swain et al in a prospective study analysing a series of
27 patients with major gastric ulcer haemorrhage who all
underwent partial gastrectomy for continuing bleeding
(SWAIN et al 1986a). All 27 patients had endoscopic
evidence of a 'visible vessel' and histological studies
confirmed a small artery (mean diameter 0.66mm: range 0.1
- 1.8mm) in 26/27 (96%) cases. The adverse prognostic
significance of the endoscopic visible vessel was
therefore confirmed.
Histological study confirmed aneurysmal dilation of
the vessel wall in 14/27 (52%) of vessels. In addition,
arteritis with polymorphonuclear cell infiltrate and
fibrinoid necrosis was seen in 24/29 (83%) vessels. This
5
FIGURE2Larget ryerodedinfloofaastriculcerwithclotinlum n.Thisubserosal arteryhasbeenerodedflu hwiththulcerbas(El ti a-VanG sotain).
inflammation was usually localised to the vessel side
closest to the ulcer floor suggesting that direct chemical
attack by acid/pepsin may have been the initiating factor
(Fig.3). Despite these arteries being pathological in
more than 80% of cases rebleeding in Swain's series
occurred in only 58% of endoscopically confirmed visible
vessels. Recanalised thrombus was also seen in about 25%
of cases suggesting the bleeding process was intermittent.
It is interesting that these vessels were so
frequently involved by extensive arteritis and necrosis
and as such would not be expected to undergo the normal
haemostatic mechanisms of vessel contraction/retraction.
Despite this the rebleeding rate from 'visible vessels'
averages only 50% in other published series (VALLON 1981;
WARA 1985), suggesting that a significant percentage of
even these diseased aneurysmally dilated vessels may
undergo haemostasis.
Pathological evidence therefore indicates that ulcer
haemorrhage even from necrotic aneurysmal arteries may be
an intermittent process suggesting the existence of
locally protective mechanisms.
6
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Gastric acid may initiate upper GI haemorrhage by
its erosive effect on vessels and may potentiate
bleeding by inhibiting normal blood coagulation and
platelet aggregation (BODI et al 1956). The
importance of gastric acid in upper GI haemorrhage
relates mainly to its potent inhibitory effects on
blood coagulation and platelet aggregation. These
inhibitory actions depend on the free hydrogen ion
activity or pH of the gastric juice as blood clotting
and platelet aggregation are particularly sensitive
to alteration in these parameters. Gastric mucosal
haemostasis, unlike the skin or vascular system,
depends primarily on processes involving the
coagulation system rather than platelet aggregation
(WHITTLE et al 1986) and is therefore particularly
sensitive to alterations in pH.
In Vitro Studies of the effect of alterations in pH
on blood coagulation and platelet aggregation
Inhibition of platelet aggregation at low pH has
been found in rabbits (McLEAN & VELOSO 1967) and man
(ROGERS, 1972). This effect at low pH was thought
to be due to either a change in platelet shape or a
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reduction in plasma factors required for aggregation.
Green et al investigated the effect of hydrochloric
acid on blood coagulation and platelet aggregation in
an in-vitro study (GREEN et al 1978). Both blood
coagulation and platelet aggregation were shown to be
extremely sensitive to relatively minor increases in
hydrogen ion concentration. All studies became
abnormal at pH 6.8 and by pH 5.4 blood coagulation
and platelet aggregation were virtually abolished.
In addition previously formed platelet aggregates
disaggregated at only slightly acid pH of 6.8.
Similar studies by Chaimoff et al have shown that
elevation of pH from acidosis to pH 7.0 induces
platelet aggregation, platelet calcium and serotonin
release and increases platelet factor VIII
availability (CHAIMOFF et al 1978).
The fasting pH in the stomach lies between 1-2
and in the proximal duodenum between 2.2-7.0 both
in normal volunteers (RUNE 1981; HANNIBAL & RUNE
1983) and in duodenal ulcer subjects (BENDTSEN et al
1987). It is surprising therefore that haemostasis
should occur at all in such an adverse acidic
environment.
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In Vivo Studies of Gastric Acid Secretion during
Upper GI Bleeding.
Gastric secretory studies were performed by
Chandler and Watkinson in 105 patients presenting
with upper GI bleeding in an attempt to recognise
patterns of acid secretion (CHANDLER & WATKINSON
1953). An important observation was made that in
patients with acute duodenal ulcers actively bleeding
at the time of investigation 89% had gastric
aspirates with pH > 3.5 (defined as achlorhydria)
which persisted for at least 24 hours. This effect
was not due to the buffering effect of blood reflux
as gastric aspirates were clear in this group who had
clinical evidence of continuing haemorrhage. On
repeat testing some weeks later, acid secretion had
returned to normal in all individuals. It is
interesting to note that this temporary acid
inhibition was taken as an indication for continuing
medical therapy suggesting that this was a favourable
prognostic factor. Although no explanation for this
suppression of gastric secretion was given it was
thought to represent a temporary failure of parietal
cell function. A later study with increased patient
numbers confirmed these patterns of acid secretion in
patients presenting with upper GI bleeding (CHANDLER
& WATKINSON 1959).
9
The observation that gastric function could be
altered following an upper GI bleed has also been
noted by Langman et al who found pentagastrin
stimulated acid secretion to be lower in 18 duodenal
ulcer subjects who had suffered a recent bleed
compared with a population of uncomplicated duodenal
ulcer patients (LANGMAN et al 1964). Wormsley and
Grossman (1965), however, studying 117 duodenal ulcer
patients showed no differences in acid secretion
between two such similar groups.
Gastric secretion may be inhibited during severe
shock due to sepsis or hypovolaemia presumably
through splanchnic circulatory shutdown and reduced
mucosal oxygen delivery (STANNARD et al 1988). It is
interesting to note that Chandler and Watkinson
showed a significant increase in the incidence of
achlorhydria in a chronic duodenal ulcer group (who
were normally hypersecretors) with a proportionate
increase in the degree of shock (CHANDLER & WATKINSON
1959). Achlorhydria, however, could be attributed to
shock alone in only a small proportion of cases
suggesting the involvement of additional factors in
reducing acid secretion.
Subsequent studies assessing gastric secretion in
GI bleeding have been mainly therapeutic aimed at
raising gastric pH by drug therapy on the assumption
that pH is normally low in the phase of active
1 0
bleeding and that this contributes to a failure of
haemostasis through inhibition of platelet
aggregation and blood coagulation (CURTIS et al 1973;
HASTINGS et al 1978; FIDDIAN-GREEN et al 1983;
REYNOLDS et al 1987). However the limited evidence
to date suggests acid secretion may already be
diminished during active bleeding. The importance
of pharmacological manipulation of acid secretion in
the treatment of upper GI bleeding may be clearer
when the accompanying local physiological responses
are better understood.
Pepsin
Pepsin is a potent proteolytic enzyme found in
the stomach which can initiate haemorrhage by eroding
an exposed vessel wall in the ulcer base and promote
rebleeding by actively digesting clot over a bleeding
lesion (BERSTAD 1982).
In human gastric juice there appear to be at
least 7 different pepsins (I-VII) and one non-pepsin
proteinase (ETHERINGTON & TAYLOR 1967). The gastric
juice from patients with chronic gastric or duodenal
ulcers contains different proteolytic activity
compared with juice from non-ulcer subjects (TAYLOR
1959) due to an increase in pepsin I concentrations
in ulcer patients (TAYLOR 1970). Pepsin I is
secreted by the fundic glands in the stomach
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(ETHERINGTON & TAYLOR 1970) and has a powerful
collagenolytic action up to five times greater than
pepsin III which is the major constituent of normal
gastric juice (ETHERINGTON et al 1980).
The mucus/bicarbonate barrier is an important
part of the protective defence mechanisms of the
gastro-duodenal mucosa (ALLEN & GARNER 1980). It is
likely that in a bleeding peptic ulcer, adherent
mucus and clot would provide the initial protection
against acid/peptic attack and therefore reduce the
risk of continuing bleeding. Pepsin has an optimum
pH range of 1.0-3.5 using protein as substrate where
pepsin I-III function at maximum rates (PIPER &
FENTON 1965). However, recent evidence has
suggested that pepsin I may remain active against
gastric glycoprotein at pH ranges up to 5.0 (PEARSON
et al 1986). In vitro studies have also shown that
the addition of pepsin increased the rate of
platelet disaggregation at only modestly lowered pH
(4.7-7.8) (GREEN et al 1978). Therefore, it seems
that pepsin may retain its ability to break down the
mucus barrier and disaggregate platelets at pH values
up to 5.0. It is evident therefore, that in
relation to upper GI bleeding acid/pepsin attack may
continue until gastroduodenal pH is above 5 and will
be abolished only at pH values approaching 6.
1 2
c) Fibrinolysis
The intermittent nature of upper GI haemorrhage
may result from cyclical temporary haemostasis with
clot formation followed by fibrinolysis, clot
disruption and rebleeding. This alteration between
clot formation and lysis depends on the presence in
the upper GI tract of both potent activators and
inhibitors of proteolysis. The gastrointestinal
mucosa is rich in plasminogen activator (COX et al
1967) and there is evidence to suggest that local
release of this activator may induce fibrinolysis and
rebleeding (COX et al 1969; NILSSON et al 1975a).
In addition gastric pepsin and pancreatic proteases
may also induce fibrinolysis and clot digestion (LOW
et al 1980). Low et al (1980) studied the in-vitro
fibrinolytic activity of human gastroduodenal juice
using a 125I-fibrin clot lysis technigue and found
that pepsin was approximately 100 times more active
against fibrin than pancreatic trypsin, chymotrypsin
or elastase. In addition gastric juice was 50
times more potent in fibrinolytic terms than the
same volume of duodenal juice. Gastroduodenal
secretion amounts to 2-3L per day under normal
conditions therefore their exists a large reservoir
of potential fibrinolytic activity in the upper GI
tract.
1 3
Limited studies of antifibrinolytic agents in
upper GI haemorrhage have suggested possible
therapeutic benefit (CORMACK et al 1973; BIGGS et al
1976; STAEL von HOLSTEIN et al 1987). It appears
therefore that haemostasis in the upper GI tract may
depend on the interaction between lytic activity
(plasminogen activators ± peptic activity ±
pancreatic enzyme activity) and clot formation.
Preliminary studies have suggested enhanced
fibrinolytic activity in gastric juice of patients
with upper GI bleeding compared to non-bleeding
patients (NILSSON et al 1975b; BUHR et al 1978;
WHEATLEY et al 1987). Whether this enhanced
fibrinolytic activity may account for the small
proportion of patients who rebleed is unknown.
1.4.2Mural Factors
a) Vascularity
The upper GI tract is highly vascularised
receiving up to one fifth of the total cardiac output
and the mucosa receives about 70% of this visceral
blood supply through an extensive anastomotic network
within the bowel wall (GUTH 1977; KONTUREK 1979).
The net result is a highly vascularised mucosal
circulation which usually has a close functional link
with gastric secretion (JACOBSON 1967; GUTH 1982).
Present knowledge suggests the gastroduodenal mucosal
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circulation may be capable of considerable
autoregulation in response to varying physiological
events (PERRY et al 1982; LARSEN & MOODY 1982; KIEL
et al 1987). Such autoregulation may be mediated
through arterio-venous shunts in the submucosa, which
could allow rapid shifting of large amounts of blood
from one region of the stomach to another.
In the event of ulcer bleeding the outcome
depends on both the size of the bleeding vessel and
the ability of local mechanisms to produce
haemostasis. Although the vessels involved in ulcer
haemorrhage are usually pathological and therefore
incapable of normal haemostatic responses, up to 68%
stop bleeding spontaneously (WARA 1985). Alternative
protective responses contributing to haemostasis may
involve alterations in mucosal blood flow as this is
clearly capable of considerable autoregulation under
other physiological conditions. Such alterations in
mucosal blood flow may also involve changes in
gastric secretion as both parameters usually change
in parallel (PIQUE et al 1988).
It is now well established that the splanchnic
circulation may be altered by GI hormonal
mediation. Several GI hormones have known
stimulatory or inhibitory action on gastric mucosal
blood flow (CHOU et al 1984). GI hormones with a
known inhibitory effect on gastro-duodenal mucosal
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blood flow include somatostatin (SONNENBERG & WEST
1983; PRICE et al 1985), neurotensin (FLETCHER et al
1985) and secretin (KONTUREK et al 1976a; FLETCHER
et al 1985). Somatostatin in particular, has a
profound inhibitory effect on splanchnic circulation,
lowering mucosal blood flow and portal venous
pressure (BOSCH et al 1981; MERKEL et al 1985).
These responses have been utilised in therapeutic
trials of somatostatin in peptic ulcer haemorrhage,
although some studies have suggested this is
beneficial (KAYASSEH et al 1980; CHRISTIANSEN &
YOTIS 1986; TORRES et al 1986), others have not
(SOMMERVILLE et al 1985; MAGNUSSON et al 1985). It
is important, however, to remember that somatostatin
also has a powerful gastric anti-secretory effect and
any benefits seen may simply be the result of
decreased secretion.
Alterations in gastric mucosal blood flow can
occur in response to varying neurohormonal stimuli
and may therefore be important in considering local
responses to upper GI haemorrhage.
b) Motility
The upper GI tract (stomach and duodenum) is
highly motile during normal physiological fasting
conditions participating in the migrating motor
complex, which is a cyclic sequence of alternating
1 6
motor activity and quiescence (HOUGHTON et al 1988).
Continuing gastro-duodenal motility, however, in the
context of upper GI bleeding is likely to be
detrimental haemostatically in two ways,
i) Increased vascular stress
Continuing active peristalsis may dislodge fresh
clot over the bleeding site and increase
intramural and intravascular pressure (BODI &
KAZAL 1965). These added stresses to already
breached vessels in an ulcer base may result in
persisting bleeding or rebleeding. In addition
powerful smooth muscle contractions may
overstretch undamaged mucosal or submucosal
vessels leading to vessel wall disruption and
bleeding (MALLORY and WEISS 1929).
ii) Enhanced acid/pepsin digestion
The physical mixing effect of gastroduodenal
peristalsis may increase the rate of acid/peptic
clot digestion (BODI et al 1956) and promote
rebleeding. In addition considering a duodenal
bleeding source, continuing gastric motility would
allow the emptying of an acid/pepsin load directly
onto the bleeding site. This may interfere with
haemostasis and induce clot and vessel
digestion. Reduction of gastroduodenal motility
during upper GI bleeding therefore seems desirable
and therapeutic regimes with early feeding have
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been introduced as a means of inhibiting gastric
peristalsis (MEULENGRACHT 1935; AVERY JONES
1947) .
The effect of gastrointestinal haemorrhage on the
motility of the upper GIT is unknown, however in
view of the propensity of upper GI bleeds to stop
spontaneously some inhibitory effect may be
expected as a means of facilitating haemostasis.
1.4.3Systemic Factors
In upper GI haemorrhage a breakdown of local
haemostasis usually occurs while systemic haemostasis
remains unimpaired. Although systemic coagulation
defects may occur and predispose to rebleeding
these are uncommon (JONES et al 1961).
It has been recently suggested that a hyper-
coagulable state is induced by upper GI haemorrhage
which may act in a protective manner to promote
haemostasis and thereby reduce rebleeding (BLAIR et
al 1986). The authors noted a hypercoagulable
response as measured by a shortening in the Biobridge
Impedance Clotting Time (ICT) in patients presenting
with acute upper GI haemorrhage compared with an age
and sex matched control group. This effect persisted
for 3-4 days before returning to normal. In a
controlled study assessing the effects of blood
transfusion on this hypercoagulable response, Blair
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et al noted that in patients randomised to receive
blood, the mean ICT was lengthened from admission
values when compared to values in patients receiving
no blood (BLAIR et al 1986). In addition, this
alteration of the ICT by blood transfusion was
accompanied by an increased transfusion requirement
and rebleeding rate.
It was concluded that in upper GI bleeding
hypercoagulability may be a protective mechanism to
promote haemostasis which may be reversed by early
blood transfusion thereby promoting the risk of
rebleeding. Whether these observed changes in
coagulation were specific to GI bleeding (and thus
may be have been induced by blood in the gut lumen)
or represented simply systemic responses to blood
loss were not discussed.
It is interesting therefore that despite the
multiplicity of aggressive factors in the upper GIT
80% of all upper GI bleeds stop spontaneously. This
paradox strongly suggests the presence of specialised
defence mechanisms to promote haemostasis.
AIMS
This thesis aims to examine the local
pathophysiological events occurring during acute upper GI
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Considering the adverse environment for haemostasis,
it is surprising that approximately 80% of acute upper GI
bleeds stop spontaneously. The resting pH of the stomach
and proximal duodenum is usually less than 2 and
platelet aggregation and plasma coagulation are abolished
in vitro at pH values of < 5.4 (GREEN et al 1978).
Gastric juice is also rich in pepsin, a potent
fibrinolytic agent which rapidly digests thrombus in acid
medium of pH < 4 (LOW et al 1980; BERSTAD 1982). The fact
that haemostasis is usually effective in the upper GI
tract suggests the presence of specialised physiological
mechanisms to facilitate haemostasis in this unusual
environment. In order to determine whether such
mechanisms exist I have studied the effect of simulated
upper GI haemorrhage on gastric acid and pepsin secretion,
gastric motility and GI hormone release. The first
study examined the effects of simulated intraduodenal
haemorrhage on these parameters.
2.2 MATERIALS AND METHODS
Gastric secretion study
The effect of simulated intraduodenal haemorrhage on
gastric acid and pepsin secretion was studied in 7 healthy
volunteers (6 males, 1 female; median age 29 years, range
25-36). After an overnight (12h) fast, a size 8 duodenal
tube (Viomedex) and size 14 vented Andersen gastric tube
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(AN 10, HW Andersen Inc, New York, USA) were passed under
fluoroscopic control into the second part of the duodenum
and body of stomach respectively. This allowed
simultaneous intraduodenal infusion and gastric aspiration
without contamination (Fig.4). At time zero, an iv
infusion of pentagastrin (Peptavlon, ICI) 0.25pg/kg/hr was
commenced and continued throughout the study to stimulate
submaximal gastric secretion. Following a 30 minute
eguilibration period, 4 x 15 minute collections of gastric
juice were obtained by continuous aspiration. After this
(time 90 minutes) each volunteer was blind-folded and
received intraduodenally either 160ml of fresh, unclotted
autologous venous blood or 160ml egg-white (which has a
similar protein and carbohydrate content to blood).
Intraduodenal infusions were administered in random order
on separate days at least one week apart. Infusions were
given as 4 x 40ml aliquots at 5 minute intervals over 20
minutes. This rate of blood infusion was chosen to
approximate to the intraduodenal bleeding rate expected
from an average sized vessel in a duodenal ulcer base
(PROTELL et al 1976; JOHNSTON et al 1987). On each study
day 40ml of venous blood was removed from each volunteer's
arm every 5 minutes for 15 minutes (total volume removed =
160ml) and either directly infused into the duodenum
prior to clotting (blood study day) or discarded (egg
study day). Following the start of duodenal infusion, a











Diagramatic representation of the experimental study
method illustrating the positions of the separate
intragastric and intraduodenal tubes in the body of
stomach and second parts of duodenum respectively. This
allowed simultaneous duodenal infusion and gastric
aspiration without contamination.
(90-150 min). Volumes of each 15 minute gastric aspirate
were measured and aliquots retained for assay. A summary
of this study method is shown in Figure 5.
Corrections were made for pyloroduodenal loss by
infusing a non-absorbable marker, phenol red solution
(1500mg/l) at 12ml/h intragastrically throughout the study
(HOBSLEY and SILEN 1969). Corrections for duodenogastric
reflux of duodenal juice were made by estimating sodium
concentration of the gastric aspirate (McCLOY 1978).
Microscopic blood reflux was quantitated
spectrophotometrically (CRAWFORD and HOBSLEY 1968). Any
study demonstrating macroscopic reflux of blood or
egg-white was abandoned. Macroscopic egg-white reflux was
detected visually by its effect on phenol red in the
aspirated gastric juice, turning the normal acidic
yellow/orange colour to pink. Four studies were repeated
due to macroscopic reflux of blood in three, and egg-white
reflux in one.
Gastric motility study
The effect of simulated intraduodenal haemorrhage on
gastric emptying of a 600ml liquid glucose meal was
studied in 6 healthy volunteers (5 males, 1 female; median
age 29 years, range 25-36) using a double sampling test
meal technique (GEORGE 1968).
Following an overnight fast, separate intraduodenal
and gastric tubes were positioned as described above. At
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FIGURE 5
Experimental study method to determine the effects of
intraduodenal blood and egg-white infusion on pentagastrin
stimulated gastric secretion.
600ml in 75mmol/l NaCl with phenol red solution 45mg/l)
was instilled into the stomach, mixed and 5ml aspirate
kept for analysis. Each volunteer was then blind-folded
and received intraduodenally either 160ml fresh autologous
venous blood (4 x 40ml aliguots over 5 minute intervals as
described above), 160ml egg white (4 x 40ml aliguots) or
intraduodenal intubation alone in random order on separate
days. At 10 minutes, 10ml of gastric aspirate was
removed and kept for analysis. Immediately 10ml of
phenol red solution (1500mg/l) was instilled into the
stomach, the gastric contents mixed and a further 10ml
gastric aliguot was kept for analysis. This double
sampling technigue was repeated at 10 minute intervals
until time 50 minutes when the stomach was emptied
completely, the volume recorded and a 10ml aliquot
retained for analysis. The stomach was then washed with
100ml of water and a 10ml aliguot also retained for
analysis.
Gastrointestinal (GI) hormone studies
To study possible hormonal mediation of any responses
shown, serial blood samples were taken before and after
intraduodenal blood and egg white infusion during the
gastric secretory study.
Three basal samples were taken at 30 minute intervals
before intraduodenal infusion and thereafter at 7 minute
intervals until study completion at 150 minutes. Samples
were added to heparinised tubes, immediately centrifuged
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and plasma stored at -20 degrees Centigrade. The
following GI hormones with known gastric secretory and/or
motility effects were studied - gastrin, secretin, gastric
inhibitory peptide (GIP), vasoactive intestinal peptide
(VIP), neurotensin and somatostatin.
ANALYSIS
Gastric secretion
Gastric juice was analysed for :
1. Hydrogen ion concentration by titration to pH 7.0
with 100mmol/l sodium hydroxide.
2. Phenol red concentration by spectrophotometric
absorption (Pye Unicam SP8-100 UV Spectrophotometer)
at 550 and 410nm and at 410nm alone to guantitate
microscopic blood reflux.
3. Sodium concentration by flame photometry (EEL Flame
Photometers Ltd).
4. Pepsin concentration by Pipers method (PIPER 1960).
Results were expressed as mg Sigma porcine pepsin.
GI hormones
GIP, gastrin, secretin, somatostatin, VIP and
neurotensin were measured by radioimmunoassay. Details of
each radioimmunoassay technigue are given in the appendix.
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CALCULATIONS
Acid output was expressed as total acid output in
mmol/h for each hour before and each hour after duodenal
infusions following correction for pyloroduodenal losses
and duodenogastric reflux. Pepsin output was expressed as
the total output in mg for each hour before and after
intraduodenal infusions.
Intragastric volumes were calculated using the method
of George (GEORGE 1968). The time taken for intragastric
volume to decrease to half volume from 600ml (t^) was
calculated in each case using linear transformation of the
data.
For each GI hormone assay pre-infusion values were
expressed as the mean of the 3 samples at 0, 30 and 60
minutes.
Statistical analysis
Results are given and mean ± standard error of the
mean (SEM). Statistical analysis was performed using the
Wilcoxon Signed Ranks test (2 sided) for paired data.
Results were considered significant when p < 0.05.
Written, fully informed consent was obtained in each






Gastric acid output (mmol/h) decreased in each of
the seven volunteers following intraduodenal blood
infusion. The mean output being 30.0 ± 3.2 in the
hour preceding intraduodenal blood infusion and 21.4
± 3.7 in the hour following infusion (p < 0.02) (Fig.
6). This represented a mean reduction in acid output
of 30.4% (range 16-67%) and was accounted for by a
reduction in both the volume and H+ concentration of
the gastric juice.
With intraduodenal egg white infusion there was no
significant change in acid output being 31.8 ± 2.8 in
the hour before infusion and 33.0 ± 4.4 in the hour
following intraduodenal infusion (Fig.6).
(b) PEPSIN OUTPUT
Pepsin output (mg/h) decreased in each of the
seven volunteers following intraduodenal blood
infusion (Fig.7). The mean output being 207.5 ±
67.7 in the hour preceding intraduodenal blood
infusion and 135.7 ± 54.7 in the hour following
infusion (p < 0.02). This represented a mean
reduction in pepsin output of 43% (range 19-80) and
was accounted for by a reduction in both volume and
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FIGURE 6
Effect of intraduodenal blood and egg-white infusion on


























Effect of intraduodenal blood and egg-white infusion on
pepsin secretion in 7 healthy volunteers.
intraduodenal egg white infusion, there was no
significant change in pepsin output being 372.2 ±
82.9 in the pre-infusion hour and 376.9 ± 54.6 in the
hour following intraduodenal infusion (Fig.7).
Calculated recovery fractions by phenol red estimation
were 91% in the blood infusion group and 94% in the egg
white infusion group. The calculated mean volume of blood
refluxed in the hour following intraduodenal blood
infusion was 3.2 ± 0.9ml.
Gastric motility study
Gastric emptying was delayed in all 6 subjects
following intraduodenal blood infusion compared with
intubation alone. Figure 8 shows the residual gastric
volumes with intraduodenal blood infusion compared with
the control study (duodenal intubation alone). The
emptying time (min) for the initial intragastric volume
(600ml) to decrease to half volume (tJr) was increased to
75.0 ± 8.2 following intraduodenal blood infusion compared
with 35.5 ± 6.6 in the control study (p < 0.02). After
blood infusion 355 ± 18ml remained in the stomach at 50
minutes, compared with 211 ± 28ml following the control
study (p < 0.02).
Compared with intubation alone, intraduodenal egg
white infusion also resulted in a delay in gastric
emptying although this was less marked than following
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FIGURE 8
Residual gastric volumes following intraduodenal blood
infusion and duodenal intubation alone in 6 healthy-
volunteers. Values are given and Mean ± SEM.
67.7 ± 12.7 compared with 35.5 ± 6.6 following the control
study (p = NS). After egg white infusion 291 ± 36ml
remained in the stomach at 50 minutes compared with 211 ±
28ml following the control study (p = NS).
GI HORMONES
GIP
Plasma GIP concentrations (ng/l) increased
significantly following blood infusion compared with
pre-infusion values (p < 0.02) (Fig. 9). Peak GIP levels
were reached 21 minutes after the commencement of blood
infusions being 127.9 ± 62.7 compared with the
pre-infusion value of 58.3 ± 2.3 (p < 0.02). GIP
concentrations remained significantly elevated above
pre-infusion values at the end of the study 56 minutes
after the start of blood infusions.
In contrast intraduodenal egg white infusion had no
effect on plasma GIP concentrations at any time point
studied (Fig.9).
GASTRIN
A small increase in plasma gastrin concentrations
(ng/l) was noted following intraduodenal blood infusion
(Fig.10) reaching peak levels of 32.1 ± 5.7 14 and 21
minutes after the start of the infusion (p < 0.02)
compared with the pre-infusion value of 24.8 ± 5.2.
Plasma gastrin remained elevated at 31.4 ± 7.1 49 minutes
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Venous plasma concentrations of GIP before and after
intraduodenal infusion of blood and egg-white in 7 healthy
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FIGURE 10
Venous plasma concentrations of Gastrin before and after
intraduodenal infusion of blood and egg-white in 7 healthy
volunteers. Values are given as Mean ± SEM.
gastrin concentrations (ng/l) also showed a small increase
after intraduodenal egg white infusion (Fig.10) reaching
peak values of 32.5 ± 5.7 and 33.3 ± 6.4, 14 and 21
minutes respectively after the start of infusions compared
with the mean pre-infusion value of 25.0 ± 3.6 (p < 0.03).
SECRETIN
A small increase in secretin concentrations (ng/l)
was seen immediately after the first intraduodenal blood
infusion at 90 minutes reaching a peak level of 51.4 ±
16.9 compared with the mean pre-infusion value of 26.9 ±
4.6 (p < 0.05) (Fig. 11). Secretin concentrations were
also significantly raised 28 and 42 minutes after blood
infusion at 40.7 ± 7.8 and 34.3 ± 7.0 respectively (p <
0.05). Following intraduodenal egg white infusion there
was also an immediate rise in plasma secretin
concentrations to a peak of 51.4 ± 16.9 at 90 minutes
compared with the pre-infusion value of 32.4 ± 9.4
although this failed to reach statistical significance
(Fig. 11).
VIP
Intraduodenal blood infusion had no effect on plasma
VIP concentrations at any time point studied (Fig. 12).
Plasma VIP concentrations (ng/l) however, rose following
intraduodenal egg white infusion reaching peak levels of
72.1 ± 11.8, seven minutes after the start of infusion
compared with the mean pre-infusion value of 45.5 ± 6.4 (p
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FIGURE 11
Venous plasma concentrations of Secretin before and after
intraduodenal infusion of blood and egg-white in 7 healthy
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Venous plasma concentrations of VIP before and after
intraduodenal infusion of blood and egg-white in 7 healthy-
volunteers. Values are given as Mean ± SEM.
NEUROTENSIN
Plasma neurotensin concentrations (ng/l) rose to 15.3
± 2.3 21 minutes after intraduodenal blood infusion and
reached a peak value of 17.3 ± 2.1 at 49 minutes compared
with the basal value of 12.9 ± 2.6 (Fig. 13) although
these just failed to reach statistical significance (p <
0.07). Intraduodenal egg white had no significant effect
on neurotensin concentrations at any time point studied
(Fig. 13).
SOMATOSTATIN
No significant changes in somatostatin concentrations
were noted after either intraduodenal blood or egg white
infusions (Fig. 14).
2.4 DISCUSSION
This study has demonstrated that intraduodenal blood
infusion in man inhibits pentagastrin stimulated gastric
acid and pepsin secretion, delays gastric emptying and
increases plasma GIP concentrations. These responses may
represent a locally protective physiological mechanism to
facilitate haemostasis.
Gastroduodenal haemorrhage is the commonest and most
clinically significant source of blood loss in patients
presenting with upper GI bleeding. In a large review of
2097 patients presenting with upper GI bleeding,
gastroduodenal sources of blood loss were found in 75% of
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Venous plasma concentrations of Neurotensin before and
after intraduodenal infusion of blood and egg-white in 7










0 30 60 90 120 150
Time (min)
FIGURE 14
Venous plasma concentrations of Somatostatin before and
after intraduodenal infusion of blood and egg-white in 7
healthy volunteers. Results are given as Mean ± SEM.
environment however, is not conducive to haemostasis.
The resting pH of the stomach and proximal duodenum is
usually less than 2 (RUNE 1981; HANNIBAL and RUNE 1983)
and platelet aggregation and plasma coagulation are
abolished at pH < 5.4 (GREEN et al 1978). Gastric juice
is rich in pepsin, a potent proteolytic enzyme which
digests thrombus and fibrin (LOW et al 1980; BERSTAD
1982). Furthermore, the highly vascular and motile
nature of the upper GIT is likely to promote haemorrhage
and inhibit haemostasis. Following simulated
intraduodenal haemorrhage the three of these factors
studied were all altered in a way that would facilitate
haemostasis. In clinical terms the 160ml of blood infused
in our study represents a very minor bleed and the changes
seen may be more marked following larger bleeds where the
volume of intraluminal blood is considerably greater. In
addition, in clinical upper GI haemorrhage blood usually
refluxes into the stomach contributing to the reduction in
gastric acidity by its buffering capacity. In a single
large clinical study by Chandler and Watkinson in 1953 a
temporary achlorhydria was noted in patients with
intraduodenal haemorrhage which was not due to blood
reflux but was thought to represent a temporary
inhibition of parietal cell function (CHANDLER and
WATKINSON 1953).
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The mechanism by which intraduodenal blood inhibits
gastric secretion and motility is unclear. Intraduodenal
infusions of acid (JOHNSTON and DUTHIE 1965; JOHNSTON and
DUTHIE 1966), fat (SHAY et al 1939; SIRCUS 1958; WINDSOR
et al 1969) or hyper/hypo- osmolar solutions (WARD et al
1969; WALLIN et al 1985) are known to inhibit acid and
pepsin secretion and delay gastric emptying (ROBERTS 1931;
VAN LIERE & SLEETH 1940; HUNT 1963). Although the
controlling mechanisms of these responses are unknown
hormonal mediation by an inhibitory 'enterogastrone1 has
been postulated (KOSAKA and LIM 1930; GREGORY 1967;
JOHNSTON & GROSSMAN 1971). An 'enterogastrone' has
therefore been defined as a substance that is released
from the intestinal mucosa by contact with acid, fat or
hypertonic solutions and which acts to inhibit gastric
secretion and motility (GREGORY 1967). Blood has a pH of
7.35 - 7.45, is iso-osmolar and has a low fat content in
the fasting state. It seems unlikely therefore that the
inhibitory responses to infused intraduodenal blood seen
in this study were initiated by any currently known
duodenal inhibitory pathway. Moreover, intraduodenal
blood being composed primarily of a protein load may be
expected to stimulate gastric secretion (ISENBERG et al
1977; LANDOR and IPAPO 1977).
This study however, has provided some evidence that
these secretory and motility changes following simulated
intraduodenal haemorrhage may be hormonally mediated. We
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have noted increases in gastric inhibitory peptide (GIP)
concentrations following blood infusion alone. GIP is a
polypeptide located primarily in the duodenum and jejunum
(POLAK et al 1973). Its primary physiological role
appears to be in the control of glucose metabolism where
it acts as an insulinotropic factor (ANDERSEN et al
1978). It has known inhibitory effects on both
pentagastrin stimulated gastric acid secretion and
gastric motility in dogs (PEDERSON & BROWN 1972), and was
originally thought to represent an enterogastrone (BROWN
1974; BROWN et al 1975). The role of GIP as an
enterogastrone in man, however, is controversial.
Systemic infusion of GIP in man produces inhibition of
pentagastrin stimulated gastric secretion only at doses
that exceed the blood concentrations seen after meals
(CLEATOR and GOURLAY 1975; ARNOLD et al 1978; MAXWELL et
al 1980). GIP's action as an enterogastrone, however, may
either be intraluminal (UVNAS-WALLENSTEN 1980) or depend
on the production of high portal concentrations which were
not monitored in these studies. Although the increases
in GIP concentrations seen in our study following
intraduodenal blood infusion were small, these again
represented systemic venous concentrations only.
Intraluminal or portal venous concentrations therefore may
have been more significantly elevated.
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The role of other GI hormones in the mediation of
these inhibitory responses is unclear, however other
recently discovered inhibitory peptides such as peptide YY
may be involved (GUO et al 1987). It is also possible
that a combination of hormones may be responsible. A
small but significant increase in secretin concentrations
was seen after intraduodenal blood infusion, with a trend
towards a late increase in neurotensin concentrations.
Both secretin and neurotensin have known inhibitory
actions on both gastric acid secretion and motility
although their roles as enterogastrones remain unproven
(BLACKBURN et al 1980a; VALENZUELA & DEFILIPPI 1981; SKOV
OLSEN et al 1983; THOMPSON 1987). Interestingly,
however, neurotensin and secretin have been shown to have
a complementary inhibitory effect on gastric secretion in
man which suggests that together they may function as an
'enterogastrone' (FLETCHER et al 1985).
The increase in VIP concentrations seen after
intraduodenal egg-white but not blood infusion is
difficult to explain. VIP is found throughout the entire
length of the gut (BRYANT et al 1976) and has been shown
to increase in man after intraluminal perfusion of acid,
fat or ethanol but not amino acids (SCHAFFALITZKY DE
MUCKADELL et al 1977). It has potent inhibitory effects
on both acid and pepsin secretion (VILLAR et al 1975)
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although the concentrations reached after egg-white
infusion in this study may have been insufficient to
induce acid inhibition.
The small increase in serum gastrin concentrations
noted after both blood and egg white infusion is
interesting. The proximal duodenum is a rich source of
gastrin in man having an equivalent mass of stored gastrin
to the gastric antrum (NILSSON et al 1973). Duodenal
gastrin, however, consists mainly of G34 (BERSON & YALOW
1971; MALMSTROM et al 1976) which may represent a
precursor molecule (GREGORY & TRACY 1975) and which
appears to be less active than the smaller G17 which
is the most common stored form in the gastric antrum
(WEINER et al 1987). The duodenal release of G34 may
explain the absence of acid stimulation in either of our
groups following duodenal infusions.
The activating agent present in blood responsible for
these inhibitory actions is unclear. The identification
of the activating agent may be important, however, both
to increase our knowledge of the pathophysiology of upper








My initial study confirmed that simulated
intraduodenal haemorrhage significantly inhibits
pentagastrin stimulated gastric acid and pepsin secretion
for at least one hour after infusion. If this apparent
protective physiological mechanism is of clinical
significance then a prolonged inhibitory response would be
expected. In this series of experiments I have
investigated the effect of simulated intraduodenal
haemorrhage on acid and pepsin secretion was investigated,
3 and 12 hours following infusion to determine the
duration of this inhibitory response.
3.2 EFFECT OF SIMULATED INTRADUODENAL HAEMORRHAGE ON
PENTAGASTRIN-STIMULATED GASTRIC ACID SECRETION UP
TO 3 HOURS POST INFUSION
3.2.1Materials and Methods
3 healthy volunteers (2 female, 1 male), median age
29 (range 28-30) were studied after an overnight fast.
The experimental study method was similar to that
described in Chapter 2 for the original study. In
summary, separate intraduodenal and intragastric tubes
were passed under radiological control into the second
part of the duodenum and body of stomach respectively.
Following a 30 minute eguilibration period (time 0-30
mins), each volunteer was commenced on an IV infusion of
pentagastrin (0.25pg/kg/hr) to produce submaximal gastric
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secretion. Gastric aspiration was then applied
continuously for 60 minutes (time 30-90 mins) with 4x15
minute collections being analysed for volume and aliquots
retained for assay. At time 90 minutes each volunteer
was blindfolded and randomly received either 300ml of
fresh, unclotted autologous venous blood or intraduodenal
intubation alone which was chosen as a control to exclude
any pentagastrin 'fade' or tachyphylaxis. On each study
day 50ml of venous blood was removed from each volunteers
arm every 5 minutes for 25 minutes (total volume removed =
300ml) and either directly infused into the duodenum
(blood study day) or discarded (intubation alone study
day). On the blood study day infusions were given as 6 x
50ml aliquots at 5 minute intervals over 30 minutes.
Following the start of duodenal infusions, a further 12 x
15 minute gastric collections were taken (90-270
minutes). Volumes of each 15 minute sample were measured
and aliquots retained for assay. Intraduodenal blood
infusion or intubation alone were performed in random
order at least one week apart. On each occasion the same
volume of blood was removed.
Corrections were made for pyloroduodenal loss by
infusing a non-absorbable marker, phenol red solution
(1500mg/l) at 12ml/h intragastrically throughout the
study (HOBSLEY & SILEN 1969). Corrections were made for
duodenogastric reflux of duodenal juice by estimating
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sodium concentration of the gastric aspirate (McCLOY
1978). Microscopic blood reflux was quantitated
spectrophotometrically as before.
ANALYSIS
Gastric juice was analysed for H+ concentration
phenol red, sodium and pepsin concentrations using the
methods described in Chapter 2.
Acid output was expressed as total acid output in
mmol/h for each hour before and each hour after duodenal
infusions following correction for pyloroduodenal losses
and duodenogastric reflux. Pepsin output was expressed as




In all 3 volunteers gastric acid output decreased
steadily during each of the 3 hours following
intraduodenal blood infusion compared with the
pre-infusion hour (Fig. 15). The acid output (mmol/h) was
35.5 ± 8.4 (mean ± SEM) in the hour preceding
intraduodenal blood infusion and 25.8 ± 9.2, 24.4 ± 5.6
and 18.4 ± 7.7 one, two and three hours following blood
infusion respectively. Compared with the pre-infusion
hour this represented median inhibition in acid output of






















Pentagastrin-stimulated gastric acid secretion before and
up to three hours following intraduodenal infusion of
blood or intubation alone in 3 healthy volunteers.
Results are given as Mean ± SEM.
infusion respectively. This inhibition was again
accounted for by a reduction in both H+ concentration and
volume of gastric juice.
In contrast with duodenal intubation alone there was
little change in acid output compared with the
pre-infusion hour (Fig.15). The acid output (mmol/h) in
the initial hour was 35.6 ± 8.3 (mean ± SEM) compared with
respective post infusion values of 33.2 ± 7.5, 31.0 ± 7.5
and 30.8 ± 8.7 one, two and three hours later. Compared
with the pre-infusion hour this represented a median
increase in acid output of 12% one hour later and median
acid inhibition of 5% and 12% respectively, two and three
hours after infusion.
No significant pentagastrin 'fade' was therefore seen
up to 4 hours after commencement of pentagastrin
infusions.
b) PEPSIN OUTPUT
In all 3 volunteers pepsin output decreased during
each of the 3 hours following intraduodenal blood infusion
compared with the pre-infusion hour (Fig. 16). Pepsin
output (= mg sigma porcine pepsin) was 117.1 ± 16.8 (mean
± SEM) in the pre-infusion hour and 83.6 ± 2.0, 68.7 ± 7.5
and 85.6 ± 16.2 one, two and three hours after blood
infusion respectively. Compared with the pre-infusion
hour this represented median inhibition in pepsin output





Pepsin output before and up to 3 hours after intraduodenal
infusion of blood or intubation alone in 3 healthy
volunteers. Results are given as Mean ± SEM.
In contrast after intraduodenal intubation alone
there was little overall change in pepsin output (Fig.
16). Pepsin output was 126.5 ± 35.1 in the pre-infusion
hour compared with 123.2 ± 33.5, 78.8 ± 31.3 and 117.1 ±
52.2 one, two and three hours later respectively.
3.3 EFFECT OF SIMULATED INTRADUODENAL HAEMORRHAGE AT 8PM
ON OVERNIGHT GASTRIC SECRETION AND 12 HOURLY
PENTAGASTRIN-STIMULATED ACID AND PEPSIN SECRETION.
In this study the effect of a simulated intraduodenal
bleed at 8.00pm was examined on -
(a) overnight basal nocturnal acid and pepsin secretion
(b) pentagastrin stimulated submaximal acid secretion 12
hours later.
3.3.1Materials and Methods
6 healthy male volunteers, median age 28 years (range
25-30) were studied in a single-blind controlled,
randomised fashion.
At 8.00pm following a 6 hour fast, a size 7 Fr
intraduodenal tube (Viomedex) was passed oragastrically
and positioned in the second part of the duodenum. The
intraduodenal position in this study was confirmed by
aspiration. When two successive 5ml aspirates had pH > 7
with bile staining the tube was assumed to be within the
duodenum. At 8.30pm (time 0) each volunteer was
blindfolded and randomised to receive either 300ml of
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fresh unclotted autologous venous blood or 300ml
egg-white. Egg-white having similar proportions of
t?
carbohydrate, protein and fat to blood was again chosen as
the control infusion (Table 1). On each occasion 300ml of
venous blood was removed as 50ml aliquots every 5 minutes
for 25 minutes, on the blood study day this was infused
intraduodenally, on the egg-white day it was discarded.
Each infusion was given as 6 x 50ml aliquots over 5 minute
intervals for 30 minutes. Intraduodenal infusions were
administered in random order on separate days at least 1
week apart.
TABLE 1
COMPARATIVE CONSTITUENTS OF BLOOD AND EGG-WHITE *
PROTEIN CHO FAT OSMOLALITY CALCIUM
(g/l00ml) (g/l00ml) (g/l00ml) (mosmol/kg) (mg/l00ml)
EGG-WHITE 10.8 0.1 0 230 6
BLOOD 22.0 0.6 0.6 280 9
*Based on Diem (1962)
a) OVERNIGHT STUDY
At 9.00pm (time 30 minutes) the intraduodenal
tube was withdrawn and a size 8 intragastric tube
(Argyll Ltd) passed oragastrically into the body of
the stomach. Five ml aspirates were withdrawn at
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hourly intervals (9.00pm-8.00am) and analysed for pH
and hydrogen ion concentration. pH was determined
using a combined glass pH electrode (Radiometer ETS
822, Copenhagen) and titratable acidity by
autotitration to pH 7 using 0.1 N sodium hydroxide
(Radiometer ETS 822).
CALCULATIONS
1) Median gastric pH was calculated for each
individual for the periods 10.00pm - 3.00am
(termed night period), 4.00am - 8.00am (termed
morning period) and 10.00pm - 8.00am (termed
overnight period).
2) Median H+ concentrations were calculated for
each individual for the periods 10.00am - 3.00am
(night period), 4.00am - 8.00am (morning period)
and 10.00pm - 8.00am (overnight period).
12 HOURLY SUBMAXIMAL PENTAGASTRIN TEST
At 8.30am (time 12h) the size 8 intragastric
tube was withdrawn and replaced by a size 12 vented
Andersen tube (Andersen Inc, New York). Its position
in the body of the stomach was confirmed by water
recovery test. An IV infusion of pentagastrin
(Peptavlon, ICI) 0.25pg/kg/hr was then commenced and
continued throughout the study to stimulate
submaximal gastric secretion. Following a 30 minute
eguilibration period the stomach was emptied by
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aspiration and the contents discarded. Four fifteen
minute collections of gastric juice were then
obtained by continuous aspiration, their volumes
noted and a 5ml aliquot retained for analysis.
Corrections were made for pyloroduodenal loss by
infusing phenol red solution (1500mg/l) as a
non-absorbable marker intragastrically at 12ml/h
throughout the study (HOBSLEY & SILEN 1969).
Duodenogastric reflux was calculated by estimating
the sodium concentration of the gastric aspirate
(McCLOY 1978).
A summary of this study's protocol is shown in Figure 17.
ANALYSIS
Gastric secretion
Samples were analysed for H+, pH, pepsin and phenol
red concentration as before. Acid output (mmol/h) and
pepsin output (mg/h) were calculated as the total output
in the hour following the start of pentagastrin infusions.
Statistical analysis
Statistical analysis was performed using the 2 sided
Wilcoxon Signed Rank Sum Test for paired data. The
significance level was taken at 5% (p < 0.05)
This study was approved by the local hospital Ethical










FIGURE17Studymethodforinvestigati nfdura iohibitoryresponseollowi gsimulated intraduodenalhaemorrhagen6v lunteers.
3.3.2Results
a) OVERNIGHT STUDY
Median gastric pH was increased following
intraduodenal blood infusion during the night period,
the morning period and the total overnight period
when compared to the values found during eguivalent
time periods after egg-white infusion (Table 2). The
integrated median pH curves demonstrated the extent
and duration of the intragastric pH rise after
intraduodenal blood compared with egg-white infusion
(Fig.18).
TABLE 2 MEDIAN INTRAGASTRIC pH VALUES FOLLOWING
INTRADUODENAL BLOOD AND EGG-WHITE INFUSION
TIME (hours)
NIGHT PERIOD MORNING PERIOD OVERNIGHT PERIOD
(2200-0300) (0400-0800) (2200-0800)
BLOOD 3.5 (2.9-5.8) 6.2 (2.3-7.3) 4.0 (2.3-7.3)
(n = 6)
EGG-WHITE 1.6 (1.4-2.2) 2.0 (1.6-4.3) 1.6 (1.4-4.3)
(n = 6)
p < 0.03 p < 0.04 p < 0.03
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Effect of intraduodenal blood and egg-white infusion on
median overnight gastric aspirate pH in 6 volunteers
Hydrogen ion concentrations of the aspirated
gastric juice were lower after intraduodenal blood
infusion for the night and overnight periods when
compared with eguivalent time periods after egg-white
infusion (Table 3).
TABLE 3 MEDIAN H+ CONCENTRATIONS (mmol/l) FOLLOWING
INTRADUODENAL BLOOD AND EGG-WHITE INFUSION
TIME (hours)
NIGHT PERIOD MORNING PERIOD OVERNIGHT PERIOD
(2200-0300) (0400-0800) (2200-0800)
BLOOD 40.3 (19-49) 20.8 (2-28) 28.3 (2-49)
(n = 6)
EGG-WHITE 45.8 (38-57) 23.7 (15-42) 39.8 (15-57)
(n = 6)
p < 0.05 NS p < 0.02
b) 12 HOURLY SUBMAXIMAL PENTAGASTRIN TEST
Gastric acid output decreased in each of the six
volunteers 12 hours after the last intraduodenal
blood infusion when compared to the acid output 12
hours after egg-white infusion (Fig.19). Mean acid
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FIGURE 19
Submaximal pentagastrin-stimulated acid secretion 12 hours
after intraduodenal blood and egg-white infusion in 6
healthy volunteers.
output (mmol/h) was 19.7 ± 2.4 (mean ± SEM) 12 hours
after blood infusion and 23.7 ± 3.8 after egg-white
infusion (p < 0.05). This represented a mean
inhibition in acid output of 14% 12 hours after
intraduodenal blood infusion compared with acid
outputs found after egg-white infusion.
Pepsin output (= mg sigma porcine pepsin) was
also decreased 12 hours after intraduodenal blood
infusion when compared to the output 12 hours after
egg-white infusion (Table 4). Mean pepsin output
was 57.4 ± 15.9 (mean ± SEM) 12 hours after
intraduodenal blood infusion and 91.2 ± 14.0 after
egg-white infusion (p < 0.05). This represented a
median reduction in pepsin output of 37% 12 hours
after intraduodenal blood infusion compared with the
pepsin output found after egg-white infusion. The
inhibition of pepsin output seen after blood infusion
was again accounted for by a reduction in both volume
and concentration of pepsin secretion.
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TABLE 4 PEPSIN OUTPUT (mg/h) IN 6 VOLUNTEERS 12 HOURS
AFTER INTRADUODENAL BLOOD AND EGG-WHITE INFUSION
VOLUNTEER EGG-WHITE BLOOD
A 59 . 7 7.4
B 70.7 37.3
C 151 .0 116.0
D 70 . 7 51 .2
E 83.9 89 . 3
F 111.3 43.3




These studies have shown that intraduodenal blood
infusion inhibits pentagastrin stimulated acid and pepsin
secretion progressively up to 3 hours following infusion
and this inhibition, although less marked, is still
present 12 hours later. In addition, intraduodenal blood
infusion at 8.00pm increases overnight (10.00pm-8.00am)
intragastric pH suggesting continued inhibition of basal
secretion over this period.
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Although the inhibition of gastric acid and pepsin
secretion demonstrated in my initial study following
simulated intraduodenal haemorrhage may indicate a locally
protective physiological mechanism any benefit in clinical
upper GI bleeding will depend on both the magnitude and
duration of the inhibitory response. This study has
shown a progressive inhibition of pentagastrin-stimulated
acid secretion up to 41% 3 hours following blood infusion
compared with pre-infusion values. The volume of infused
blood used in this study to simulate intraduodenal
haemorrhage still represents a small volume in terms of
clinically significant upper GI bleeding. It is possible
therefore the changes may be even more marked following
larger bleeds. In addition, the absence of any decline in
pentagastrin-stimulated gastric secretion over the four
hours of infusion in the control study adds further
evidence to the lack of demonstrable pentagastrin fade in
human studies (CHIN et al 1986).
Although the exact duration of these acid inhibitory
responses to simulated intraduodenal haemorrhage has not
been clearly defined, the effect appears to persist for at
least twelve hours with a maximum response reached between
three to twelve hours after the 'bleed'. Continuing acid
and pepsin inhibition for such a period of time may
increase intragastric pH allowing coagulation to return to
normal with stabilisation of platelet aggregates and
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thrombus formation. Clot stabilisation by fibrin
deposition may then provide a protective haemostatic plug
thereby reducing the risk of rebleeding.
The prolonged duration of this acid inhibitory
response up to 12 hours following blood infusion is
interesting. Such inhibition of gastric acid secretion
is unlikely to be neurally mediated and if hormonally
mediated suggests that either the circulating hormone has
a prolonged duration of action or that the hormone release
continues long after blood loss into the gut. GIP, a
possible mediator of these responses discussed in Chapter
2, has a relatively long half life, around 20 minutes,
with a low metabolic clearance rate of 2.6mh/kg (KHALIL et
al 1987). Neurotensin, another 'candidate' hormone has a
shorter half life of 3.8min (BLACKBURN et al 1980b)
although being a terminal ileal gut peptide is released
much later than GIP after duodenal instillation. There is
now also increasing evidence that colonic release of
inhibitory peptides may be important in control of gastric
secretion (SOON-SHIONG et al 1980; LLUIS & THOMPSON
1988). It is interesting to speculate that in GI bleeding
luminal blood traversing the GI tract may sequentially
activate inhibitory GI hormones resulting in prolonged
gastric secretory inhibition.
In conclusion, this study has added further evidence
that intraduodenal blood infusion inhibits gastric acid
and pepsin secretion, the process appears progressive up
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to 3 hours following infusion and persists up to 12 hours
later. These inhibitory effects may have important
clinical relevance in initiating a prolonged locally
protective physiological response in upper GI bleeding.
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CHAPTER 4




My initial study showed a significant reduction in
gastric acid and pepsin secretion and gastric motility
following simulated intraduodenal haemorrhage which may
represent a protective physiological response to promote
haemostasis. A recent study by Blair has suggested that
upper GI bleeding may induce a hypercoagulable state
which may also act in a protective manner to facilitate
haemostasis (BLAIR et al 1987). It is not clear however
whether this hypercoagulable response simply reflected a
systemic response to haemorrhage or whether the effect
was unigue to GI bleeding suggesting a luminally
activated mechanism.
This study was therefore performed to examine the
effects of simulated intraduodenal haemorrhage on blood
coagulation parameters in healthy volunteers.
4.2 MATERIALS AND METHODS
Seven healthy volunteers (6 female, 1 male) with a
median age of 29 years (range 25-36) were studied in a
single blind controlled fashion.
The experimental design was identical to my original
method as described in Chapter 2. In summary, a size 8
duodenal tube (Viomedex Ltd) was passed under fluoroscopic
control into the second part of the duodenum allowing
infusion of either 160ml autologous venous blood or 160ml
egg-white (similar protein and carbohydrate content to
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blood). Each infusion was given as 4 x 40ml aliquots over
5 minute intervals in randomised order at least 1 week
apart. On each occasion the same volume of blood was
removed (160ml). Ten ml aliquots of venous blood were
collected for coagulation studies at time 0 min,
immediately prior to intraduodenal infusion at 90 min and
one hour following the start of infusions at 150 mins. At
each time period the following were measured.
1) prothrombin time
2) partial thromboplastin time
3) thrombin time.
Statistical Analysis
Paired samples for each individual were compared for
equivalent time periods after intraduodenal blood and
egg-white infusion using the Wilcoxon Signed Rank Sum test
(2 sided). Significance was taken as p < 0.05.
4.3. RESULTS
The prothrombin time (PT) was similar on each study
day before intraduodenal infusions at 0 and 90 mins (Table
5). Sixty minutes following intraduodenal infusions at
time 150 mins the PT (mean ± sem) was 15.0 ± 0.5
(seconds) following blood infusion and 14.9 ± 0.3
following egg-white infusion (p = NS).
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± 0.5 15.0 ±
±0.5 14.9 ±
Mean ± SEM
0.5 15.0 ± 0.5
0.3 14.9 ± 0.3
Partial thromboplastin time (PTT) was also similar
before intraduodenal infusions on each study day at 0 and
90 minutes (Table 6). Sixty minutes following
intraduodenal infusions at time 150 mins, the PTT
(seconds) was 45.5 ± 2.4 after blood infusion and was
similar at 39.3 ± 1.0 (mean ± sem) following egg-white
infusion (p = NS).
TABLE 6 PARTIAL THROMBOPLASTIN TIME (sees)
TIME (min)
0 90 150
BLOOD (n=7) 45.4 ± 1.3 42.6 ± 1.7 45.5 ± 2.4




Thrombin time (TT) was similar before intraduodenal
infusions in both study groups at 0 and 90 mins (Table
7). Sixty minutes after intraduodenal infusions at 150
min TT (seconds) was 9.3 ± 0.3 (mean ± sem) following
blood infusion and 9.3 ± 0.6 after egg-white infusion (p =
NS) .
TABLE 7 THROMBIN TIME (sees)
TIME (min)
0 90 150
BLOOD (n=7) 9.3±0.2 9.3±0.4 9.3±0.3




This study has demonstrated that simulated
intraduodenal haemorrhage has no effect on blood
coagulation as measured by the prothrombin time, partial
thromboplastin time or thrombin time. This preliminary
study suggests the hypercoagulation demonstrated by Blair
et al following upper GI haemorrhage may represent a
general response to haemorrhage rather than a specific GI
mediated event.
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There are certain important limitations however in
attempting to devise an experimental model of upper GI
haemorrhage in healthy volunteers to investigate changes
in coagulation parameters. Firstly, when considering a
possible GI mediated response, the volume of intraduodenal
blood infusion may be important. In this study we
examined the effect of only 160ml of intraduodenal blood
infusion on coagulation parameters. Considerably larger
volumes of blood are lost into the gut lumen in clinical
upper GI haemorrhage, therefore GI mediated changes in
systemic blood coagulation may still occur with larger
volumes of blood loss. Secondly, the time period
following GI haemorrhage may be important when considering
a hypercoagulable response. Blair et al examined
coagulation parameters within 24 hours of presentation
with upper GI bleeding. In this study, blood coagulation
was examined only one hour following blood infusion. It
is therefore possible that coagulation changes may require
a longer period to develop.
Although the parameters of blood coagulation measured
in this study did not change after simulated duodenal
haemorrhage, it is possible that more sensitive indicators
of hypercoagulation may have detected alterations.
In conclusion, intraduodenal infusion of blood
produced no alterations in blood coagulation as measured
by PT, PTT and TT in seven healthy volunteers.
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One of the initial lines of defence against
continuing intragastric haemorrhage may be the endogenous
buffer system present in the stomach. Intraluminal blood
itself is probably one of the most important early buffers
providing a more physiological pH locally at the bleeding
site allowing haemostasis to occur. As blood coagulation
is particularly sensitive to alterations in pH, being
abolished at pH < 5.4 (GREEN et al 1978) it is important
to confirm the exact buffering capabilities of blood in
gastric juice. A series of in-vitro experiments was
therefore designed to determine the buffering capacity of
blood in gastric juice.
5.2 METHODS
Gastric juice was collected and pooled from duodenal
ulcer patients undergoing pentagastrin stimulated
(Peptavlon, ICI 6pg/kg) acid secretory studies. A 5ml
aliguot of this fresh gastric juice was then taken for
estimation of pH (Radiometer Glass Electrode ETS 822,
Radiometer, Copenhagen) and hydrogen ion activity by
titration to pH 7 with 0.1M sodium hydroxide using an
autotitrator (Radiometer ETS 822). Further 5 ml aliquots
of this gastric juice were then removed, added to a glass
beaker and maintained at 37 degrees Centigrade. To each
5ml gastric juice sample was then added increasing volumes
of fresh unclotted human venous blood from 0ml up to 10ml
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in 0.5ml increments. Each sample was stirred and the
final volume kept constant at 15ml by the addition of
distilled water. A 5ml aliquot of each sample was then
taken after mixing for estimation of pH and hydrogen ion
activity. Ten studies were performed on separate days
with pentagastrin-stimulated gastric juice of varying pH
and hydrogen ion activity from duodenal ulcer subjects.
All venous blood samples were taken from healthy
volunteers and were of equivalent haemoglobin
concentration and pH.
As a control experiment the buffering effect of raw
egg-white (which has approximately similar protein and
carbohydrate content to blood) on gastric juice was
studied in identical fashion in 9 separate studies. The
egg-white used was obtained from a similar batch of eggs
from a single chicken strain. Egg-white protein does not
differ widely between identical strain chickens (PARKINSON
1966).
Analysis
Results were expressed as pH and hydrogen ion
concentration. For each sample the added blood or
egg-white volume was expressed as a percentage of the
gastric juice volume (total = 5ml) and called % blood or %
egg-white volume respectively.
Comparisons between blood and egg-white groups were
made using the unpaired Student's T test. Significance
was taken at the 5% level (p < 0.05)
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5.3 RESULTS
The addition of increasing volumes of venous blood to
a fixed volume of gastric juice increased the pH
progressively (Fig.20). After 4mls of blood the median
pH of the blood/gastric juice mixture was increased from
1.9 to 5.9 (range 4.4-6.2). The addition of further
volumes of blood however, had only a minor effect on the
pH of the gastric juice with a median pH of 6.3 (range
5.9-6.7) being reached after 1Omls blood. The combination
of increasing volumes of egg-white with gastric juice
resulted in a slower rise in pH compared with the
blood:gastric juice mixture (Fig. 20). This resulted in a
significant decrease in the buffering capacity of
egg-white compared with blood after the addition of 1,
1.5, 2.0 and 2.5mls of their respective solutions to the
fixed volume of gastric juice (Fig. 20).
The addition of increasing volumes of either blood or
egg-white had no significant effect on the titratable
acidity of gastric juice (Fig.21).
5.4 DISCUSSION
These results have shown that blood may act as an
endogenous buffer in the presence of gastric juice
however a near equivalent volume of blood:gastric juice
was required to raise the pH well above 5.4 where
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FIGURE 20
The buffering effects of increasing volumes of blood and
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FIGURE 21
The effect of increasing volumes of blood or egg-white on
the titratable acidity of gastric juice. Values are given
as Means.
buffering capacity of blood was slightly greater than that
of egg-white which was used as control having a similar
protein content.
The titratable acidity of gastric juice being the sum
of free hydrogen ion concentration and unionised hydrogen
concentration as expected did not show any marked change
following the addition of either buffering agent (BARON
1978).
There are several endogenous buffering systems
present in the upper GI tract which may be activated
during haemorrhage. Firstly intraluminal blood which
acts locally both at the mucosal bleeding site and
throughout the stomach; secondly,the non-parietal
alkaline component of gastric juice (HOLLANDER 1952);
thirdly, gastric mucus which, being a glycoprotein, may
buffer acid and protect against peptic erosion (BODI et
al 1956) and whose production may be stimulated by
contact with gastric acid (HENNING 1949; JANOWITZ &
HOLLANDER 1954); and fourthly, tissue proteins exposed by
a mucosal breach may also add to the local buffering
capacity. Intragastric blood is probably the most
important early buffering system providing initial
protection against continuing acid/pepsin attack. These
studies have shown however that the relative volumes of
blood:gastric juice are important in determining the
overall buffered pH with a ratio of >1 being required to
raise the combined pH above 6.0 where coagulation may
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proceed. In the clinical situation upper GI bleeding may
occur in both the fasting and stimulated stomach where
gastric juice volumes vary considerably. It seems likely
therefore that this buffering capability of intragastric
blood represents only a transient defence mechanism
allowing initial haemostasis to occur prior to possibly
more effective protective mechanisms.
The important buffering agents in blood are
bicarbonate, haemoglobin, plasma proteins and phosphates
(BAGGOT 1982). Intracellular proteins, phosphate and
other inorganic compounds are also important buffers which
may be released by cell lysis on contact with gastric
juice. Deoxygenated haemoglobin is a weaker acid in the
reduced form and therefore venous blood is a slightly
better buffer than arterial blood (LINTON 1984). Peptic
ulcer bleeding is usually arterial in nature and therefore
its intrinsic buffering capacity may be slightly poorer
than shown in these in vitro studies. Although there are
high concentrations of these buffers in blood, the
buffering power of a system depends not only on the
buffer's concentration but also on the pH at which it is
working (GANONG 1977). Intragastric pH lies normally
between 1-2 (McLAUCHLAN et al 1988), well below the
optimum working pH of the blood's buffers. The pK of
venous blood which is equivalent to the optimum pH for
each of these buffers lies between 6.2 - 7.4 (BAGGOT
1982). Egg-white consists essentially of an aqueous
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solution of proteins - ovalbumin, conalbumin and
ovomucoid, which are all glycoproteins and have a similar
pK (PARKINSON 1966).
From these in-vitro experiments despite the low pH in
the stomach, intragastric blood should act, at least
initially, as a buffer raising the local mucosal pH and
allowing coagulation to occur. As bleeding stops
however local buffering power is diminished, with
continuing acid/peptic activity local mucosal pH may
again fall, coagulation is disrupted and rebleeding may
occur. Clearly these endogenous buffering systems are
not the only line of defence as this cycle of
bleeding/cessation of bleeding occurs in only a small
percentage of patients. It may be that the presence of
intragastric blood as in the intraduodenal bleeding
studies also initiates protective effects on acid/pepsin
secretion and/or gastric motility which may facilitate
haemostasis.
In conclusion blood acts as a buffering agent in
gastric juice, but requires an equivalent volume of
blood:gastric juice to raise the pH above 5.4 where
coagulation may be initiated. This may represent the
first line of defence against continuing acid/pepsin
attack and haemorrhage, however it is likely that other




EFFECT OF SIMULATED INTRAGASTRIC HAEMORRHAGE ON GASTRIC




Initial experimental studies in normal volunteers
have demonstrated that simulated duodenal haemorrhage
inhibits acid and pepsin secretion and delays gastric
emptying, responses which may facilitate haemostasis in
the adverse environment of the upper GI tract. It is
common in upper GI bleeding however, for blood to be found
in the stomach either indirectly from an oesophageal or
duodenal source, or directly from a gastric lesion.
Intragastric blood constitutes a concentrated protein meal
which would be expected to stimulate gastric secretion by
both neural and hormonal mechanisms (BEAUMONT 1833;
WOODWARD et al 1954; GROSSMAN 1967) and possibly overcome
any protective responses induced by duodenal blood. It is
important therefore to establish the effects of
intragastric blood on gastric secretory and motility
parameters to determine whether similar protective
responses occur. The aim of this study was therefore to
determine the effects of simulated intragastric
haemorrhage on gastric acid secretion, gastric emptying
and serum gastrin.
6.2 MATERIALS AND METHODS
Gastric Secretion and Motility Study
The effect of simulated intragastric haemorrhage on
acid secretion and motility was studied in six healthy
male volunteers (median age 29 years, range 28-36).
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Following an overnight (12 hrs) fast a size 10 vented
nasogastric tube (Andersen Inc, New York) was passed
perorally into the body of the stomach and its position
confirmed by water recovery test (HASSAN and HOBSLEY
1970). At time -30min continuous nasogastric suction was
commenced and two basal gastric collections were taken at
15 min intervals, the volume of each noted and a 5ml
aliguot retained for analysis. At time -10min each
volunteer was blindfolded and 160ml venous blood removed
in 4 x 40ml heparinised syringes (250u sodium heparin/40ml
syringe) at 2 minute intervals. Volunteers were then
randomised to receive intragastrically either 160ml of
autologous heparinised venous blood or 160ml egg-white
acting as control having similar nutrient content pH and
osmolarity (ROMANOFF and ROMANOFF 1949). At time 0 mins
the blood or egg-white were delivered intragastrically as
4x40ml aliguots at 1min intervals, each aliquot having 5ml
14C-polyethylene glycol (PEG) (Amersham International)
added acting as a non-absorbable marker. A 5ml aliquot of
this test meal mixture was retained for 14C-PEG assay.
The total dose of 14C-PEG infused into the stomach was
equivalent to 0.9MBq. Immediately after the last aliquot
of blood or egg-white was given the intragastric contents
were mixed and a 10ml aliquot retained for analysis. The
gastric contents continued to be mixed at regular
intervals and a further 10ml aliquot was removed at 1Omin
for analysis. At 20min the stomach was emptied
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completely, the volume noted and a 10ml aliquot retained
for analysis. After this, the stomach was then lavaged
with 100ml distilled water, the residual volume recorded
(wash volume) and a 10ml sample retained for analysis.
Each subject underwent an identical study with the
alternate intragastric infusate at least 1 week later. On
each occasion the same volume of blood was removed, on
egg-white infusion days this was discarded.
Gastrin Studies
Serial blood samples were taken before and after
intragastric infusions to investigate changes in gastrin
secretion. Three 10ml samples of venous blood were
removed at 15min intervals during the basal collection
period and added to heparinised tubes at times -30, -15,
and 0 minutes. After intragastric infusions further
venous blood samples were taken at 15min intervals until
time 60min with the final sample taken 90min after the
start of the infusions. All heparinised venous blood
samples were immediately centrifuged, the plasma removed




Gastric juice was analysed for:
1. Hydrogen ion concentration by automatic titration to
pH 7.0 with 100mmol/l sodium hydroxide using an
Autotitrator (Radiometer, ETS 822, Copenhagen).
2. 14C-PEG radioassay was measured by liquid
scintillation counting (Packard Tri-Carb 300,
Canberra Packard, Berks). Aliquots (0.2ml) of each
gastric sample were initially added to a solubiliser
solution Soluene 350 (Canberra Packard) and
150-propyl alcohol in a 1:2 volume ratio. After
overnight incubation to allow complete
solubilisation, 0.5ml hydrogen peroxide solution was
added and samples incubated at 40 degrees Centigrade
for a further 30 minutes. At this stage, 10ml
Hionic Fluor Scintillator (Canberra Packard) was then
added and counted for 10 minutes under 14C conditions
with an inbuilt quench correction.
Gastrin
The gastrin assay was performed by radioimmunoassay
(appendix) using antibody R98 which has a lower limit of
detection of 5ng/l (ARDILL 1973). The gastrin estimations
were all performed in a single batch.
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CALCULATIONS
Gastric secretion and motility
a) Basal acid output (mmol/h) was calculated by summing
the outputs during the two 15 minute basal collection
periods and multiplying by two.
b) To calculate net gastric secretion and transpyloric
loss of gastric contents the method of Hunt (1951)
was employed. The following symbols have been
used:
V1 = volume of test meal instilled
V2 = volume aspirated after 20 min
V3 = wash volume
Vp = volume discharged through the pylorus in
20min
Vs = volume secreted in 20min (this represents
the resultant of the volume of gastric
secretions plus the volume of contaminant
secretions i.e. saliva, duodeno-gastric
reflux, minus the volume of water absorbed
from the stomach)
PEG1 = PEG concentration in test meal
PEG2 = PEG concentration in aspirate at 1Omin
PEG3 = PEG concentration in aspirate at 20min
PEG4 = PEG concentration in wash
C1 = H+ concentration in test meal
C2 = H+ concentration in aspirate at 1Omin
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C3 = H+ concentration at 20min
The following equations were then used to calculate
net fluxes and volume changes.
1) Residual Volume (Vr) = V3 (PEG4/PEG3)
2) Corrected volume recovered from stomach (Vc) =
V2 + Vr
3) Vp = (V1 PEG1 - Vc PEG3)/PEG2
4) Vs = Vc + Vp - V1
5) Net secretion of H+ = (Vc. C3 + Vp. C2 - V1. C1)
A positive net flux denotes secretion into the
gastric lumen. The delivery of acid into the
duodenum (Hp) was calculated as follows:
Hp = Vp (H1 + H2)/2
where H1 = acid concentration in the instillate and
H2 = acid concentration in the aspirate.
Gastrin
Fasting gastrin values were expressed as the mean of
the 3 pre-infusion samples at -30, -15 and 0 minutes. The
integrated response to intragastric blood and egg-white
was calculated for each individual by estimating the area
under the plasma gastrin/time curve using the trapezoid
method (YEH and KWAN 1978).
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Statistical Analysis
Results are given as mean ± standard error of the
mean (SEM). Statistical analysis was performed using the
paired Wilcoxon Signed Rank Test (2 sided). Results were
considered significant when p < 0.05.
Written, fully informed consent was obtained in each





The mean basal acid output (mmol/hr) prior to
infusions was 5.9 ± 2.6 on the blood infusion day and
4.7 ± 1.9 on the egg-white infusion day (p = NS) .
b) Acid concentration:
The concentration of acid (mmol/l) aspirated from the
stomach after 20 minutes was 40.4 ± 9.9 (mean ± SEM)
after egg-white infusion and 16.6 ± 7.2 after blood
infusion (p < 0.05) (Table 8).
c) Volume secreted (Vs):
There was an increase in secretion rates (ml/20min)
following intragastric egg-white infusion being 198.2
± 68.6 compared with 36.1 ± 13.3 after intragastric
blood infusion (p < 0.05) (Table 9).
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d) Net acid secretion:
There was a positive net flux of acid (net secretion
of acid) in all six volunteers following both
egg-white and blood infusion. Net acid secretion
(mmol/20min) however, was less following intragastric
blood infusion being 2.3 ± 1.3 compared with 5.6 ±
3.1 after egg-white infusion (p < 0.05) (Table 8).
e) Acid delivery into the duodenum (Hp):
The acid load (mmol/20min) delivered into the
duodenum was less following intragastric blood
infusion being 1.1 ± 0.6 compared with 7.2 ± 2.6
after egg-white infusion (p < 0.03) (Table 8).
Gastric Emptying
a) Corrected residual volume (Vc):
The corrected residual gastric volume (ml) at 20min
was 57.4 ± 10.3 following intragastric egg-white
infusion and 102.4 ± 15.3 after blood infusion (p =
0.07) (Table 9).
b) Volume emptied through the pylorus (Vp)
The volume (ml/20min) emptied from the stomach was
less following intragastric blood infusion being 105
± 28.5 compared with 320.8 ± 66.2. after intragastric
egg-white infusion (p < 0.03) (Table 9).
74
TABLE 8 GASTRIC SECRETORY PARAMETERS AFTER
INTRAGASTRIC BLOOD AND EGG-WHITE IN
6 VOLUNTEERS
ACID CONC NET H+ SEC Hp
SUBJECT (mmol/1) (mmol/20min) (nunol/20min)
NO Eqq-white Blood Eqq—white Blood Eqq-white Blood
1 20.8 16.1 2.0 0.6 3.5 1 .6
2 66. 3 4.9 5.0 0 . 5 8.3 0 . 2
3 59.6 48.5 20.9 8.3 19.0 3.6
4 50.7 2.4 1 .2 0 . 3 6.7 0.0
5 42 . 2 23.9 4 . 2 3.8 5.4 0.8
6 2.8 3.6 0.2 0.3 0.3 0.2
Mean 40 . 4 16.6 5 . 6 2.3 7.2 1 .1
SEM 9.9 7.2 3.1 1 .3 2.6 0 . 6
p < 0. 05 P < 0. 05 p < 0. 03
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TABLE 9 GASTRIC SECRETION AND VOLUME CHANGES AFTER
INTRAGASTRIC BLOOD AND EGG-WHITE IN 6 VOLUNTEERS
Vc Vp Vs
SUBJECT (ml) (ml/20min) (ml/20min)
NO Eaa-white Blood Eqg-white Blood Eqq-white Blood
1 94.2 37.3 334.0 204.9 248.3 62.2
2 35 . 0 107.5 250.2 94.2 105.2 21 .6
3 60.9 119.4 637.0 148.6 518.0 87 .9
4 23.3 124.8 265.9 2.6 109.2 52.6
5 61 .4 142.6 255.2 63.9 136.6 26.5
6 69.4 83.0 182.7 115.5 72.0 18.5
Mean 57 . 4 102.4 320.8 105.0 198.2 36.1
SEM 10.3 15.3 66.2 28.5 68.6 13.3
p = 0 .07 P < 0.03 P < 0.03
Correlation between rate of emptying and rate of secretion
There was a significant positive correlation between
the volume emptied through the pylorus (Vp) and net acid
secretion over 20min following intragastric egg-white
infusion (r = 0.94; p < 0.01) but not after blood infusion
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Plasma gastrin concentrations before and after intra¬
gastric infusion of blood and egg-white in 6 healthy




Integrated gastrin response after intragastric blood and
egg-white infusion in 6 healthy volunteers.
positive correlation between the Vp and the volume
secreted into the stomach over 20 minutes (Vs) after both
intragastric egg-white infusion (r = 0.99; p < 0.001) and
blood infusion (r = 0.86; p < 0.03).
Gastrin
Fasting serum gastrin concentrations (ng/l) were 47.8
± 7.9 prior to intragastric blood infusion and 47.5 ± 7.8
prior to egg-white infusion (p > 0.1) (Fig.22). Gastrin
concentrations (ng/l) increased significantly above
fasting values 15 minutes after intragastric egg-white
infusion at 71.7 ± 15.0 and 30 minutes after blood
infusion being 63.3 ± 9.3 (Fig.22). Gastrin
concentrations were significantly increased after
egg-white compared with blood 15 minutes after the
commencement of infusions (p < 0.05) (Fig.22). Integrated
gastrin response (ng/l/min), however, was similar after
intragastric blood infusion being 4558.4 ± 685.1 compared
with 4656.2 ± 981.2 after egg-white infusion (Fig.23).
6.4 DISCUSSION
This study has demonstrated that intragastric blood
infusion stimulates significantly less acid secretion and
delays gastric emptying compared with an equivalent
protein meal. In contrast there were no differences in the
integrated serum gastrin response following either
intragastric blood or egg-white infusion.
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These results suggest that intragastric blood does
not act as a protein meal and is not therefore a potent
stimulus to acid secretion. In the context of an upper GI
bleed these responses may be beneficial in promoting
haemostasis.
Intragastric protein normally acts as a potent
stimulus to acid secretion (BEAUMONT 1833; SAINT-HILAIRE
1960; ELWIN 1974) and serum gastrin (GROSSMAN 1967;
GANGULI 1970). This stimulatory action of intragastric
protein is initiated by particular amino acids and/or
peptone fragments (IVY and JAVOIS 1925; ELWIN 1974) and is
gastrin-mediated (WALSH et al 1971). Egg-white being
essentially an albumin solution has approximately similar
amino acid content to blood (ROMANOFF and ROMANOFF 1949;
BRAGG and HOUGH 1961; PARKINSON 1966). It is therefore
particularly surprising to demonstrate significantly less
acid secretion after infusion of intragastric blood
compared with egg-white. In this study intragastric blood
induced a median acid secretion of 0.5mmol/20min which was
70% less than that induced by egg-white infusion (median
3.1 mmol/20min).
With intragastric egg-white infusion there was a
significant positive correlation between the volume
emptied into the duodenum and the rate of acid secretion.
The mechanism underlying this correlation is not clear
however evidence exists that intraduodenal protein may
stimulate acid secretion (SIRCUS 1953; ISENBERG et al
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1977) and intraduodenal acid has also been shown in
duodenal ulcer subjects to stimulate acid secretion
(SAUNDERS et al 1975). The absence of any correlation
between the volume of intragastric blood emptied into the
duodenum and acid secretion is interesting. On the basis
of my previous experiments I had expected that duodenal
blood would inhibit gastric acid secretion and therefore
predicted a negative correlation between these
parameters. In this study, however, the venous blood was
heparinised and stored for a few minutes prior to
intragastric infusion. It is possible therefore that the
duodenal inhibitory response was mediated either through
blood coagulation or some short-lived blood factor which
would explain the failure to demonstrate a correlation.
This may also explain the absence of any overall acid
inhibition after intragastric blood. The practicalities
of this study however, necessitated the use of heparinised
blood.
The differences in secretion rates after intragastric
egg-white and blood cannot be explained on the basis of
differences in gastrin release although gastrin
concentrations were significantly higher after egg-white
infusion compared with blood at a single time point. This
would suggest inhibitory mediation of parietal cell
function either directly or indirectly by inhibition of
gastrin induced acid secretion. Somatostatin is a
candidate inhibitory mediator which suppresses both
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gastrin-stimulated (RAPTIS et al 1975) and food-stimulated
(KONTUREK et al 1976b) acid secretion possibly by a direct
action on the parietal cells (BLOOM et al 1974). Other
possible inhibitory mediators include the hormones of the
secretin group (secretin, glucagon, GIP, VIP) which also
inhibit the action of gastrin on parietal cells possibly
through somatostatin release (CHIBA et al 1980; McINTOSH
et al 1981; WOLFE et al 1983).
The inhibition of gastric emptying noted in this
study following intragastric blood infusion compared with
egg-white infusion is in agreement with the intraduodenal
infusion studies. Known influences on gastric emptying
of a liquid meal include the pH (SHAY and GERSHON-COHEN
1934; VAN LIERE and SLEETH 1940; HUNT and KNOX 1962),
osmolality (McSWINEY and SPURRELL 1933; GERSHON-COHEN et
al 1938; HUNT 1963), nutrient content (WHITE et al 1983;
DOOLEY et al 1984), and volume (HUNT and McDONALD 1954) of
the meal although these parameters were similar in each of
the study groups. Recent evidence suggests that gastric
emptying of a liquid meal may involve alteration of antro-
pyloroduodenal motor activity possibly by stimulation of
duodenal receptors (HOUGHTON et al 1988). Such duodenal
receptors are not simply pH or osmolarity sensors but may
be sensitive to other intraluminal stimuli such as glucose
(MEI 1978). It is interesting to speculate that the
duodenal receptors may also respond to intraluminal blood
or its products to slow gastric emptying possibly mediated
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by inhibitory GI hormones. In the context of upper GI
bleeding reduced gastric motility is likely to be
beneficial by preventing clot dislodgement, decreasing
duodenal acid delivery and gastric blood flow
requirements.
In conclusion, this study has demonstrated that
intragastric blood infusion induces weak gastric acid
secretion and inhibits gastric emptying without alteration
of integrated gastrin response compared with an equivalent
egg-white infusion. This suggests that contrary to
expectations intragastric blood does not behave as a
protein meal, an effect which may represent an additional
protective mechanism in upper GI haemorrhage.
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CHAPTER 7




The inhibition of gastric secretory function seen
after simulated upper GI haemorrhage may represent a
protective physiological response to facilitate
haemostasis although confirmation that these changes occur
in true upper GI haemorrhage is required. This study was
designed to investigate the effect of upper gastro¬
intestinal haemorrhage on intragastric pH in patients with
endoscopic evidence of recent or active haemorrhage.
7.2 PATIENTS AND METHODS
Patients admitted with clinical evidence of upper GI
haemorrhage were routinely endoscoped within 24 hours of
presentation and those with peptic ulcers which were
either actively bleeding (oozing or spurting) or had
stigmata of recent haemorrhage (black/red spots) were
studied. Patients were classified as active haemorrhage
and/or stigmata of recent haemorrhage (SRH) (Group 1). A
group of six normal healthy volunteers acted as the
control group (Group 2).
Following endoscopy a combined glass pH electrode
(Radiometer GK 2802C) was passed perorally into the body
of the stomach and its position confirmed radiologically.
The pH electrode was connected to a Digitrapper MKII
(Synectics Medical) solid state recorder which registers
pH every 4 seconds. The electrodes were calibrated at the
start of each recording period using standard buffers of
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pH 1.07 (Synectics 5002) and 7.02 (Synectics 5001).
Intragastric pH was monitored for 24 hours after the
diagnostic endoscopy (0900-0900). In order to document
intragastric blood which could increase intragastric pH by
its buffering capacity an attempt was made to quantitate
the intragastric blood content in those Group 1 patients
actively bleeding at the time of diagnostic endoscopy.
This was performed by passing a size 8 intragastric tube
(Viomedex Ltd) into the body of the stomach and collecting
5ml gastric aspirates at 2 hourly intervals which were
then stored for estimation of haemoglobin concentration.
All group 1 patients remained fasted and received no
drug therapy during the study period. Group 2 volunteers
were also studied for 24 hours but each received standard
meals (700kcal each) at 12.30h and 17.30h.
Analysis
a) INTRAGASTRIC pH
The intragastric pH data were transferred from the
Digitrapper MKII recorder (Synectics Medical) to an
IBM compatible computer (Amstrad PC1512 HD20) and
analysed using the EsopHogram and Gastrograph
programs (Ver. 5.0, 1987, Gastrosoft Inc). For each
group median pH profiles were created by combining
individual median values at 10 minute intervals
throughout the 24 hour study period using the
StatpHac program (Ver. 2.07, 1987, Gastrosoft Inc).
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Integrated median pH curves were then created for
each study day. In addition for each individual
median pH values were calculated for (a) 0900-2100
termed daytime pH, (b) 2100-0900 termed night-time
pH, and (c) the entire 24 hour study period. This
was facilitated by using a compatible statistical
package for analysis of pH data (StatpHac, ver. 2.07,
1987, Gastrosoft Inc.). Statistical comparisons
between paired data were performed for each of these
study periods using the one-sided Wilcoxon Signed
Rank Sum Test. Significance was taken at the 5%
level (p < 0.05).
b) HAEMOGLOBIN ASSAY
This was performed with a colourimetric method using
the cyanmethaemoglobin technique (Van KAMPEN and
ZIJLSTRA 1961). Standardised dilutions of
haemoglobin (Boehringer Corporation, London) were
used to create a concentration curve. Each treated
gastric sample was then analysed spectro-
photometrically and its haemoglobin concentration
(g/dl) estimated from the standardised curves.
Written fully informed consent was obtained in each




Six patients (5 males, 1 female, median age 56 years
(range 37-68)) with peptic ulcer bleeding were studied
(Group 1). The clinical and endoscopic findings in this
group are shown in Table 10. Four patients from this
group were actively bleeding at time of endoscopy and two
had stigmata of recent haemorrhage (black/red spots).
The controls (Group 2) consisted of six healthy
normal volunteers (3 males, 3 females, median age 33 years
(range 26-56)).
a) Intragastric pH
The integrated pH curve for Group 1 patients
revealed short periods when median pH values were
significantly higher than those of the control Group
2 (Fig. 24). In Group 1 patients median daytime pH
was 3.7 (range 1.2-6.8) and night-time pH 1.8 (range
1.1-7.2). The median daytime pH in Group 2
volunteers was 2.0 (1.7-3.6) and night-time pH 1.5
(1.1-2.3). Overall 24 hour median pH however was 2.8
(range 1.2-6.3) in Group 1 and 1.8 (range 1.6-2.2) in
Group 2 (p = NS). In patients with duodenal ulcer
the overall 24 hour median intragastric pH was 1.8
(range 1.3-2.2) and in gastric ulcers 3.5 (range
1.2-6.3).
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When Group 1 patients actively bleeding at the
time of endoscopy (n=4) were analysed as a separate
group, the median integrated pH curve was
significantly higher over longer time periods
compared with the pH values for equivalent time
periods in the control Group 2 (Fig.25). Each of
these four Group 1 patients exhibited characteristic
individual 24 hour pH curves with prolonged periods
when intragastric pH rose to 7 (Figs 26 & 27). In
contrast Group 1 patients with SRH only exhibited
similar pH curves to Group 2 volunteers with
intragastric pH remaining between 1-2 throughout the
24 hour recording period (Figs 28 & 29).
Haemoglobin Concentrations
None of the 4 patients with active haemorrhage
at time of endoscopy had evidence of frank blood
staining on gastric sampling throughout the 24 hour
study period indicating the absence of continuing or
recurrent haemorrhage during this period. In
addition, haemoglobin concentrations also remained
low throughout the study period (Table 11) at levels
which from my previous in-vitro work (Chapter 5)
could not have altered intragastric pH by buffering
alone.
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TABLE 11 INTRAGASTRIC HAEMOGLOBIN CONCENTRATIONS (g/dl)
IN GROUP 1 PATIENTS ACTIVELY BLEEDING AT TIME
OF ENDOSCOPY
TIME (hours)
PAT 1400 1600 1800 2000 2200 2400 0200 0400 0600 0900
1 0.88 0.42 0.05 0.06 0.33 0.01 0.54 0.33 0.20 0.07
2 0.08 0.06 0.00 0.02 0.02 0.04 0.02 0.11 0.01 0.03
3 0.15 0.05 0.87 0.07 0.00 0.01 0.02 0.04 0.02 0.00
4 0.12 0.20 0.60 0.10 0.15 0.30 0.30 0.20 0.20 0.10
Mean 0.31 0.18 0.38 0.06 0.12 0.09 0.22 0.17 0.11 0.05
SEM 0.19 0.09 0.21 0.02 0.08 0.07 0.12 0.06 0.05 0.02
c) Correlation of Intragastric pH with Hydrogen Ion
Concentration of aspirated Gastric Juice in 2
Patients Actively Bleeding from Peptic Ulcers
In order to further eliminate intragastric blood
clot or duodenogastric reflux as a cause of the high
intragastric pH in patients actively bleeding, 5ml
aliquots of gastric juice were collected in 2 Group 1
patients (1 and 2) at 2 hourly intervals throughout
the 24 hour study period for estimation of hydrogen
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ion activity. Titratable acidity was calculated by
autotitration (Radiometer ETS 822) to pH 7 using 0.1
N sodium hydroxide.
In both patients intragastric contents remained
anacid for 8 hours (Table 12). In patient 1
intragastric acidity increased after 10 hours to 55.6
mmol/1 and remained at high basal acid concentrations
until 6.00am the next day. These concentrations
corresponded well with his intragastric pH recordings
(Fig.26). Patient 2 remained effectively
achlorhydric for the entire 24 hour recording period
(Table 12) again corresponding well with the
intragastric pH recordings (Fig.27).
TABLE 12 TITRATABLE ACIDITY (mmol/l) OF ASPIRATED
GASTRIC JUICE IN 2 PATIENTS WITH ACTIVELY
BLEEDING PEPTIC ULCERS
TIME (hours)
PAT 10am 1224 6 8 10 12 2 4 6am
1.JG 0000 2.4 55.6 77.9 81.9 55.0 33.9 41.3
2.AY 0 0 0 0 0 3.60 2.20 0 0
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7.4 DISCUSSION
This study has demonstrated that in patients actively
bleeding from peptic ulcers there were prolonged periods
during the following 24 hours where intragastric pH was
elevated compared to a healthy control group. Moreover
although these patients were actively bleeding at the time
of endoscopy subseguent regular gastric aspirates
indicated a low concentration of intragastric blood
suggesting the bleeding had stopped and minimising the
possibility of any simple buffering effect. In the
absence of active bleeding however, intragastric pH
remained similar to that of healthy volunteers.
The demonstration of raised intragastric pH often to
neutrality (pH 7) during active peptic ulcer bleeding
suggests a marked inhibition of gastric acid secretion.
This finding is in agreement with the original
demonstration of acid inhibition following simulated
intraduodenal haemorrhage and with Chandler & Watkinson's
observations in clinical upper GI bleeding (CHANDLER and
WATKINSON 1959). The very low levels of intragastric
haemoglobin concentrations throughout the 24 hour
recording period adds further supporting evidence to acid
inhibition rather than a blood buffering effect being the
cause of the observed increase in intragastric pH. In
addition, the demonstration of long periods of
achlorhydria by gastric aspiration makes duodenogastric
reflux less likely as a cause for the periods of high
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intragastric pH, although confirmation of this by
estimation of sodium concentration requires further
study. The absence of hypovolaemic shock in the study
group also excludes the possibility that these changes in
intragastric pH were due to shock induced inhibition of
gastric function (STANNARD et al 1988).
These studies also add further evidence to the
estimated duration of this acid inhibitory effect after
upper GI bleeding. In one patient actively bleeding at
the start of pH recording the intragastric pH was noted to
return to normal values after approximately 12 hours
(Fig.26) while in others it remained elevated up to 24
hours later (Fig.27). This suggests the effect lasts for
up to 12 hours and may persist for at least 24 hours which
is in broad agreement with my experimental studies in
Chapter 3. It may be relevant however that the early
return of normal intragastric pH in patient 1 was followed
by a significant rebleed 60 hours later requiring surgical
intervention. It is interesting to speculate that this
early return of normal intragastric pH may have
represented the loss of the protective acid inhibitory
response and predisposed to rebleeding.
Although the control group used in this study was not
fasted, food has only a short-lived effect on gastric pH
by way of its buffering capacity (McLAUGHLAN et al 1988).
It was felt therefore that the groups were broadly
comparable. In addition, the intragastric pH ranges in
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the volunteer group used in this study were similar to
those demonstrated in duodenal ulcer subjects (BENDTSEN et
al 1987; FULLARTON et al 1988).
A previous study monitored the effects of intravenous
cimetidine and ranitidine on 24 hour intragastric pH in
patients with peptic ulceration admitted with upper GI
bleeding (REYNOLDS et al 1987). In those duodenal ulcer
patients randomised to receive placebo median intragastric
pH was 1.8 (range 1.0-4.9). This study, however, assessed
only patients with SRH and the authors do not comment on
whether any patients were actively bleeding at the time of
endoscopy. Although only one patient in this study
reguired surgery for rebleeding it was of interest to note
that his 24 hour median pH was 1.8 despite ranitidine
therapy. This also suggests that an early return of
normal acidity or a failure of H2 receptor antagonist
therapy to maintain a high intragastric pH may represent
an adverse prognostic sign in peptic ulcer haemorrhage.
In conclusion intragastric pH is elevated in patients
during active peptic ulcer bleeding, an event which occurs
without high concentrations of intragastric blood. This
further suggests that gastric secretory function is
inhibited in the early phase of peptic ulcer haemorrhage
which may represent an early protective mechanism to
facilitate haemostasis and clot stabilisation.
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CHAPTER 8
THE EFFECT OF UPPER GI HAEMORRHAGE ON GI HORMONES
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8.1 INTRODUCTION
My earlier experimental studies have suggested that
the acid and pepsin inhibition and decreased gastric
emptying seen following simulated upper GI haemorrhage may
have been mediated by gastric inhibitory peptide (GIP), a
candidate enterogastrone. This study was therefore
designed to examine the effects of true upper GI
haemorrhage on GI hormones to determine whether similar
changes occur.
8.2 PATIENTS AND METHODS
Eight patients, 6 males, 2 females - median age 74
years (range 69-76), presenting to the Western Infirmary
Haematemesis Management Team with upper GI haemorrhage,
(documented haematemesis and/or melaena) were studied.
All patients were fasted for at least 6 hours before study
and all underwent upper GI endoscopy within 24 hours of
presentation to accurately identify the source of
haemorrhage. Potentially eligible patients for this
study had an identifiable lesion in the upper GI tract
with either active haemorrhage or stigmata of recent
haemorrhage at endoscopy. When a patient was deemed
eligible for study entry 10ml of venous blood was removed
(time 0) from a forearm vein and added to heparinised
tubes. Each sample was then immediately centrifuged, the
plasma removed and stored at -20 degrees Centigrade for
later GI hormone assay. Repeat venous blood samples were
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taken at 4 hourly intervals during the day and at 6 hourly
intervals during the night until time 24 hours. All
patients remained fasted throughout this 24 hour period.
Patients were managed by members of the HMT and 6 received
H2 receptor antagonist therapy (IV Ranitidine 50mg 6
hourly) during the study period. Rebleeding and
requirement for surgery were decided independently by a
member of the HMT who was not involved in the GI hormone
study. The clinical and endoscopic features of the study
group are shown in Table 13.
TABLE 13 CLINICAL AND ENDOSCOPIC FEATURES OF STUDY GROUP
AGE SEX BLEEDING NSAID* SHOCK REBLEED SURG
PAT (Years) (M/F) SOURCE (Y/N) (Y/N) (Y/N) (Y/N)
AH 69 M DU Y N N N
WC 76 M Oesoph.Varices Y N N N
JA 75 M Oes. ulcer N N N N
SM 73 F Gastric Eros. Y N N N
AR 76 M DU N Y N N
AF 76 F Gastric Eros. Y N Y(3/7) N
RC 73 M Varices N N Y(3/7) N
JO 73 M Oes. ulcer N N N N




The following GI hormones with known effects on
gastric secretion and/or motility were studied - GIP,
gastrin, VIP and neurotensin. Each sample was analysed by
individual radio-immunoassay (Appendix) by Professor K.
Buchanan's laboratory, Department of Medicine, Queens
University, Belfast.
Analysis
Individual hormone values for each time period
studied after admission were plotted and compared with the
laboratory's upper limit of normal for fasting patients
(based on mean + 2SD for normal healthy fasting
volunteers). For each patient the median 24 hour GI
hormone concentration was also calculated and termed 24
hour hormone concentration.
8.3 RESULTS
Each patient had a median number of 4 (range 3-5)
samples taken over the first 24 hours of admission with
upper GI bleeding.
1 ) GIP
GIP concentrations were consistently elevated above
the normal range over the 24 hour study period in all
but two samples (Fig.30). The median 24 hour GIP
concentration (ng/1) for the 8 patients ranged from
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FIGURE 30
Plasma GIP concentrations during the 24 hours following
endoscopy in 8 patients admitted with acute upper GI
haemorrhage. Dotted line represents laboratory's upper
limit of normal.
2) Gastrin
All fasting gastrin concentrations were within the
normal range over the 24 hour study period (Fig.31).
The median 24 hour gastrin concentration (ng/l) for
the 8 patients ranged from 10-43 (median 33) compared
with the normal range of 0-100ng/l.
3) Neurotensin
Neurotensin concentrations were consistently within
the normal range over the 24 hour study period
(Fig.32). The median 24 hour neurotensin
concentration (ng/l) for the 8 patients ranged from
10-15 (median 12) compared with the normal range of
0-20ng/1.
4) VIP
All VIP concentrations were within the normal range
over the 24 hour study period (Fig.33). The median
24 hour VIP concentration (ng/l) for the 8 patients
ranged from 10-55 (median 29) compared with the
normal range of 0-100ng/l.
8.4 DISCUSSION
This study has shown that fasting GIP concentrations
are elevated in patients admitted with acute upper
gastrointestinal haemorrhage. This adds further evidence




















Plasma gastrin concentrations during the 24 hours
following endoscopy in 8 patients admitted with acute
upper GI haemorrhage. Dotted line represents laboratory's























Plasma neurotensin concentrations during the 24 hours
following endoscopy in 8 patients admitted with acute
upper GI haemorrhage. Dotted line represents laboratory's














Plasma VIP concentrations during the 24 hours following
endoscopy in 8 patients admitted with acute upper GI
haemorrhage. Dotted line represents laboratory's upper
limit of normal.
concentrations after simulated intraduodenal haemorrhage
suggesting intraluminal blood may act as a stimulus to GIP
secretion.
GIP was originally isolated from an impure
preparation of cholecystokinin which had been shown to
produce less stimulation of acid secretion than a purer
preparation (BROWN and PEDERSON 1970). It was later
purified (BROWN et al 1970) and localised to the duodenum
and jejunum (POLAK et al 1973; BUFFA et al 1975) in
specific endocrine cells classified as K-cells (BUCHAN et
al 1978). Although the known intraduodenal stimuli to GIP
release include glucose (THOMAS et al 1977) fat (LUCEY et
al 1984), amino acids (THOMAS et al 1978) and acid (LE
ROITH et al 1980), the only known physiological effect of
GIP relates to its insulinotropic action (PEDERSON et al
1975; ANDERSEN et al 1978). The enterogastrone effect,
however, remains controversial and incompletely understood
in man (FLATEN 1983) although this effect may be mediated
by gastric somatostatin release (McINTOSH et al 1981).
The specific increase in GIP concentrations seen in
this study after GI bleeding is interesting and may be
relevant to the observed alterations in gastric acid
secretion seen after simulated upper GI haemorrhage and
the increases in gastric pH seen in clinical upper GI
haemorrhage. A non-specific effect of intraluminal blood
is unlikely as the GIP increase was unigue and other
candidate hormones released by the duodenum and jejunum
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remained unaltered. In this study GIP concentrations
remained elevated above normal fasting values for the
entire 24 hour study period suggesting continued release
despite the relatively long plasma half-life of 20 minutes
(SARSON et al 1982). If intraluminal blood, however, acts
as a stimulus to GIP secretion, then continued prolonged
secretion may be expected as all the study patients had
evidence of fresh blood in the upper GI tract at endoscopy
which would persist in the small bowel for at least
several hours. In addition, my previous studies have
suggested that GI motility may be inhibited by
intraluminal blood which may further prolong a luminally
mediated response. The present study, however, was
uncontrolled and confirmation that these increases are
truly specific to upper GI bleeding await further
controlled studies.
In conclusion I have observed specific increases in
GIP concentrations in patients admitted with upper GI
bleeding adding further evidence to suggest intraluminal
blood may be a stimulus to its release.
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CHAPTER 9
PREDICTION OF REBLEEDING IN PEPTIC ULCERS - BY
VISUAL STIGMATA AND ENDOSCOPIC DOPPLER ULTRASOUND CRITERIA
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9.1 INTRODUCTION
The mortality rate of acute upper gastrointestinal
haemorrhage remains at 10% due mainly to rebleeding in an
increasingly elderly population (ALLAN & DYKES 1976;
MORGAN et al 1977; HUNT et al 1979). Early identification
of patients at high risk of rebleeding with subseguent
prompt therapy (endoscopic or surgical) may lead to an
improvement in the rebleeding and mortality rates for
peptic ulcer.
At present the prediction of recurrent haemorrhage
relies on clinical and endoscopic criteria. Clinical
factors based on age or the severity of the presenting
bleed have been used to predict rebleeding and at best may
be correct in 70% of patients (MORGAN et al 1977; MacLEOD
et al 1982; BORNMAN et al 1985). Endoscopic prediction
relies on the diagnosis of visible stigmata of recent
haemorrhage (SRH) (FOSTER et al 1978) and in particular on
the presence of a visible vessel in the ulcer base
(GRIFFITHS et al 1979). There is, however, controversy
over the endoscopic appearances of a visible vessel and
its significance with published rebleeding rates in the
visible vessel group of 32-100% (GRIFFITHS et al 1979;
STOREY et al 1981; MacLEOD and MILLS 1982; WARA 1985). In
addition, rebleeding as a result of a visible vessel,
accounts for a variable proportion (28-95%) of all
rebleeds in published series (GRIFFITHS et al 1979; STOREY
et al 1981). Consideration of both clinical and
1 02
endoscopic features however, may allow better
determination of outcome than either factor alone
(BREARLEY et al 1987a).
There is clearly therefore a need for further
definitive criteria allowing early prediction of
rebleeding and early therapeutic intervention. The aim
of this study was to establish the significance of a
patent arterial vessel in a peptic ulcer base as detected
by transendoscopic Doppler Ultrasound in an attempt to
improve prediction of rebleeding.
9.2 PATIENTS AND METHODS
All patients admitted to the Western Infirmary,
Glasgow with acute upper GI haemorrhage over the 18 month
period of the trial (August 1986-January 1988) were
considered for inclusion. Patients presenting with
haematemesis and/or melaena were routinely endoscoped
within 24 hours of admission by an experienced member of
the Haematemesis Management Team (HMT). Potentially
eligible patients were diagnosed endoscopically to have
a single peptic ulcer in the stomach, pyloric canal or
duodenal cap.
When a patient was recognised to be potentially
eligible for study entry the ulcer was assessed by the
TVD endoscopist (myself). The patient was only deemed
eligible for entry into the study if the following
criteria were also met:
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a) actively bleeding sites on the ulcer before or after
washing and/or
b) a visible vessel in the ulcer base before or after
washing and
c) confirmed accessibility of the TVD probe to the ulcer
site.
Active bleeding was defined as a continuous flow of blood
from the ulcer base continuing for the duration of the
endoscopy. A visible vessel was defined as an elevated
red or blue spot, a pulsatile pseudoaneurysm or active
arterial spurting.
Patients who fulfilled these criteria were then
entered into the study and each ulcer base screened with
the transendoscopic vascular detector probe (TVD-1, outer
diameter 2.5mm, KeyMed Ltd., Southend-On-Sea), using an
Olympus IT10 gastroscope (Olympus Corp, Japan). Five
separate recordings were taken from each ulcer base i.e. 4
at 90 degree intervals around the ulcer periphery and one
in the centre. The output was transmitted through
headphones and a positive signal recorded if an
unequivocal pulsatile sound was heard at a localised area
of the ulcer base, which disappeared on minor movement of
the transducer. Larger deeper vessels such as the aorta
or left gastric artery could also be detected using the
TVD probe although such signals persisted despite minor
probe movement unlike more superficially placed vessels
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(BECKLY and CASEBOW 1986). Each patient's Doppler
information was only available to the TVD endoscopist
(myself) and he took no further part in their management.
Following endoscopy patients were managed by members
of the HMT unaware of the Doppler findings and their
progress documented until discharge or death. Rebleeding
was diagnosed by HMT members if one of the following
features was present.
a) fresh blood in the upper gastrointestinal tract
(UGIT) at re-endoscopy or surgery.
b) vomiting fresh blood at any time other than
immediately after endoscopy where fresh blood had
been noted in the UGIT.
c) fresh melaena plus one of the following:
1. haemodynamic and clinical evidence of hypo-
volaemic shock (systolic BP < 100, pulse
rate > 100).
2. a falling Hb despite blood transfusion.
(Failure to raise Hb by more than 0.5g/dl
per unit of blood transfused).
Surgical intervention for haemostasis was undertaken when
deemed appropriate by the attending HMT surgeon.
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9.3 RESULTS
During the 18 month trial period (August 1986-January
1988) 711 patients presenting with suspected acute upper
gastrointestinal haemorrhage were endoscoped within 24
hours of presentation to the Western Infirmary, Glasgow.
180 (25%) were found to have a peptic ulcer. 124 (69%)
had either no stigmata of recent haemorrhage (SRH) or
minor SRH (flat black/red spots) at the time of
endoscopy. This group was deemed a low risk group in
terms of rebleeding but their progress was also documented
until discharge. In the initial stages of this study ten
patients from this group also underwent TVD assessment.
None of these 124 patients rebled and none of the 10
patients assessed had positive Doppler signals from their
ulcer bases. 56 patients had a single peptic ulcer with
either active haemorrhage or a visible vessel and 22 were
entered into the trial. There were 34 exclusions due
mainly to patient recruitment to a concomitant heater
probe study (Table 14). The clinical and endoscopic
features of the twenty two patients entered into the study
are shown in Tables 15 and 16. Ten had active oozing from
the ulcer base, 9 had visible vessels in the ulcer base
and three had clot resistant to washing. Eight of the 9
visible vessels were not bleeding at the time of
endoscopy, 1 showed non-pulsatile active bleeding.
Overall nine patients (41%) rebled, seven (32%) required
surgery and one died (5%). Of the 9 patients who rebled,
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8 had a visible vessel in the ulcer base giving a
sensitivity for this endoscopic feature of 89%. Only one
patient without a visible vessel (ulcer base oozing)
rebled, giving a specificity for visible vessel rebleeding
of 92%.There were 6 rebleeds from duodenal ulcers (all
postero-inferior in position) and 3 rebleeds from gastric
ulcers (2/3 high lesser curve in position).
Eight of the twenty two patients assessed were
Doppler positive (36%) and of these 7 rebled giving a
sensitivity of 87% (Table 17). Two patients who were
Doppler negative rebled giving a specificity for this
investigation of 12/14 (86%).
When the presence of a visible vessel and a Doppler
positive signal were assessed together to predict
rebleeding the sensitivity was increased to 100% (Table
17). All patients therefore, with an endoscopic visible
vessel and a Doppler positive signal rebled.
TABLE 14 EXCLUSIONS (n = 34)
Entered into heater probe study 20
Inaccessibility 5





TABLE 15 STUDY ENTRY CLINICAL CHARACTERISTICS (n=22)
Age 56.9 ± 4.8
Admission Hb(gdl -1) 10.6 ± 0.6
Shocked on admission 6
(systolic BP < 100,
pulse > 100)
Pre-endoscopy blood 1.6 ± 0.4
transfusion (units
packed cells)
* Mean ± SEM












DOPPLER +ve DOPPLER -ve TOTAL REBLEEDS
CLOT 0/1 (0%) 0/2 (0%) 0/3 (0%)
VISIBLE VESSEL 7/7 (100%) 1/2 (50%) 8/9 (89%)
ACTIVE OOZING 0/0 (0%) 1/10(10%) 1/10(10%)
TOTAL 7/8 (87%)* 2/14(14%) 9/22(41%)
*p < 0.05
9.4 DISCUSSION
This study has demonstrated that the Doppler
ultrasound can predict rebleeding in peptic ulcers with a
similar accuracy to that achieved by endoscopic assessment
of 'high-risk' stigmata of recent haemorrhage (visible
vessel). Moreover, the combination of a visible vessel
and a Doppler positive scan appeared in this study to
further improve prediction of rebleeding.
Major peptic ulcer bleeding is typically from a small
(mean diameter 0.6mm) single submucosal artery just below
the ulcer base which can often be identified
endoscopically as a 'visible vessel' (SWAIN et al 1986a).
Johnston (1984) however, has suggested that the term
'visible vessel' is a misnomer and that the endoscopic
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appearance represents the nipple-like appearance of
protruding clot from the breached vessel with the
underlying artery being invisible. Considering rebleeding
from such vessels the important factors are firstly
whether an artery of significant size is involved in the
ulcer base and secondly whether there is arterial blood
flow in the vessel. In predicting rebleeding therefore,
the ability to diagnose a patent vessel in the ulcer base
may be important.
With the advent of urgent endoscopy the predictive
value of stigmata of recent haemorrhage was first
identified. Although studies have confirmed the
prognostic significance of the 'visible vessel' there
remains considerable variation in the rebleeding rate of
such lesions between 32-100% (GRIFFITHS et al 1979; STOREY
et al 1981; MacLEOD et al 1982; WARA 1985). Several
possible reasons exist for this wide variation. There is
a lack of agreement on what endoscopically constitutes a
visible vessel; different studies may have detected
vessels with varying success depending on the extent of
ulcer base washing applied; the predictive value of a
visible vessel may vary according to ulcer site (WARA
1985; SWAIN et al 1986b), a fact not often considered in
published studies, and until recently the ability to
diagnose a vessel in the ulcer base with pulsatile blood
flow has been lacking. In this study the most accepted
endoscopic definition of a 'visible vessel' as described
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by Swain et al (1981) was used and a vigorous washing
policy was pursued resulting in a low incidence of
adherent clot in the ulcer bases.
The use of an endoscopic Doppler device to localise
arterial blood flow in the upper GI tract was first
described by BECKLY et al (1982). Beckly and Casebow
(1986) first assessed the predictive value of a Doppler
positive signal in peptic ulcer haemorrhage and found that
a positive signal correctly predicted rebleeding in 73% of
cases with a specificity of 95%. When visible vessels
were assessed the sensitivity increased to 80% with
specificity of 100%. Although forty-nine cases with
various SRH were assessed, the overall rebleeding rate was
only 20% with a visible vessel rebleeding rate of only
44%. Interestingly, the rebleeding rate of ulcers with
fresh clot was 30% with a predictive value of a Doppler
positive signal of 67% suggesting vessels may have been
obscured by clot. My study in a more select high risk
group of patients confirms the findings of Beckly and
Casebow and also the predictive value of the visible
vessel. The high rebleeding rate of visible vessels (89%)
in this study may reflect our policy of vigorous washing
allowing increased definition of this particular
endoscopic feature. The one false positive Doppler signal
in this study in an ulcer base with clot may have resulted
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from inadvertent recording of a deeper vessel and the two
false negatives from inadequate or incomplete probe
coverage of the ulcer base.
The major drawback of endoscopic Doppler ultrasound
at present is its reliance on subjective data in the form
of audible signals. If Doppler ultrasound assessment is
to be generally available then more objective means of
confirming arterial blood flow must be developed. Direct
graphic recording of the Doppler signal output has been
assessed and appears to improve objectivity (RUTGEERTS et
al 1988).
The ability to accurately predict which patients will
rebleed is of considerable clinical importance. I have
demonstrated in this study that all patients with a patent
vessel in their ulcer base as identified endoscopically by
visual and Doppler ultrasound criteria rebled. If this is
confirmed in further studies then early therapeutic
intervention by either endoscopic or surgical means may
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10.1 INTRODUCTION
The most important adverse prognostic factor in
patients admitted with peptic ulcer haemorrhage is
continuing bleeding or rebleeding (COGHILL and WILLCOX
1960; SCHILLER et al 1970; JONES et al 1973). Although
this group may constitute only 20% or less of all upper GI
bleeding cases they present a major therapeutic challenge
(ALLAN & DYKES 1976).
Medical therapeutic regimes in peptic ulcer
haemorrhage using acid inhibitory agents (COLLINS and
LANGMAN 1985), synthetic vaso-inhibitory GI hormones
(SOMERVILLE et al 1985), antifibrinolytic agents (BARER
et al 1983) or mucosal protective agents (RASKIN et al
1985) have shown no convincing evidence of benefit.
Although surgery has established efficacy in terms of
control of bleeding or rebleeding (READ et al 1965;
MORRIS et al 1984), with an increasingly elderly
population surgery as the sole therapeutic manoeuvre is
likely to be accompanied by an unacceptable morbidity and
mortality. Endoscopic therapy in contrast carries a low
morbidity and has the advantage of potential combination
with the diagnostic endoscopy. Although endoscopic
treatment of bleeding peptic ulcers is at present the most
promising therapeutic modality, only a few studies
assessing thermal (RUTGEERTS et al 1982; MacLEOD et al
1983; SWAIN et al 1986c; LAINE 1987), or injection
technigues (PANES et al 1987; CHUNG et al 1988), have
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shown convincing evidence of improvement in terms of
reduced rates of rebleeding, surgery or overall mortality.
In addition, several other studies using similar
techniques have failed to show any benefit (ROHDE et al
1980; IHRE et al 1981; ESCOURROU 1981; KERNOHAN et al
1984; GOUDIE et al 1984; KREJS et al 1987; BREARLEY et al
1987b). There remains therefore a need for improved
endoscopic techniques with each being carefully assessed
in controlled clinical trials. Of the currently available
thermal methods, the heater probe developed by David Auth
in Seattle in 1978 has been shown in experimental studies
to be the safest and most effective in producing vessel
coagulation (PROTELL et al 1978; SWAIN et al 1984;
JOHNSTON et al 1987).
I have recently completed a prospective, randomised,
controlled study assessing the efficacy of heater probe
therapy in bleeding peptic ulcers.
10.2 PATIENTS AND METHODS
All patients admitted to the Western Infirmary,
Glasgow with acute upper GI haemorrhage over the 16 month
period of the trial (August 1986 - November 1987) were
considered for inclusion. Patients presenting with
haematemesis and/or melaena were routinely endoscoped
within 24 hours of admission by an experienced member of
the Haematemesis Management Team (HMT). Potentially
eligible patients were diagnosed endoscopically to have:
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a) a single peptic ulcer in the stomach, pyloric canal
or duodenal cap.
b) no other significant upper gastrointestinal source of
blood loss such as oesophageal varices, carcinoma or
multiple bleeding erosions.
When a patient was recognised to be potentially
eligible for study entry the ulcer was assessed by the
Heater Probe endoscopist (myself). The patient was only
deemed eligible for entry into the study if the following
criteria were also met:
a) actively bleeding sites on the ulcer before or after
washing and/or
b) a visible vessel in the ulcer base before or after
washing and
c) confirmed accessibility of the heater probe to the
source of blood loss.
Active bleeding was defined as a continuous flow of
blood from the ulcer base continuing for the duration of
the endoscopy. A visible vessel was defined as an
elevated red or blue spot, a pulsatile pseudoaneurysm or
active arterial spurting. These endoscopic criteria are
known to be associated with the highest risk of
rebleeding (FOSTER et al 1978; GRIFFITHS et al 1979;
STOREY et al 1981).
Patients who fulfilled these criteria were then
stratified for age (<60, >60), shock (systolic BP < 100,
pulse > 100: present/absent on admission) and ulcer site
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(GU/DU). Randomisation was carried out within each group,
a sealed envelope being opened to indicate either heater
probe (HP) or sham therapy.
HP therapy was applied by a single operator (myself)
using an Olympus GIF-IT10 endoscope and Olympus Heatprobe
Unit (HPU) CD 10Z (3.7mm diam). The HP technique
applied was that recommended by Johnston (JOHNSTON et al
1985). With active haemorrhage the HP was used to
tamponade the bleeding point until haemostasis was
achieved. The HP, through its proximal water ports,
allowed continuous washing during tamponade which helped
to indicate when haemostasis had been successful. The HP
was then activated at the 25 joule setting and further
therapy applied until complete haemostasis was secured.
In the absence of active bleeding, a clot overlying an
ulcer was washed until the underlying bleeding point or
visible vessel was seen. Following this cautery was
applied as described above (Fig.34). On average 7 HP
applications/patient delivered at 25-30 J setting were
required to achieve complete haemostasis. Sham therapy
consisted of the HP being held inactivated in the gut
lumen. Only the HP endoscopist was aware of which
treatment each patient had received and he took no further
part in their management.
Following endoscopy patients were managed by members
of the HMT unaware of the initial randomisation and their
progress documented until discharge or death. All
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FIGURE 34
Visible vessel in pre-pyloric gastric ulcer base (a)
before and (b) after 6 x 25J heater probe applications.
The black spots after therapy represent the coagulated
vessel.
patients received H2 receptor antagonist therapy
(Ranitidine 50mg IV 6 hourly) and blood transfusion where
deemed appropriate by the attending clinician. Rebleeding
was diagnosed by HMT members if one of the following
features was present.
a) fresh blood in the upper gastrointestinal tract
(UGIT) at re-endoscopy or surgery.
b) vomiting fresh blood at any time other than
immediately after endoscopy where fresh blood had
been noted in the UGIT.
c) fresh melaena plus one of the following:
1. haemodynamic and clinical evidence of hypo-
volaemic shock (systolic BP < 100, pulse rate
> 100)
2. a falling Hb despite blood transfusion (failure
to raise Hb by more than 0.5g/dl per unit of
blood transfused).
Surgical intervention for haemostasis was undertaken when
deemed appropriate by the attending HMT surgeon.
Quantitative data (expressed as Mean ± SEM) was
analysed by the unpaired, two-sided Wilcoxon Rank Sum
Test. Integral data was compared by the Fishers exact
test. Significance was taken at the 5% level (p < 0.05).
All patients gave written, informed consent and the




During the 16 month trial period (August 1986 -
November 1987) 630 patients presenting with suspected
acute upper gastrointestinal haemorrhage were endoscoped
within 24 hours of presentation to the Western Infirmary,
Glasgow. One hundred and sixty six (26%) were found to
have a peptic ulcer. One hundred and fifteen (69%) had
either no stigmata of recent haemorrhage (SRH) or minor
SRH (flat black/red spots) at the time of endoscopy. This
group was deemed a low risk group in terms of rebleeding
but their progress was also documented until discharge.
None of these patients rebled. Fifty one patients had a
single peptic ulcer with either active haemorrhage or a
visible vessel and 43 were entered into the trial. There
were 8 exclusions; 4 high lesser curve gastric ulcers
were inaccessible to endoscopic treatment and were
therefore not randomised; the HP endoscopist was not
available for 2 patients; in 1 patient there was
torrential arterial haemorrhage from a posterior wall DU
necessitating immediate surgery and in 1 patient the
attending surgeon had decided on immediate surgery
following endoscopy and therefore this patient was not
randomised. Of the 4 patients excluded because of
inaccessibility, 4 rebled, 3 required emergency surgery
for haemostasis and 2 died.
1 1 9
Of the 43 patients entered into the trial 20 were
randomised to receive HP therapy and 23 sham therapy.
Both groups were well matched with regard to clinical and
endoscopic criteria known to influence prognosis (Table
18) .
TABLE 18
CLINICAL AND ENDOSCOPIC CHARACTERISTICS OF THE STUDY GROUPS
















Active oozing 19 13
Bleeding vessel 2 5
Non bleeding vessel 2 2
*Clinical entry characteristics are given as Mean ± SEM
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In patients actively bleeding at the time of
endoscopy immediate haemostasis was achieved in 14/18
(78%) HP treated patients compared with 0/21 following
sham treatment (p<0.0002). The post treatment blood
transfusion reguirements (units packed cells) were 1.7 ±
0.4 (mean ± SEM) in the HP group and 2.8 ± 0.6 in the sham
group. Mean non-operative hospital stay (days) was 4.1 ±
0.2 (mean ± SEM) in the HP group and 4.4 ± 0.4 in the sham
group. No rebleeding occurred in the HP treated group
(0/20) while 5/23 (22%) of the sham treated group rebled
(p = 0.05). Surgery for haemostasis was reguired in 3/5
of the sham treated patients who rebled. No HP or sham
treated patients died.
When endoscopic characteristics were assessed, 0/7
ulcers with visible vessels rebled in the HP group while
3/4 rebled in the sham treated group. Considering all
untreated ulcers with a visible vessel in the study, 7/8
(88%) rebled compared with 0/7 following HP therapy
(p<0.04). In ulcers with active oozing 0/13 rebled in the
HP group while 2/19 rebled in the sham group.
One perforation occurred 3 hours following HP
treatment in a 76 year old male patient who had an
actively bleeding anterior wall DU. He had a prolonged
endoscopy and had a total HP application of 250J. At
laparotomy a clean acute anterior duodenal perforation was
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noted with no macroscopic evidence of thermal induced
perforation. A truncal vagotomy and pyloroplasty was
performed and he made an uncomplicated recovery.
10.4 DISCUSSION
This study has demonstrated that heater probe therapy
reduces rebleeding rates in patients presenting with acute
upper GI haemorrhage from peptic ulcers with endoscopic
criteria suggesting a high risk of rebleeding. As
expected no significant differences in requirements for
surgery or mortality rates were seen due to the relatively
small numbers involved.
As the population presenting with acute upper GI
haemorrhage ages, there is a need for a simple,
inexpensive and effective endoscopic therapy for peptic
ulcer haemorrhage. Endoscopic injection therapy with
adrenaline and polidocanol (PANES et al 1987)or adrenaline
alone (CHUNG et al 1988) have recently been used to treat
ulcer haemorrhage and have shown convincing benefit in
producing immediate haemostasis and reducing the
requirement for emergency surgery. Further controlled
studies assessing these treatment regimes are however
required to confirm these findings.
The heater probe (HP) is small, portable and
relatively inexpensive. In addition, it has specific
technical advantages over other currently available
endoscopic thermal devices. Firstly, it has a powerful
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washing facility which, by improving visibility, allows
accurate targetted therapy directly onto the bleeding
site. Secondly, the HP produces coagulation by combining
heat and pressure simultaneously (coaptive coagulation).
This results in more effective haemostasis with less
tissue erosion than with laser photocoagulation which
reguires tissue heating alone to induce vessel shrinkage
(zonal heating) due to the considerable thermal energy
lost in flowing arterial blood (JOHNSTON et al 1987)
(Fig. 35 A & B). Thirdly, the HP, unlike other thermal
devices, can be applied and activated tangentially
allowing better access to difficult ulcers. Disadvantages
encountered with the HP are few although with any device
requiring physical pressure to produce vessel tamponade
there is always the risk, albeit small, of visceral
perforation. Several experimental studies however, have
confirmed the HP to be the safest and most effective
thermal device currently available (PROTELL et al 1978;
SWAIN et al 1984; JOHNSTON et al 1987).
The results of this study differ from a preliminary
report by Matthewson and his colleagues where laser but
not HP showed a benefit over controls (MATTHEWSON et al
1987). The studies, however, are not entirely comparable
in that their randomisation was biased towards HP therapy
and in addition data from previous laser work was
recruited to improve the significance of laser over HP
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compressed vessel
FIGURE 35 Diagramatic representation of arterial
coagulation by (a) zonal heating and (b)
coaptive coagulation.
a) Section through intestine wall demonstrating
submucosal artery with Nd-YAG laser beam applied.
The laser produces deep tissue penetration but only
minimal vessel shrinkage due to 'heat-sink' effect of
flowing arterial blood. With increasing power the
artery is coagulated however surface tissue erosion
and deep tissue penetration have occurred.
b) The heater probe is applied with moderate force (50G)
to tamponade the underlying submucosal artery. With
the vessel occluded, the heater probe is activated to
seal the vessel. After HP treatment a deep
impression remains in the mucosa but with less tissue
erosion than after laser treatment.
al (1985) showed the HP to be more effective than the
Nd-YAG laser in producing haemostasis. Furthermore,
recent uncontrolled studies have also suggested that HP
therapy is highly effective in arresting peptic ulcer
haemorrhage (LIN et al 1988a; LIN et al 1988b).
In evaluating new endoscopic therapeutic methods in
upper GI haemorrhage it is important to identify and study
only patients at high risk of rebleeding, where benefit
from an interventional treatment regime may be seen
early. This study evaluated only patients who were either
actively bleeding or who had visible vessels, both 'high
risk' factors in predicting rebleeding (GRIFFITHS et al
1979; WARA 1985). In this study the rebleeding rate of
untreated visible vessels was 88% confirming the
significance of this endoscopic feature. In contrast no
rebleeding was noted in the 7 visible vessels treated with
the HP emphasising the efficacy of the HP in treating
these lesions.
The high rebleeding rate of the 5 inaccessible high
lesser curve gastric ulcers is interesting. Evidence
exists to suggest that ulcer position in addition to
stigmata may be important in prediction of rebleeding
(SWAIN et al 1986b). Ulcers which lie in close proximity
to major vessels particularly high lesser curve gastric
ulcers (left gastric artery) and postero-inferior duodenal
ulcers (gastroduodenal and pancreatico-duodenal arteries)
have the highest risk of rebleeding. Such ulcers
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presumably may erode into arterial branches close to these
main trunks and occasionally into the main vessel itself
with consequent torrential haemorrhage (Fig.1).
Unfortunately these ulcer sites are also the most
inaccessible and difficult to treat endoscopically, a
problem which has been encountered in previous series
(MacLEOD et al 1983; SWAIN et al 1986c; BREARLEY et al
1987b; KREJS et al 1987).
Endoscopic thermal coagulation with the heater probe
can therefore produce immediate haemostasis (endostasis)




OVERVIEW AND FUTURE AREAS OF RESEARCH
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This thesis has attempted to improve our knowledge of
the pathophysiology of upper gastrointestinal
haemorrhage. In particular I have endeavoured to explain
the paradox that the majority of upper GI bleeds should
stop spontaneously despite the hostile local environment.
The discovery that simulated duodenal haemorrhage
should produce significant inhibition of
pentagastrin-stimulated gastric secretion and gastric
motility suggests that locally protective physiological
mechanisms may exist in the upper GI tract to promote
haemostasis. The prolonged nature of this gastric
secretory inhibition and the production of comparable
motility changes after simulated intragastric haemorrhage
supports the existence of such defence mechanisms.
Moreover preliminary clinical studies have revealed
increases in gastric pH following active peptic ulcer
bleeding independent of any blood buffering effect which
may also reflect gastric secretory inhibition. Further
studies to confirm these findings are required.
The mediation of these events has been investigated
both in simulated and true upper GI bleeding assessing
changes in GI hormones associated with gastric secretion
and motility. The significant increase in GIP
concentrations seen in each group suggests that this
hormone may be involved in the mediation of these
inhibitory responses. Further controlled studies are
warranted to investigate the effect of upper GI bleeding
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on GIP release. Other possible defence mechanisms
relevant to upper GI bleeding not studied in this these
but worthy of assessment include alterations in gastric
mucosal blood flow and changes in local mucosal
haemostasis.
Current medical treatment of upper GI haemorrhage is
based on inhibiting acid secretion, enhancing mucosal
defence mechanisms or reducing gastric mucosal blood
flow. These treatment regimes have been used without a
true understanding of the physiological changes induced in
the upper GI tract by haemorrhage. Confirmation of the
apparent locally protective physiological mechanisms
studied in this thesis may allow a more rational basis to
therapy. If for example, acid secretion is already
inhibited during active peptic ulcer haemorrhage, it is
not surprising that the widespread use of H2 receptor
antagonists in this condition have failed to improve the
outcome.
Identification of the blood factor responsible for
these inhibitory responses may allow the development of
new forms of therapy exploiting in-built physiological
protective mechanisms. A cellular or plasma based
constituent may be responsible. To identify whether the
inhibitory agent is present in cells or plasma the effect
of intraduodenal infusion of separated cells and plasma
could be studied in humans using the experimental method
described in Chapter 2. There are several possible
1 28
activating factors present in blood. First, there may be
a circulating factor present in plasma which is activated
by contact with the GI tract to inhibit gastric secretion
and motility. The ability of plasma proteins to act as a
circulating source of biologically active peptide
fragments activated by proteolysis from inactive
precursors is a well recognised physiological control
mechanism in several systems (NEURATH and WALSH 1976;
REID et al 1978). The recent demonstration that
biologically active peptides with neurotensin-like
properties could be generated from mammalian plasma by
pepsin (CARRAWAY and REINECKE 1984; MOGARD et al 1986)
suggests that such plasma dependent control mechanisms may
also exist in the GI tract to aid homeostasis. It seems
possible therefore that intraduodenal infusion of whole
blood may stimulate production of biologically active
peptide fragments through proteolysis of plasma proteins
which then exert acid inhibitory effects. Second,
platelets contain several active metabolites including
serotonin and prostaglandins (SILVER et al 1972; HOLMSEN
and KARPATKIN 1986; WILLIAMS 1986) which have known acid
inhibitory properties (BECH and ANDERSEN 1985; SOLL
1988). In addition, platelet-activating factor (PAF), an
endogenous mediator of inflammation has been shown to
reduce gastric bleeding time in rats (BERSTAD et al 1988)
possibly by acid inhibition. Interestingly, if these
protective responses to haemorrhage in the upper GI tract
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are prostaglandin mediated then this may offer an
alternative explanation for the high incidence of bleeding
encountered after treatment with prostaglandin synthetase
inhibitors (SOMERVILLE et al 1986). Third, blood
coagulation and platelet aggregation also release
serotonin, leukotrienes (SAMUELSSON 1983) and
prostaglandins (SILVER et al 1972; HOLMSEN and KARPATKIN
1986; WILLIAMS 1986) all agents which have known acid
inhibitory properties (BECH and ANDERSEN 1985; KONTUREK et
al 1987; SOLL 1988). The secretory effects of serotonin
(5HT), a peptide found in high concentrations both in the
upper GI tract and platelets, however are also thought to
be mediated by prostaglandins (PGE2) (RASK-MADSEN and
BUKHAVE 1983; BEUBLER et al 1984). It seems possible
therefore that the gastric inhibitory responses to
intraluminal blood may be mediated via initiation of blood
coagulation or platelet aggregation by either serotonin,
prostaglandins or other arachidonic acid derivatives such
as leukotrienes. In physiological terms it would seem
appropriate that in the haemostatically adverse upper GI
tract bleeding may induce a protective haemostatic
response mediated via activation of the coagulation
system. Identification of such a coagulation based
inhibition of gastric acid secretion could also be
performed by comparing the effect of intraduodenal
infusion of fresh whole blood and fresh heparinised venous
blood on pentagastrin-stimulated acid secretion.
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Potential problems however may occur with this study
technique particularly if the activating factor has a
short plasma half-life. Endogenous prostaglandins, for
example, are very rapidly metabolised in plasma to less
active metabolites (MATE et al 1987).
In the present clinical situation until underlying
pathophysiological mechanisms are fully understood, the
identification and treatment by endoscopic means of those
patients at highest risk of rebleeding is important. I
have demonstrated an improvement in the ability to predict
rebleeding by identifying 'high risk' peptic ulcer
patients with a patent vessel in their ulcer base. In
these high risk patients, endoscopic therapy by heater
probe has also been shown to provide haemostasis
effectively and safely.
In conclusion, protective physiological responses
involving alterations in gastric secretion and motility
may occur after upper GI haemorrhage to account for the
high spontaneous haemostasis rate. Furthermore, early
prediction and treatment of those patients in whom
endogenous defence mechanisms fail may lead to more
rational and effective therapeutic regimes.
1 31
REFERENCES
ALLAN R., DYKES P. (1976) A study of the factors
influencing mortality rates from gastrointestinal
haemorrhage.
Quarterly Journal of Medicine 45: 533-550.
ALLEN A., GARNER A. (1980) Gastric mucus and bicarbonate
secretion and their possible role in mucosal protection.
Gut 21: 249-62.
ANDERSEN D.K., ELAHI D., BROWN J.C., TOBIN J.D., ANDRES R.
(1978) Oral glucose augmentation of insulin secretion.
Interactions of gastric inhibitory polypeptide with
ambient glucose and insulin levels.
Journal of Clinical Investigation 62: 152-161.
ARDILL J.E.S. (1973) The measurement of gastrin by
radioimmunoassay.
Ph.D. Thesis Queen's University of Belfast.
ARDILL J.E.S. (1979) Radioimmunoassay of GI hormones. In
Buchanan K.D (ed), Clinics in Endocrinology and
Metabolism, London, W.B. Saunders, 8(2): 265-280.
ARNOLD R., EBERT R., CREUTZFELDT W., BECKER H.D., BORGER
H. (1978). Inhibition of gastric acid secretion by
gastric inhibitory polypeptide (GIP) in man.
Scandinavian Journal of Gastroenterology 13 (Suppl. 49):
11.
AVERY JONES F. (1947) Haematemesis and melaena - with
special reference to bleeding peptic ulcer.
British Medical Journal 2: 441-446.
BAGGOT J. (1982) Gas transport and pH regulation. In:
Devlin T.M. (Ed), Textbook of Biochemistry: with Clinical
Correlations. 2nd ed. New York, John Wiley and Sons.
p875-906.
BARER D., OGILVIE A., HENRY D., DRONFIELD M., COGGON D.,
FRENCH S., ELLIS S., ATKINSON M., LANGMAN M. (1983)
Cimetidine and Tranexamic acid in the treatment of acute
upper gastrointestinal tract bleeding.
New England Journal of Medicine 308: 1571-75.
BARON J.H. (1978) Clinical tests of gastric secretion.
London, Macmillan Press Ltd., pp 13-21.
BEAUMONT W. (1833) Experiments and observations on the
gastric juice and the physiology of digestion.
Plattsburgh, F.P. Allen pp 125-130.
1 32
BECH K., ANDERSEN D. (1985) Effect of serotonin on
pentagastrin-stimulated gastric acid secretion and gastric
antral motility in dogs with gastric fistula.
Scandinavian Journal of Gastroenterology 20: 1115-1123.
BECKLY D.E., CASEBOW M.P., PETTENGELL K.E. (1982) The use
of a Doppler ultrasound probe for localising arterial
blood flow during upper gastrointestinal endoscopy.
Endoscopy 14: 146-156.
BECKLY D.E., CASEBOW M.P. (1986) Prediction of rebleeding
from peptic ulcer experience with an endoscopic Doppler
device.
Gut 27: 96-99.
BENDTSEN F., ROSENKILDE-GRAM B., TAGE-JENSEN U., OVENSEN
L., RUNE S.J. (1987) Duodenal bulb acidity in patients
with duodenal ulcer.
Gastroenterology 93: 1263-69.
BERSON S.A. and YALOW R.S. (1971) Nature of immunoreactive
gastrin extracted from tissues of gastrointestinal tract.
Gastroenterology 60: 215-222.
BERSTAD A. (1982) Management of acute upper
gastrointestinal bleeding.
Scandinavian Journal of Gastroenterology 17 (suppl 75):
103-108.
BERSTAD A., ALMODOVAR K., WEATHERSTONE R.G., HIRSCHOWITZ
B.I. (1988) Effect of platelet-activating factor and its
receptor antagonist SRI 63-675, on gastric bleeding in
rats.
Scandinavian Journal of Gastroenterology 23: 738-42.
BEUBLER E., BUKHAVE K., RASK-MADSEN J. (1984) Colonic
secretion mediated by prostaglandin E2 and
5-hydroxytryptamine may contribute to diarrhoea due to
morphine withdrawal in the rat.
Gastroenterology 8: 1042-1048.
BIGGS J.C., HUGH T.B., DODDS A.J. (1976) Tranexamic acid
and upper gastrointestinal haemorrhage - a double-blind
trial.
Gut 17: 729-734.
BLACKBURN A.M., FLETCHER D.R., BLOOM S.R., CHRISTOFIDES
N.D., LONG R.G., FITZPATRICK M.L., BARON J.H. (1980a)
Effect of Neurotensin on gastric function in man.
Lancet 1: 987-989.
1 33
BLACKBURN A.M., FLETCHER D.R., ADRIAN T.E., BLOOM S.R.
(1980b) Neurotensin infusion in man: Pharmacokinetics
and effect on gastrointestinal and pituitary hormones.
Journal of Clinical Endocrinology and Metabolism 51:
1257-1261.
BLAIR S.D., JANVRIN S.B., McCOLLUM C.N., GREENHALGH R.M.
(1986) Effect of early blood transfusion on
gastrointestinal haemorrhage.
British Journal of Surgery 73: 783-785.
BLOOM S.R., MORTIMER C.H., THORNER M.D., BESSER G.M., HALL
R., GOMEZ-PAN A., ROY V.M., RUSSELL R.C.G., COY D.H.,
KASTIN A.J., SCHALLY A.V. (1974) Inhibition of gastrin and
gastric-acid secretion by growth hormone
release-inhibiting hormone.
Lancet 2: 1106-9.
BODI T., WIRTS C.W., TOCANTINS L.M. (1956) Local
environmental factors affecting haemostasis in bleeding
from the upper gastrointestinal tract. In: Bodi T. (ed),
Progress in Haematology, New York, Grune and Stratton, pp
221-248.
BODI T., KAZAL L.A. (1965) Some aspects of the
pathophysiology and the multiple contributing factors in
haemorrhage from the upper gastrointestinal tract.
American Journal of Gastroenterology 44: 202-231.
BORNMAN P.C., THEODOROU N.A., SHUTTLEWORTH R.D., ESSEL
H.P., MARKS I.N. (1985) Importance of hypovolaemic shock
and endoscopic signs in predicting recurrent haemorrhage
from peptic ulceration: a prospective evaluation.
British Medical Journal 291: 245-247.
BOSCH J., KRAVETZ D., RODES J. (1981) Effects of
somatostatin on hepatic and systemic hemodynamics in
patients with cirrhosis of the liver: comparison with
vasopressin.
Gastroenterology 80: 518-24.
BRAGG P.D., HOUGH L. (1961) An investigation of the
egg-white mucoproteins, ovomucoid and ovalbumin.
Biochemical Journal 78: 11-23.
BREARLEY S., HAWKER P.C., MORRIS D.L., DYKES P.W.,
KEIGHLEY M.R.B. (1987a) Selection of patients for
surgery following peptic ulcer haemorrhage.
British Journal of Surgery 74: 893-896.
1 34
BREARLEY S., HAWKER P.C., DYKES P.W., KEIGHLEY M.R.B.
(1987b) Per-endoscopic bipolar diathermy coagulation of
visible vessels using a 3.2mm probe - a randomised
clinical trial.
Endoscopy 19: 160-163.
BROWN J.C., PEDERSON R.A. (1970) A multiparameter study on
the action of preparations containing
cholecystokinin-pancreozymin.
Scandinavian Journal of Gastroenterology 5: 537-541.
BROWN J.C., MUTT V., PEDERSON R.A. (1970) Further
purification of a polypeptide demonstrating enterogastrone
activity.
Journal of Physiology (Lond). 209: 57-64.
BROWN J.C. (1974) "Enterogastrone" and other new gut
peptides.
Medical Clinics of North America 58: 1347-58.
BROWN J.C., DRYBURGH J.R., ROSS S.A., DUPRE J. (1975)
Identification and actions of gastric inhibitory
polypeptide.
Recent Progress in Hormone Research 31: 487-532.
BRYANT M.G., POLAK J.M., MODLIN I., BLOOM S.R.,
ALBUQUERQUE R.H., PEARSE A.G.E. (1976) Possible dual role
for vasoactive intestinal peptide as gastrointestinal
hormone and neurotransmitter substance.
Lancet 1: 991-993.
BUCHAN A.M.J., POLAK J.M., CAPELLA C., SOLCIA E., PEARSE
A.G.E. (1978) Electroimmunocytochemical evidence for the
K-cell localisation of gastric inhibitory polypeptide
(GIP) in man.
Histochemistry 56: 37-44.
BUCHANAN K.D., McCARROLL A.M. (1971) Comparison of
methods of separation of free from bound hormones in the
RIA of insulin. In: Kirkham K.E., Hunter W.M. (eds),
Radioimmunoassay Methods, Edinburgh, Churchill
Livingstone, pp 136-142.
BUCHANAN K.D., TEALE J.D., HARPER G. (1972) Antibodies to
unconjugated synthetic and natural secretins.
Hormone and Metabolic Research 507: 4.
BUFFA R., POLAK J.M., PEARSE A.G.E., SOLCIA E., GRIMELIUS
L., CAPELLA C. (1975) Identification of the intestinal
cell storing gastric inhibitory peptide.
Histochemistry 43: 249-255.
1 35
BUHR H.J., ENCKE A., SEUFERT R.M. (1978) Untersuchungen
zur lokalen fibrinolyse des magens.
Chirurg (Berlin) 49/7: 431-435.
CARRAWAY R.E., REINECKE M. (1984) Neurotensin-like
peptides and a novel model of the evolution of signalling
systems. In: Falkmer S., Hakanson R., Sundler F. (eds).
Evolution and Tumour Pathology of the Neuroendocrine
System. Amsterdam, Elsevier Science Publishers, pp
245-283.
CHAIMOFF C., CRETER D., DJALDETTI M. (1978) The effect of
pH on platelet and coagulation factor activities.
American Journal of Surgery 136: 257-9.
CHANDLER G.N. and WATKINSON G. (1953) Gastric aspiration
in haematemesis.
Lancet 2: 1170-1175.
CHANDLER G.N., and WATKINSON G. (1959) The early diagnosis
of the causes of haematemesis.
Quarterly Journal of Medicine 28: 371-395.
CHIBA T., TAMINATO T., KADOWAKI S., ABE H., CHIHARA K.,
SEINO Y., MATSUKURA S., FUJITA T. (1980) Effects of
glucagon, secretin, and vasoactive intestinal polypeptide
on gastric somatostatin and gastrin release from isolated
perfused rat stomach.
Gastroenterology 79: 67-71.
CHIN T.W.F., MACLEOD S.M., MAHON W.A. (1986) Absence of
tachyphylaxis in gastric acid secretion during
pentagastrin infusion.
Journal of Clinical Pharmacology 26: 281-285.
CHOU C.C., MANGINO M.J., SAWMILLER D.R. (1984)
Gastrointestinal hormones and intestinal blood flow. In:
Shepherd A.P., Granger D.N. (eds), Physiology of the
intestinal Circulation, New York, Raven Press, pp121-130.
CHRISTIANSEN J., YOTIS A. (1986) The role of somatostatin
and a long-acting analogue, SMS 201-995 in acute bleeding
due to peptic ulceration.
Scandinavian Journal of Gastroenterology 21 (Suppl 119):
109-114.
CHUNG S.C.S., LEUNG J.W.C., STEELE R.J.C., CROFTS T.J., LI
A.K.C. (1988) Endoscopic injection of adrenaline for
actively bleeding ulcers: a randomised trial.
British Medical Journal 296: 1631-1633.
1 36
CLEATOR I.G.M., GOURLAY R.H. (1975) Release of
immunoreactive gastric inhibitory polypeptide (IR-GIP) by
oral ingestion of food substances.
American Journal of Surgery 130: 128-135.
COGHILL N.F., WILLCOX R.G. (1960) Factors in the
prognosis of bleeding chronic gastric and duodenal ulcers.
Quarterly Journal of Medicine 29: 575-596.
COLLINS R., LANGMAN M. (1985) Treatment with histamine H2
antagonists in acute upper gastrointestinal haemorrhage,
implications of randomized trials.
New England Journal of Medicine 313: 660-6.
CORMACK F., JOUHAR A.J., CHAKRABARTI R.R., FEARNELY G.R.
(1973) Tranexamic acid in upper gastrointestinal
haemorrhage.
Lancet 1: 1207-1208.
COTTON P.B., ROSENBERG M.T., WALDRAM P.P.L., AXON A.T.R.
(1973) Early endoscopy of oesophagus, stomach and duodenal
bulb in patients with haematemesis and melaena.
British Medical Journal 2: 505-509.
COX H.T., POLLER L., THOMSON J.M. (1967) Gastric
fibrinolysis. A possible aetiological link with peptic
ulcer.
Lancet 1: 1300-02.
COX H.T., POLLER L., THOMSON J.M. (1969) Evidence for the
release of gastric fibrinolytic activity into peripheral
blood.
Gut 10: 404-407.
CRAWFORD G. and HOBSLEY M. (1968) Spectrophotometry
estimation of phenol red in gastric juice in the presence
of blood.
Biochemical Journal 107: 26-34.
CRUVEILHIER J. (1829) Anatomie pathologique du corps
humaine.
Paris: Balliere, Vol. 42.
CURTIS L.E., SIMONIAN S., BUERK C.A., HIRSCH E.F., SOROF
H.S. (1973) Evaluation of the effectiveness of controlled
pH in management of massive upper gastrointestinal
bleeding.
American Journal of Surgery 125: 474-476.
DIEM K. (ed) (1962). Documenta Giegy Scientific Tables.
Macclesfield Giegy, UK, pp 509.
1 37
DOOLEY C.P., REZNICK J.B., VALENZUELA J.E. (1984)
Variations in gastric and duodenal motility during gastric
emptying of liquid meals in humans.
Gastroenterology 87: 1114-19
ELWIN C.E. (1974) Gastric acid responses to antral
application of some amino acids, peptides and isolated
fractions of a protein hydrolysate.
Scandinavian Journal of Gastroenterology 9: 239-247.
ESCOURROU J. (1981) Nd:YAG laser therapy for acute
gastrointestinal hemorrhage. In: Atsumi, Nimsakul (eds),
Laser Tokyo, Tokyo, Intergroup Corp, pp 45-50.
ETHERINGTON D.J., TAYLOR W.H. (1967) Nomenclature of
pepsins.
Nature 216: 279-80.
ETHERINGTON D.J., TAYLOR W.H. (1970) The pepsins from
human gastric mucosal extracts.
Biochemical Journal 118: 587-94.
ETHERINGTON D.J., ROBERTS N.B., TAYLOR W.H. (1980) The
collagen degrading activity of purified human pepsins 1
and 3.
Clinical Science 58: 30.
FIDDIAN-GREEN R.G., McGOUGH E., PITTENGER G., ROTHMAN E.
(1983) Predictive value of intramural pH and other risk
factors for massive bleeding from stress ulceration.
Gastroenterology 85: 613-620.
FLATEN O. (1983) Gastric inhibitory polypeptide:
Physiology and novel aspects.
Scandinavian Journal of Gastroenterology 18: 1-4.
FLETCHER D.R., SHULKES A., HARDY K.J. (1985) The effect of
neurotensin and secretin on gastric acid secretion and
mucosal blood flow in man.
Regulatory Peptides 11: 217-226.
FORREST J.A.H., FINLAYSON N.D.C., SHEARMAN D.J.C. (1974)
Endoscopy in gastrointestinal bleeding.
Lancet ii: 394-397.
FOSTER D.N., MILOSZEWSKI K.J.A., LOSOWSKY M.S. (1978)
Stigmata of recent haemorrhage in diagnosis and prognosis
of upper gastrointestinal bleeding.
British Medical Journal 1: 1173-77.
FULLARTON G.M., Mac LAUCHLAN G., MACDONALD A., CREAN G.P.,
McCOLL K.E.L. (1988) Rebound nocturnal hypersecretion
after four weeks H2 receptor antagonist therapy.
Gut (In press).
1 38
GANGULI P.C. (1970) The effect of protein, carbohydrate or
fat on plasma gastrin concentration in human subjects.
Gut 11: 1061 (abs).
GANONG W.F. (1977) Review of Medical Physiology, 8th
ed. California, Lange Medical Publications, p494-500.
GEORGE J.D. (1968) New clinical method for measuring the
rate of gastric emptying: the double sampling test meal.
Gut 9: 239-242.
GERSHON-COHEN J., SHAY H., FELS S.S. (1938) Experimental
studies on gastric physiology in man. IV. The influence of
osmotic pressure changes of salts and sugar solutions on
pyloric action and gastric emptying in normal and operated
stomachs.
American Journal of Roentgenology 40: 335-343.
GIBBON E. (1901) The history of the decline and fall of
the Roman Empire. Vol III, London Methuen and Company,
pp 474.
GOUDIE B.M., MITCHELL K.G., BIRNIE G.G., MacKAY C. (1984)
Controlled trial of endoscopic bipolar electrocoagulation
in the treatment of bleeding peptic ulcers.
Gut 25: A1185.
GREEN W.F., KAPLAN M.M., CURTIS L.E., LEVINE P.H. (1978)
Effect of acid and pepsin on blood coagulation and
platelet aggregation: a possible contribution to prolonged
gastroduodenal haemorrhage.
Gastroenterology 74: 38-43.
GREGORY R.A. (1967) Enterogastrone - a reappraisal of the
problem. In: Shritka T.K., Gilbert J.A.L., Harrison R.C.
(eds): Gastric Secretion, New York, Pergamon Press, pp
469-477.
GREGORY R.A. and TRACY H.J. (1975) The chemistry of the
gastrins: some recent advances. In: Thomson J.C. (ed),
Gastrointestinal Hormones, Austin, University of Texas
Press, pp 13-24.
GRIFFITHS W.J., NEUMANN D.A., WELSH J.D. (1979) The
visible vessel as an indicator of uncontrolled or
recurrent gastrointestinal haemorrhage.
New England Journal of Medicine 300: 1411-13.
GROSSMAN M.I. (1967) Neural and hormonal stimulation of
gastric secretion of acid. In: Code C.F., ed. Alimentary
Canal. Washington DC: American Physiological Society, pp
835-863. (Heidel W. ed. Handbook of Physiology, section 6:
vol II).
139
GUO Y., SINGH P., GOMEZ G., GREELEY G.H., THOMPSON J.C.
(1987) Effect of peptide YY on cephalic gastric and
intestinal phases of gastric acid secretion and on the
release of gastrointestinal hormones.
Gastroenterology 92: 1202-8.
GUTH P.H. (1977) The gastric microcirculation and gastric
mucosal blood flow under normal and pathological
conditions. In: Glass G. & J. (eds) Progress in
Gastroenterology, New York, Grune and Stratton,
pp323-347.
GUTH P.H. (1982) Stomach blood flow and acid secretion.
Annual Review of Physiology 44: 3-12.
HANNIBAL S. and RUNE S.J. (1983) Duodenal bulb pH in
normal subjects.
European Journal of Clinical Investigation 13: 455-460.
HASSAN M.A., HOBSLEY M. (1970) Positioning of subject and
of nasogastric tube during a gastric secretion study.
British Medical Journal 1: 458-60.
HASTINGS P.R., SKILLMAN J.J., BUSHNELL L.S., SILEN W.
(1978) Antacid titration in the prevention of acute
gastrointestinal bleeding.
New England Journal of Medicine 298: 1041-45.
HEDING L.G. (1971) Radioimmunological determination of
pancreatic and gut glucagon in plasma.
Diabetologia 7: 10-19.
HENNING N. (1949) Lehrbuch der Verdauungskrankheiten.
Stuttgart, G.Thieme, 298-305
HIPPOCRATES (400BC) (1849) Aphorisms. The genuine works
of Hippocrates. Translated by Frances Adams for the
Sydenham Society, London, Adlard C. and J. Section VII,
no. 21.
HOBSLEY M and SILEN W. (1969) Use of an insert marker
(phenol red) to improve accuracy in gastric secretion
studies.
Gut 10: 787-795.
HOLLANDER F. (1952) Gastric secretion of electrolytes.
Federation Proceedings 11: 706-714.
HOLMSEN H., KARPATKIN S. (1986) Metabolism of platelets.
In: Williams W.J., Beutler E., Erslev A.J., Lichtman M.A.
(eds). Hematology, New York, McGraw Hill pp 1149-76.
1 40
HOLOHAN K.N., MURPHY R.F., FLANAGAN R.W.J., BUCHANAN K.D.,
ELMORE D.T. (1973) Enzymic iodination of the histidyl
residue of secretin: a radioimmunoassay of the hormone.
Biochimica et Biophysica Acta 322: 178-180.
HOUGHTON L.A., READ N.W., HEDDLE R., MADDERN G.J., DOWNTON
J., TOOULI J., DENT J. (1988) Motor activity of the
gastric antrum, pylorus and duodenum under fasted
conditions and after a liquid meal.
Gastroenterology 94: 1276-84.
HUNT J.N. (1951) The secretory pattern of the stomach in
man.
Journal of Physiology (Lond) 113: 169-184.
HUNT J.N. (1963) The duodenal regulation of gastric
emptying.
Gastroenterology 45: 149-156.
HUNT J.N. and McDONALD I. (1954) The influence of volume
on gastric emptying.
Journal of Physiology (Lond) 126: 459-474.
HUNT J.N and KNOX M.T. (1962) The regulation of gastric
emptying of meals containing citric acid and salts of
citric acid.
Journal of Physiology (Lond) 163: 34-45.
HUNT P.S., HANSKY J., KORMAN M.G. (1979) Mortality in
patients with haematemesis and melaena: a prospective
study.
British Medical Journal 1: 1238-40.
IHRE T., JOHANSSON C., SELIGSON U., TORNGREN S. (1981)
Endoscopic YAG laser treatment in massive upper
gastrointestinal bleeding: report of a controlled
randomised study.
Scandinavian Journal of Gastroenterology 16: 633-40.
ISENBERG J.I., IPPOLITI A.F., MAXWELL V.L. (1977)
Perfusion of the proximal small intestine with peptone
stimulates gastric acid secretion in man.
Gastroenterology 73: 746-752.
IVY A.C., JAVOIS A.J. (1925) Contributions to the
physiology of gastric secretion.
American Journal of Physiology 71: 591-603.
JACOBSON E.D., SWAN K.G., GROSSMAN M.I. (1967) Blood flow
and secretion in the stomach.
Gastroenterology 52: 414-420.
1 41
JANOWITZ H.D., HOLLANDER F. (1954) Viscosity of cell-free
canine gastric mucus.
Gastroenterology 26: 582-591
JOHNSON L.R. and GROSSMAN M.I. (1971) Intestinal hormones
as inhibitors of gastric secretion.
Gastroenterology 60: 120-144.
JOHNSTON D. and DUTHIE H.L. (1965) Inhibition of gastrin
secretion in the human stomach - effect of acid in the
duodenum.
Lancet ii: 1032-1036.
JOHNSTON D. and DUTHIE H.L. (1966) Inhibition of
histamine-stimulated gastric secretion by acid in the
duodenum in man.
Gut 7: 58-68.
JOHNSTON J.H. (1984) The sentinel clot and invisible
vessel: pathologic anatomy of bleeding peptic ulcer.
Gastrointestinal Endoscopy 30: 313-315.
JOHNSTON J.H., SONES J.Q., LONG B.W., POSEY E.L. (1985)
Comparison of heater probe and YAG laser in endoscopic
treatment of major bleeding from peptic ulcers.
Gastrointestinal Endoscopy 31: 175-80.
JOHNSTON J.H., JENSEN D.M., AUTH D.C. (1987) Experimental
comparison of endoscopic Yttrium-aluminium-garnet laser,
electrosurgery and heater probe for canine gut arterial
coagulation.
Gastroenterology 92: 1101-8.
JONES H.L., BALL R.F., JENKINS L.J., GALLIPON Q., DEMMER
C.A., JUDA T.A., GILLIPEAU R.E. (1961) Studies of
systemic haemostatic factors in patients with bleeding
duodenal ulcer.
American Journal of Gastroenterology 35: 243-257.
JONES P.F., JOHNSTON S.J., McEWAN A.B., KYLE J., NEEDHAM
C.D. (1973) Further haemorrhage after admission to
hospital for gastrointestinal haemorrhage.
British Medical Journal 3: 660-664.
KAMPEN Van E.J., ZIJLSTRA W.G. (1961) Standardisation of
hemoglobinometry. II. The hemoglobincyanide method.
Clinica Chimica Acta 6: 538-544.
KAYASSEH L., GYR K., KELLER U., STALDER G.A., WALL M.




KERNOHAN R.M., ANDERSON J.R., McKELVEY S.T.D., KENNEDY
T.L. (1984) A controlled trial of bipolar
electrocoagulation in patients with upper gastrointestinal
bleeding.
British Journal of Surgery 71: 889-91.
KHALIL T., ALINDER G., RAYFORD P.L. (1987) Gastric
inhibitory polypeptide. In: Thompson J.C., Greeley G.H.,
Rayford P.L., Townsend C.M. (eds). Gastrointestinal
Endocrinology, New York:McGraw-Hill, pp248-259.
KIEL J.W., RIEDEL G.L., SHEPHERD A.P. (1987)
Autoregulation of canine gastric mucosal blood flow.
Gastroenterology 93: 12-20.
KONTUREK S.J., DEMBINSKI A., THOR P., KROL R. (1976a)
Comparison of vasoactive intestinal peptide (VIP) and
secretin on gastric secretion and mucosal blood flow.
European Journal of Physiology 361: 174-181.
KONTUREK S.J., TASLER J., CIESZKOWSKI M., COY D.H.,
SCHALLY A.V. (1976b) Effect of growth hormone
release-inhibiting hormone on gastric secretion, mucosal
blood flow, and serum gastrin.
Gastroenterology 70: 737-746.
KONTUREK S.J. (1979) Gastric secretion: physiological
aspects. In Duthie H.L. and Wormsley K.G. (eds).
Scientific Basis of Gastroenterology, Edinburgh,
Churchill-Livingstone pp 133-162.
KONTUREK S.J., BILSKI J., DEMBINSKI A., WARZECHA A., BECK
G., JENORALLA H. (1987) Effect of leukotrienes on gastric
acid and alkaline secretion.
Gastroenterology 92: 1209-1214.
KOSAKA T., LIM R.K.S. (1930) Demonstration of the humoral
agent in fat inhibition of gastric secretion.
Proceedings of the Society for Experimental Biology and
Medicine 27: 890-1.
KREJS G.J., LITTLE K.H., WESTERGAARD H., HAMILTON J.K.,
SPADY D.K., POLTER D.E. (1987) Laser photocoagulation for
the treatment of acute peptic ulcer bleeding: a
randomised controlled clinical trial.
New England Journal of Medicine 316: 1618-21.
LAINE L. (1987) Multipolar electrocoagulation in the
treatment of active upper gastrointestinal tract
haemorrhage.
New England Journal of Medicine 316: 1613-17.
143
LANDOR J.H., IPAPO V.S. (1977) Gastric secretory effect of
amino acids given enterally and parenterally in dogs.
Gastroenterology 73: 781-784.
LANGMAN M.J.S., HANSKY J.N., DRURY R.A.B., AVERY JONES F.
(1964) The gastric mucosa in radiologically negative acute
gastrointestinal bleeding.
Gut 5: 550-552.
LARSEN K.R., MOODY F.G. (1982) Clinical significance of
gastric blood flow autoregulation during stimulation.
Digestive Diseases and Sciences 27: 673-4.
LE ROITH D., SPITZ I.M., EBERT R., LIEL Y., ODES S.,
CREUTZFELDT W. (1980) Acid induced gastric inhibitory
polypeptide secretion in man.
Journal of Clinical Endocrinology and Metabolism 51:
1385-89.
LIN H.J., TSAI Y.T., LEE S.D., LAI K.H., LEE F.Y., LIN
C.Y., LEE C.H. (1988a) A prospective randomised trial of
heat probe thermocoagulation versus pure alcohol injection
in nonvariceal peptic ulcer haemorrhage.
American Journal of Gastroenterology 83: 283-286.
LIN H.J., TSAI Y.T., LEE S.D., LAI K.H., LEE C.H. (1988b)
Heat probe therapy for severe hemorrhage from a peptic
ulcer with a visible vessel.
Endoscopy 20: 131-133.
LINTON R.A.F. (1984) Pulmonary gas exchange and acid-base
status. In: Churchill-Davidson H.C. (ed), A Practice of
Anaesthesia. London, Lloyd-Luke, pp 89-124.
LLUIS F., THOMPSON J.C. (1988) Neuroendocrine potential
of the colon and rectum.
Gastroenterology 94: 832-4.
LOW J., DODDS A.J., BIGGS J.C. (1980) Fibrinolytic
activity of gastroduodenal secretions - a possible role in
upper gastrointestinal haemorrhage.
Thrombosis Research 17: 819-830.
LUCEY M.R., FAIRCLOUGH P.D., WASS J.A.H., KWASOWSKI P.,
MEDBAK S., WEBB J., REES L.H. (1984) Response of
circulating somatostatin, insulin, gastrin and GIP to
intraduodenal infusion of nutrients in normal man.
Clinical Endocrinology 21: 209-217.
MacKAY C.R. (1954) The significance of local vascular
changes in bleeding peptic ulcer.
Surgery 35: 724-733.
1 44
MacLEOD I.A., MILLS P.R., MacKENZIE J.F., JOFFE S.N.,
RUSSELL R.I., CARTER D.C. (1983) Neodymium Yttrium
aluminium garnet laser photocoagulation for major
haemorrhage from peptic ulcers and single vessels: a
single blind controlled study.
British Medical Journal 286: 345-348.
MAGNUSSON I., IHRE T., JOHANSSON C., SELIGSON U., TORNGREN
S., UVNAS-MOBERG K. (1985) Randomised double blind trial
of somatostatin in the treatment of massive upper
gastrointestinal haemorrhage.
Gut 26: 221-6.
MALLORY G.K., WEISS J. (1929) Haemorrhages from
lacerations of the cardiac orifice of stomach due to
vomiting.
American Journal of the Medical Sciences 178: 506-515.
malmstrom J., stadil f., rehfield J.f. (1976) Gastrins in
Tissue. Concentration and component pattern in gastric,
duodenal and jejunal mucosa of normal human subjects and
patients with duodenal ulcer.
Gastroenterology 70: 697-703.
MATE L., BEAUCHAMP R.D., THOMPSON J.C. (1987)
Prostaglandins. In Thompson J.C., Greeley G.H., Rayford
P.L., Townsend C.M. (eds). Gastrointestinal
Endocrinology, New York: McGraw Hill, pp 372-79.
MATTHEWSON K., SWAIN C.P., BLAND M., KIRKHAM J.S., BOWN
S.G., NORTHFIELD T.C. (1987) Randomised comparison of
Nd-YAG laser, heater probe (HP) and no endoscopic therapy
for bleeding peptic ulcers.
Gastroenterology 92: A1522.
MAXWELL V., SHULKES A., BROWN J.C., SOLOMON T.E., WALSH
J.H., GROSSMAN M.I. (1980) Effect of gastric inhibitory
polypeptide on pentagastrin-stimulated acid secretion in
man.
Digestive Diseases and Sciences 25: 113-116.
McCLOY R.F. (1978) In: Baron J.H.(ed) Clinical tests of
gastric secretion. London, MacMillan Press Limited, pp
212-217.
Mcintosh c.h.s., pederson r.a., koop h., brown j.c.
(1981) Gastric inhibitory polypeptide stimulated secretion
of somatostatin-like immunoreactivity from the stomach:
inhibition by acetylcholine or vagal stimulation.
Canadian Journal of Physiology & Pharmacology 59: 468-72.
1 45
McLAUCHLAN G., FULLARTON G.M., CREAN G.P., McCOLL K.E.L.
Regional variations in intragastric pH: a 24 hour
ambulatory study in healthy volunteers.
Gut (in press).
McLEAN J.R., VELOSO H. (1967) Change of shape without
aggregation caused by ADP in rabbit platelets at low pH.
Life Sciences 6: 1983-84.
MacLEOD I.A., MILLS P.R. (1982) Factors identifying the
probability of further haemorrhage after acute upper
gastrointestinal haemorrhage.
British Journal of Surgery 69: 256-8.
McSWINEY B.A., SPURRELL W.R. (1933) Influence of osmotic
pressure upon the emptying time of the stomach.
Journal of Physiology 79: 437-442.
MEI N. (1978) Vagal glucoreceptors in the small intestine
of the cat.
Journal of Physiology 282: 485-506.
MERKEL C., GATTA A., ZUIN R., FINUCCI G.F., NOSADINI R.,
RUOL A. (1985) Effect of somatostatin on splanchnic
hemodynamics in patients with liver cirrhosis and portal
hypertension.
Digestion 32: 92-98.
MEULENGRACHT E. (1935) Treatment of haematemesis and
melaena with food.
Lancet ii: 1220-22.
MOGARD M.H., KOBAYASHI R., CHEN C.F., LEE T.D., REEVE
J.R., SHIVELY J.E., WALSH J.H. (1986) The amino acid
sequence of Kinetensin, a novel peptide isolated from
pepsin-treated human plasma: homology with human serum
albumin, neurotensin and angiotensin.
Biochemical and Biophysical Research Communications 136:
983-988.
MORGAN A.G., McADAM W.A.F., WALMSLEY G.L., JESSOP A.,
HORROCKS J.C., DE DOMBAL F.T. (1977) Clinical findings,
early endoscopy and multivariate analysis in patients
bleeding from the upper gastrointestinal tract.
British Medical Journal 2: 237-40.
MORRIS D.L., HAWKER P.C., BREARLEY S., SIMMS M., DYKES
P.W., KEIGHLEY M.R.B. (1984) Optimal timing of operation
for bleeding peptic ulcer: prospective randomised trial.
British Medical Journal 288: 1277-80.
1 46
NEURATH H., WALSH K.A. (1976) Role of Proteolytic enzymes
in biological regulation.
Proceedings of the National Academy of Sciences of the
United States of America 73: 3825-32.
NILSSON G., YALOW R.S., BERSON S.A. (1973) Distribution of
gastrin in the gastrointestinal tract of human, dog, cat
and hog. In: Anderson S (ed), Frontiers in
Gastrointestinal Hormone Research, Stockholm, Almquist and
Wiksell, pp.95-101.
NILSSON I.M., BERGENTZ S.E., HEDNER U., KULLENBERG K.
(1975a) Gastric fibrinolysis.
Thrombosis et Diathesis Haemorrhagica (Stuttgart) 34:
409-418.
NILSSON I.M., BERGENTZ S.E., WIKLANDER O., HEDNER U.
(1975b) Erosive haemorrhagic gastroduodenitis with
fibrinolysis and low factor XII.
Annals of Surgery 182: 677-682.
NORTHFIELD T.C. (1971) Factors predisposing to recurrent
haemorrhage after acute gastrointestinal bleeding.
British Medical Journal 1: 26-28.
OSBORN G.R. (1954) The pathology of gastric arteries, with
special reference to fatal haemorrhage from peptic ulcer.
British Journal of Surgery 41: 585-94.
PANES J., VIVER J., FORNE M., GARCIA-OLIVARES E., MARCO
C., GARAU J. (1987) Controlled trial of endoscopic
sclerosis in bleeding peptic ulcers.
Lancet ii: 1292-94.
PARKINSON T.L. (1966) The chemical composition of eggs.
Journal of the Science of Food and Agriculture 17:
101-111.
PEARSON J.P., WARD R., ALLEN A., ROBERTS N.B., TAYLOR W.H.
(1986) Mucus degredation by pepsin: comparison of
mucolytic activity of human pepsin 1 and pepsin 3:
implications in peptic ulceration.
Gut 27: 243-248.
PEDERSON R.A. and BROWN J.C. (1972) The inhibition of
histamine, pentagastrin- and insulin-stimulated canine




PEDERSON R.A., SCHUBERT H.E., BROWN J.C. (1975) Gastric
inhibitory polypeptide. Its physiological release and
insulinotropic action in the dog.
Diabetes 24: 1050-56.
PERRY M.A., MURPHREE D., GRANGER D.N. (1982) Oxygen uptake
as a determinant of gastric blood flow autoregulation.
Digestive Diseases and Sciences 27: 675-679.
PIPER D.W. (1960) The estimation of peptic activity in
gastric juice using radio-iodinated serum albumin as
substrate.
Gastroenterology 38: 616-621.
PIPER D.W., FENTON D.B. (1965) pH stability and activity
curves of pepsin with special reference to their clinical
importance.
Gut 6: 506-508.
PIQUE J.M., LEUNG F.W., TAN H.W., LIVINGSTON E., SCREMIN
O.U., GUTH P.H. (1988) Gastric mucosal blood flow
response to stimulation and inhibition of gastric acid
secretion.
Gastroenterology 95: 642-650.
POLAK J.M., BLOOM S.R., KUZIO M., BROWN J.C., PEARSE
A.G.E. (1973) Cellular localisation of gastric inhibitory
polypeptide in the duodenum and jejunum.
Gut 14: 284-288.
PRICE B.A., JAFFE B.M., ZINNER M.J. (1985) Effect of
exogenous somatostatin infusion on gastrointestinal blood
flow and hormones in the conscious dog.
Gastroenterology 88: 80-85.
PROTELL R.L., SILVERSTEIN F.E., PIERCEY J., DENNIS M.,
SPRAKE W., RUBIN C.E. (1976) A reproducible animal model
of acute bleeding ulcer - the "ulcer maker".
Gastroenterology 71: 961-964.
PROTELL R.L., RUBIN C.E., AUTH D.C., SILVERSTEIN F.E.,
TEROU F., DENNIS M., PIERCEY J.R.A. (1978) The heater
probe: a new endoscopic method for stopping massive
gastrointestinal bleeding.
Gastroenterology 74: 257-262.
RAPTIS S., DOLLINGER H.C., VON BERGER L., SCHLEGEL W.,
SCHRODER K.E., PFEIFFER E.F. (1975) Effects of




RASKIN J., CAMARA D., LEVINE B., AKDAMAR K., REDLHAMMER
D.E., GASKILL H.V., EULER A.R. (1985) Effect of
15(R)-15-methyl prostaglandin E2 on acute upper
gastrointestinal hemorrhage.
Gastroenterology 88: 1550.
RASK-MADSEN J., BUKHAVE K. (1983) The difficulties of
establishing the pathophysiological role of prostaglandins
in secretion. In: Skadhange E., Heintze K. (eds).
Intestinal Absorption and Secretion. Lancaster, MTP Press
Ltd, pp 453-468.
READ R.C., HUEBL H.C., THAL A.P. (1965) Randomized study
of massive bleeding from peptic ulceration.
Annals of Surgery 162: 561-70.
REID I.A., MORRIS B.J., GANONG W.F. (1978) The
renin-angiotensin system.
Annual Review of Physiology 40: 377-410.
REYNOLDS J.R., WALT R.P., CLARK A.G., HARDCASTLE J.D.,
LANGMAN M.J.S. (1987) Intragastric pH monitoring in acute
upper gastrointestinal bleeding and the effect of
intravenous cimetidine and ranitidine.
Alimentary Pharmacology & Therapeutics 1: 23-30.
ROBERTS W.M. (1931) Effect of oils on gastric secretion
and motility.
Quarterly Journal of Medicine 24: 133-152.
ROGERS A.B. (1972) The effect of pH on human platelet
aggregation induced by epinephrine and ADP.
Proceedings of the Society for Experimental Biology and
Medicine 139: 1100-09.
ROHDE H., THON K., FISCHER M., STOLTZING H., ELSASSER P.,
HAIBACH L., OHMANN C., LORENZ W., JOHNSTON D. (1980)
Results of a defined therapeutic concept of endoscopic
neodymium-YAG-laser therapy in patients with upper
gastrointestinal bleeding.
British Journal of Surgery 67: 360.
ROKITANSKY C.F. (1842) Handbuch der allgemeinen
pathologischen Anatomie.
Vienna: Braunmuller & Siedel, 3: 193-194.
ROMANOFF A.L., ROMANOFF A.J. eds.(1949) The Avian Egg.
New York: John Wiley and Sons Inc. pp 311-490.
RUNE S.J. (1981) Problems associated with in situ
measurements of duodenal pH. In: Domschke W., Wormsley
K.G., eds. Magen Und Magenkrankheiten, Stuttgart, Georg
Thieme Verlag, pp 150-161.
1 49
RUTGEERTS P., VANTRAPPEN G., BROECKAERT L., JANSSENS J.,
COREMANS G., GEBOES K., SCHURMANS P. (1982) Controlled
trial of YAG laser treatment of upper digestive
haemorrhage.
Gastroenterology 83: 410-416.
RUTGEERTS P., VANTRAPPEN G., D'HEYGERE F., BROECKAERT L.
(1988) Transendoscopic Doppler ultrasound: Usefulness for
diagnosis and treatment of vascular malformations.
Endoscopy 20: 99-101.
SAINT-HILAIRE S., LAVERS J., KENNEDY J., CODE C.F. (1960)
Gastric acid secretory value of different foods.
Gastroenterology 39: 1-11.
SAMUELSSON B. (1983) Leukotrienes: mediators of immediate
hypersensitivity reactions and inflammation.
Science 220: 568-575.
SARSON D.L., HAYTER R.C., BLOOM S.R. (1982) The
pharmacokinetics of porcine glucose-dependent
insulinotropic polypeptide (GIP) in man.
European Journal of Clinical Investigation 12: 457-461.
SAUNDERS J.H.B., THJODLEIFSSON B., WORMSLEY K.G. (1975)
Aspects of 'basal' gastric secretion.
Digestion 12: 183-188
SCHAFFALITZKY DE MUCKADELL O.B., FAHRENKRUG J., HOLST
J.J., LAURITSEN K.B. (1977) Release of vasoactive
intestinal peptide (VIP) by intraduodenal stimuli.
Scandinavian Journal of Gastroenterology 12: 793-799.
SCHILLER K.F.R., TRUELOVE S.C., GWYN WILLIAMS D. (1970)
Haematemesis and melaena with special reference to factors
influencing the outcome.
British Medical Journal ii: 7-14.
SCHINDLER R. (1937) Gastroscopy Chicago: The University of
Chicago Press. pp 156-172.
SHAW C., BUCHANAN K.D. (1983) Intact neurotensin (NT) in
human plasma: response to oral feeding.
Regulatory Peptides 7: 145-153.
SHAY H., GERSHON-COHEN J. (1934) Experimental studies in
gastric physiology in man. II. A study of pyloric control:
the role of acid and alkali.
Surgery, Gynecology & Obstetrics 58: 935-955.
150
SHAY H., GERSHON-COHEN J., FELS S.S. (1939) The role of
the upper small intestine in the control of gastric
secretion; the effect of neutral fat, fatty acid and
soaps; the phase of gastric secretion influenced and the
relative importance of the psychic and chemical phases.
Annals of Internal Medicine 13: 294-307.
SILVER M.J., SMITH J.B., INGERMAN C., KOCSIS J.J. (1972)
Human blood prostaglandins: formation during clotting.
Prostaglandins 1: 429-436.
SILVERSTEIN F.E., GILBERT D.A., TEDESCO F.J., BUENGER
N.K., PERSING J. (1981) The national ASGE survey on upper
gastrointestinal bleeding. I. Study design and baseline
data.
Gastrointestinal Endoscopy 27: 73-79.
SIRCUS W. (1953) The intestinal phase of gastric
secretion.
Quarterly Journal of Experimental Physiology 38: 91-100.
SIRCUS W. (1958) Studies on the mechanisms in the duodenum
inhibiting gastric secretion.
Quarterly Journal of Experimental Physiology 43: 114-133.
SKOV OLSEN P., HOLST PEDERSEN J., KIRKGAARD P., STADIL F.,
FAHRENKRUG J., CHRISTIANSEN J. (1983) Neurotensin inhibits
meal-stimulated gastric acid secretion in man.
Scandinavian Journal of Gastroenterology 18: 1073-76.
SOLL A.H. (1988) Prostanoid inhibition of acid secretion -
cellular mechanisms in canine fundic mucosa. In: Domschke
W, Sammann H.G. (eds). Prostaglandins and Leukotrienes in
Gastrointestinal Diseases. Berlin, Springer-Verlag, pp
118-126.
SOMERVILLE K.W., HENRY D.A., DAVIES J.G., HINE K.R.,
HAWKEY C.J., LANGMAN M.J.S. (1985) Somatostatin in
treatment of haematemesis and melaena.
Lancet i: 130-32.
SOMERVILLE K.W., FAULKNER G., LANGMAN M.J.S. (1986)
Non-steroidal anti-inflammatory drugs and bleeding peptic
ulcer.
Lancet 1: 462-4.
SONNENBERG A., WEST C. (1983) Somatostatin reduces gastric
mucosal blood flow in normal subjects but not in patients
with cirrhosis of the liver.
Gut 24: 48-153.
1 51
SOON-SHIONG P., DEBAS H.T., SEAL A.M., WALSH J.H., CHEUNG
G. (1980) Colonic inhibition of gastric acid secretion in
man.
Surgical Forum (Chicago) 31: 152-4.
STAEL Von HOLSTEIN C.C.S., ERIKSSON S.B.S., KALLEN R.
(1987) Tranexamic acid as an aid to reducing blood
transfusion requirements in gastric and duodenal bleeding.
British Medical Journal 297: 7-10.
STANNARD V.A., HUTCHINSON A., MORRIS D.L., BYRNE A.
(1988) Gastric exocrine "failure" in critically ill
patients: incidence and associated features.
British Medical Journal 296: 155-156.
STOREY D.W., BOWN S.G., SWAIN C.P., SALMON P.R., KIRKHAM
J.S., NORTHFIELD T.C. (1981) Endoscopic prediction of
recurrent bleeding in peptic ulcers.
New England Journal of Medicine 305: 915-16.
SWAIN C.P., BOWN S.G., STOREY D.W., KIRKHAM J.S.,
NORTHFIELD T.C., SALMON P.R. (1981) Controlled trial of
argon laser photocoagulation in bleeding peptic ulcers.
Lancet 2: 1313-16.
SWAIN C.P., MILLS T.N., SHEMESH E., DARK J.M., LEWIN M.R.,
CLIFTON J.S., NORTHFIELD T.C., COTTON P.B., SALMON P.R.
(1984) Which electrode? A comparison of four endoscopic
methods of electrocoagulation in experimental bleeding
ulcers.
Gut 25: 1424-43.
SWAIN C.P., STOREY D.W., BOWN S.G., HEATH J., MILLS T.N.,
SALMON P.R., NORTHFIELD T.C., KIRKHAM J.S., 0'SULLIVAN
J.P. (1986a) Nature of the bleeding vessel in recurrently
bleeding gastric ulcers.
Gastroenterology 90: 595-608.
SWAIN C.P., SALMON P.R., NORTHFIELD T.C. (1986b) Does
ulcer position influence presentation or prognosis of
acute gastrointestinal bleeding.
Gut 27: A632.
SWAIN C.P., KIRKHAM J.S., SALMON P.R., BOWN S.G.,
NORTHFIELD T.C. (1986c) Controlled trial of Nd-YAG laser
photocoagulation in bleeding peptic ulcers.
Lancet 1: 1113-17.
TAYLOR W.H. (1959) Gastric proteolysis in disease II.
The proteolytic activity of gastric juice and gastric
mucosal extracts from patients with chronic gastric and
duodenal ulcer.
Journal of Clinical Pathology 12: 338-343.
1 52
TAYLOR W.H. (1970) Pepsins of patients with peptic ulcer.
Nature 227: 76-7.
THOMAS F.B., SHOOK D.F., O'DORISIO T., CATALAND S.,
MEKHJIAN H.S., CALDWELL J.H., MAZZAFERRI E.L. (1977)
Localization of gastric inhibitory polypeptide release by
intestinal glucose perfusion in man.
Gastroenterology 72: 49-54.
THOMAS F.B., SINAR D., MAZZAFERRI E.L., CATALAND S.,
MEKHJIAN H.S., CALDWELL J.H., FROMKES J.J. (1978)
Selective release of gastric inhibitory polypeptide by
intraduodenal amino acid perfusion in man.
Gastroenterology 74: 1261-1265.
THOMPSON J.C. (1987) Actions of gut peptides in gastric
secretion. In: Thompson J.C., Greeley G.H., Rayford
P.L., Townsend C.M. (eds), Gastrointestinal Endocrinology,
New York, McGraw-Hill, pp 91-108.
TORRES A.J., LANDA I., HERNANDEZ F., JOVER J.M., SUAREZ
A., ARIAS J., CUBERES R., SANTOYO J., FERNADEZ R., CALLEJA
J., NISA E., RODRIGUEZ J.L., MORENO E., BALIBREA J.L.
(1986) Somatostatin in the treatment of severe upper
gastrointestinal bleeding: a multicentre controlled trial.
British Journal of Surgery 73: 786-789.
TROUSSEAU A. (1889) Lecture on Clinical Medicine Vol. IV:
Translated by John Rose Cormack for the New Sydenham
Society London, pp 68-69.
UVNAS-WALLENSTEN K. (1980) Luminal secretion of gut
peptides.
Clinics in Gastroenterology 9: 545-553.
VALENZUELA J.E. and DEFILIPPI C. (1981) Inhibition of
gastric emptying in humans by secretin, the octapeptide of
cholecystokinin and intraduodenal fat.
Gastroenterology 81: 898-902.
VALLON A.G., COTTON P.B., LAURENCE B.H., MIRO J.R.A., OSES
J.C.S. (1981) Randomised trial of endoscopic argon laser
photocoagulation in bleeding peptic ulcer.
Gut 22: 228-233.
VAN LIERE E.J. and SLEETH C.K. (1940) The emptying time of
the normal human stomach as influenced by acid and alkali
with a review of the literature.
American Journal of Digestive Diseases 7: 118-123.
1 53
VILLAR H.V., FENDER H.R., RAYFORD P.L. (1975) Inhibition
of gastrin release and gastric secretion by GIP and VIP.
In: Thompson J.C. (ed). Gastrointestinal Hormones,
Austin, University of Texas Press. pp 467-474.
WALLIN C., EMAS S., NYLANDER G. (1985) Acid and
hyperosmolar solutions in the upper intestine of chronic
gastric fistula rats inhibit gastric acid secretion by
different mechanisms.
Scandinavian Journal of Gastroenterology 20: 1083-1090.
WALSH J.H., YALOW R.S., BERSON S.A. (1971) The effect of
atropine on plasma gastrin response to feeding.
Gastroenterology 60: 16-21.
WARA P. (1985) Endoscopic prediction of major rebleeding:
a prospective study of stigmata of haemorrhage in bleeding
ulcer.
Gastroenterology 88: 1209-14.
WARD A.S., WILKINS R.A. COCKEL R., WINDSOR C.W.O. (1969)
Duodenal inhibition of gastric secretion by osmotic agents
in normal subjects and patients with duodenal ulcer.
Gut 10: 1020-1028.
WEINER I., KHALIL T., THOMPSON J.C., RAYFORD P.L. (1987)
In: Thomson J.C., Greeley G.H., Rayford P.L., Townsend
C.M. (eds): Gastrointestinal Endocrinology, New York,
McGraw-Hill, p.194-212.
WHEATLEY K.E., POXON V.A., DYKES P.W., DEIGHLEY M.R.B.
(1987) Intragastric fibrinolysis in bleeding peptic ulcer
disease.
Gut 28: A1402.
WHITE C.M., POXON V., ALEXANDER-WILLIAMS J. (1983) Effects
of nutrient liquids on human gastroduodenal motor
activity.
Gut 24: 1109-16.
WHITTLE B.J.R., KAUFFMAN G.L., MONCADA S. (1986)
Hemostatic mechanisms, independent of platelet aggregation
arrest gastric mucosal bleeding.
Proceedings of the National Academy of Sciences 83:
5683-87.
WILLIAMS W.J. (1986) Sequence of coagulation reactions.
In: Williams W.J., Beutler E., Erslev A.J., Lichtman M.A.
(eds). Hematology, New York, McGraw Hill, pp 1238-47.
WINDSOR C.W.O., COCKEL R., LEE M.J.R. (1969) Inhibition of
gastric secretion in man by intestinal fat infusion.
Gut 10: 135-142.
154
WOLFE M.M., REEL G.M., McGUIGAN J.E. (1983) Inhibition of
gastrin release by secretin is mediated by somatostatin in
cultured rat antral mucosa.
Journal of Clinical Investigation 72: 1586-93.
WOODWARD E.R., LYON E.S., LANDOR J., DRAGSTEDT L.R.
(1954) The physiology of the gastric antrum: experimental
studies on isolated antrum pouches in dogs.
Gastroenterology 27: 766-85.
WORMSLEY K.G., GROSSMAN M.I. (1965) Maximal histolog test
in control subjects and patients with peptic ulcer.
Gut 6: 427-435.
YEH K.C., KWAN K.C. (1978) A comparison of numerical
integrating algorithms by trapezoidal, Lagrange, and
spline approximations.





1. FULLARTON G.M., Boyd E.J.S., Crean G.P., Buchanan K.,
McColl K.E.L. Inhibition of gastric secretion and
motility by simulated upper gastrointestinal
haemorrhage - a response to facilitate haemostasis ?
Gut 1988 (in press)
2. FULLARTON G.M., MacLauchlan G., Macdonald A., Crean
G.P., McColl K.E.L. Rebound nocturnal hypersecretion
after four weeks H2 receptor antagonism.
Gut 1988 (in press)
3. MacLauchlan G., FULLARTON G.M., Crean G.P., McColl
K.E.L. Regional variations in intragastric pH: a 24
hour ambulatory study in healthy volunteers.
Gut 1988 (in press)
4. FULLARTON G.M., Birnie G.G., Macdonald A., Murray
W.R. A controlled study of heater probe (HP) therapy
in bleeding peptic ulcers.
British Journal of Surgery 1988 (in press)
5. FULLARTON G.M., McColl K.E.L., Crean G.P. Effects of
four weeks treatment with nizatidine on nocturnal
gastric acid secretion, daytime pH and integrated
gastrin respopnse.
Proceedings of European Nizatidine Symposium,
Brussels, November 12-13, 1987, pp 51-58.
6. FULLARTON G.M., Birnie G.G., Macdonald A., Murray
W.R. Controlled study of heater probe (HP) in
bleeding peptic ulcers.
Gut 1988; 29: 1 701 .
7. FULLARTON G.M., Birnie G.G., Macdonald A., Murray
W.R. Controlled study of heater probe (HP) in
bleeding peptic ulcers.
Gastroenterology 1988; 94: A138.
8. FULLARTON G.M., MacLauchlan G., Crean G.P., McColl
K.E.L. Rebound nocturnal acid hypersecretion
following 4 weeks H2 receptor antagonism.
Gastroenterology International 1988; 1: (Suppl 1)
A21 .
9. Murray W.R., FULLARTON G.M. A controlled study of
endoscopic heater probe (HP) treatment in bleeding
peptic ulcers.
Endoscopy 1988; 20 (Suppl II): 17.
1 57
10. FULLARTON G.M., Boyd E.J.S., Crean G.P., Buchanan K. ,
McColl K.E.L. Effect of simulated upper
gastrointestinal (GI) haemorrhage on gastric acid
secretion and GI hormones.
Gut 1987; 28: A1401.
11. FULLARTON G.M., Boyd E.J.S., Crean G.P., Buchanan K.,
McColl K.E.L. Effect of simulated intraduodenal
haemorrhage on gastric acid secretion, gastric
motility and gastrointestinal (GI) hormones.
British Journal of Surgery 1988; 75: 615.
12. FULLARTON G.M., MacLaughlan G., Macdonald A., Crean
G.P., McColl K.E.L. Rebound nocturnal
hypersecretion after four weeks H2 receptor
antagonism.
Gut 1988; 29: A1439.
1 58
COMMUNICATIONS TO LEARNED SOCIETIES
1. The effect of simulated intraduodenal haemorrhage on
gastric acid secretion and GI hormones.
British Society of Gastroenterology, London,
September 18th, 1987.
2. The effect of simulated intraduodenal haemorrhage on
gastric acid secretion, gastric emptying and GI
hormones.
Caledonian Society of Gastroenterology, Western
Infirmary, Glasgow, November 4th, 1987.
3. Effects of simulated upper gastrointestinal
haemorrhage on gastric secretion, gastric motility
and GI hormones.
Surgical Research Society, Belfast, January 8th,
1988.
4. Controlled study of the heater probe in bleeding
peptic ulcers.
Caledonian Society of Gastroenterology, Royal College
of Surgeons, Edinburgh, February 12th, 1988.
5. Controlled study of the heater probe in bleeding
peptic ulcers.
British Society of Gastroenterology, Leicester, March
24th, 1988.
6. Controlled study of heater probe therapy in bleeding
peptic ulcers.
American Gastroenterological Association, New
Orleans, May 17th, 1988.
7. Rebound acid hypersecretion after 4 weeks H2 receptor
antagonism.
Caledonian Society of Gastroenterology, June 3rd,
1988.
8. A controlled study of endoscopic heater probe (HP)
treatment in bleeding peptic ulcers.
VI European Congress of Digestive Endoscopy, Rome,
4-1Oth September, 1988.
9. Rebound nocturnal acid hypersecretion following 4
weeks H2 receptor antagonism.
XIII International Congress of Gastroenterology,
Rome, 4-1Oth September, 1988.
10. Rebound nocturnal hypersecretion after 4 weeks H2
receptor antagonism.







Blood samples for gastrin assay were added to
heparinised tubes and centrifuged at 4 degrees
Centigrade. The plasma was separated and stored at -20
degrees Centigrade pending assay. The antibody was
raised in rabbits against synthetic human gastrin I
(ICI). The antibody used in the assay 0098 was used at an
approximate final dilution of 1:10,000. The antibody does
not cross react with any known gastrointestinal peptides
including gastric inhibitory polypeptide (GIP), gift from
J. Brown; Motilin, gift from J. Brown; vasoactive
intestinal peptide (VIP), gift from V. Mutt; human insulin
(Medical Research Council); glucagon (Novo); natural
secretin, gift from V. Mutt; except cholecystokinin-
pancreozymin, gift from V. Mutt where greater than 10,000
times concentration of this material is reguired to
produce a similar fall in bound counts as standard
gastrin. The antibody also recognised Big gastrin (G34)
(gift from Rehfeld) and chromatographic studies suggest
that the antibody recognised not only the hepta deca
peptide but also G34. The standards used are supplied by
the Medical Research Council (gastrin human type synthetic
68/439). Human synthetic gastrin is iodinated by the
chloramine T method. Human plasma rendered hormone free
by charcoal is added to the standards in order to
equilibrate the conditions between plasma samples and
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standards. A charcoal separation technique is used
(BUCHANAN and McCARROLL 1971). The sensitivity of the
assay is 5-10 ng/l of gastrin. The assay is described in
greater detail elsewhere (ARDILL 1973).
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Secretin Radioimmunoassay
Plasma samples were prepared as before and stored at
-20 degrees Centigrade pending assay.
Pork synthetic secretin (SG 18773, Batch ES XX1-14A,
donated by Dr. Michael Ondetti, Sguibb) was used for
standards and labelling. Secretin was labelled with 1251
(Radiochemical Centre, Amersham) by the method of Holohan
et al (1973) and antibodies were raised to pork natural
secretin (BUCHANAN et al 1972) (donated by Dr. V. Mutt).
The antibody BB101 was used at a final titre of 1:36,000.
The antibody appeared specific for secretin in that no
cross-reaction was noted with pancreatic glucagon, large
gut glucagon-like immunoreactivity (GLI), human insulin
(MRC), gastric inhibitory polypeptide and motilin (both
donated by Dr. J.C. Brown), 99% pure cholecystokinin-
pancreozymin and vasoactive intestinal polypeptide (both
donated by Dr. V. Mutt), or human synthetic gastrin
(ICI). Extracts of human jejunum cross-reacted in the
assay in an identical manner to the standards. Using a
highly purified 1251 secretin, a sensitivity of 6 ng/l was
achieved.
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Gastric Inhibitory Peptide (GIP) Radioimmunoassay
Blood samples for GIP assay were added to heparinised
tubes and centrifuged at 4 degrees Centigrade. The plasma
was separated and stored at -20 degrees Centigrade pending
assay. The antibody was raised in sheep against porcine
GIP (donated by Dr. J.C. Brown, Vancouver). The antibody
(S705) was used at a final dilution of 1:600,000 in the
assay tube. The iodination method used was the
chloramine-T technique and the iodinated peptide purified
on a SPLC system (pro or pc column). Separation of free
from antibody bound hormones was by dextran coated
charcoal (BUCHANAN and McCARROLL 1971). The sensitivity
of the assay was 5ng/l.
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Radioimmunoassay of Vasoactive Intestinal Peptide (VIP)
Blood samples for VIP assay were added to chilled
heparinised tubes, centrifuged at 4 degrees Centigrade and
the plasma extracted by the method of Heding (1971). The
extracts were reconstituted prior to assay in 0.04 M
phosphate buffer (pH 7.4). Natural porcine VIP was used
for standards, immunisation and iodination. VIP (2 pg)
was iodinated by the chloramine T method, the labelled
hormone purified by absorption to silica and eluted into
acidified ethanol. The labelled hormone was then stored
at -20 degrees Centigrade in acidified ethanol.
Antibodies to VIP were raised in New Zealand white
rabbits, the rabbits being immunised with a conjugate of
VIP to ovalbumin. Separation of free from bound hormone
radioimmunoassay was accomplished by serum and dextran
coated charcoal (BUCHANAN and McCARROLL 1971). The
standards used were natural porcine VIP, and were prepared
in an alcohol extract of plasma to mimick the unknown
plasma extract sample. The assay could detect 5 ng/1
with 95% certainty and was sensitive over the ranges 0-300
ng/1. There was no cross reactivity in the assay with
glucagon, secretin or gastric inhibitory polypeptide and
the antibody was predominantly C-terminal reactive.




Synthetic bovine NT (Bacham, Torrance, CA, USA) was
used for immunisation, radioiodination and for RIA
standards.
One mg of peptide and 2.1mg of human serum albumin
(HSA) (Behringwerke AG, Marburg, FRG) were dissolved in
lml of 0.05 M Na phosphate-buffered saline (PBS), pH 7.5.
One ml of 1% (v/v) double-distilled glutaraldehyde (Agar
Aids Ltd., Stansted, Essex, UK) in PBS was added dropwise
with constant gentle magnetic stirring. The reaction
mixture was dialysed against 2 litre of PBS for 48h. The
efficiency of peptide to albumin coupling was
approximately 30% as assessed by gel filtration
chromatography of an immunogen aliguot after dialysis.
New Zealand white rabbits were immunised with 80 pg
of coupled peptide in Freund's adjuvant (2ml)
subcutaneously in the nape. Booster injections of 16 pg
coupled peptide were administered at 4-weekly intervals.
After 4 such boosters one animal, NT3, produced a suitable
antiserum for RIA. This particular antibody was used at
a final dilution of 1/90,000 in the assay tube.
Radioiodination of NT was achieved as follows: 7-10
pg of peptide were dissolved in 100 pi of 0.3 M
NaH2P04/Na2HP04 buffer, pH 7.5, by gentle magnetic
stirring. 1 mCi Na 1251 (Amersham) in a volume of 10 pi
was added and the iodination reaction was initiated by
addition of 50 pg of chloramine-T in 100 pi 0.3 M sodium
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phosphate buffer. After 15s the reaction was terminated
by addition of 150 pg of sodium metabisulphite in 100 pi
of 0.3 M sodium phosphate buffer. A further 200 pi of
0.3 M sodium phosphate buffer containing 200 pg KI and 20
pg HSA was added to the reaction mixture prior to
purification.
Separation of unincorporated 1251 and iodinated
derivatives of NT was achieved by cation exchange
chromatography. Separation of free from antibody bound
hormone was achieved by dextran coated charcoal. The
assay could distinguish 3 pmol/l neurotensin from zero




Plasma samples were prepared as before and stored at
-20 degrees Centigrade pending assay. The samples were
reconstituted prior to assay in 0.04 M phosphate buffer pH
7.4. The standard was synthetic cyclic somatostatin
(Serono). The antibody OB 5(1) was raised in rabbits to
cyclic somatostatin and was used at a 1:15,000 final
dilution in the assay tube. No cross reactivity with any
other gut or islet peptide was found. The antibody is
C-terminally directed although reaction with fragments is
low, suggesting that the whole molecule is required for
full cross reactivity. N-tyrosylated somatostatin
(Serono) was iodinated by the chloramine-T technique and
the iodinated peptide purified on a cation exchanger,
(Whatman CM52) using 0.05 M and 0.25 M acetate buffer.
Horse serum was charcoaled to remove endogenous peptides,
extracted in an identical manner to the plasma samples,
and added to the calibration samples to equilibrate
conditions between standards and unknowns. Separation of
free from antibody bound peptide was achieved by dextran
coated charcoal. The assay could detect 3 ng/1 (pg/ml)
with 95% confidence. When 3 samples measuring mean
values of 8 ng/l, 42 ng/l and 193 ng/l were repeatedly
assayed 8 times in different batches, the coefficient of
variance was 10.6%, 5.5% and 4.4% respectively.
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